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Background: Ultrasonography has been the mainstay of antenatal screening programmes in the UK for
many years. Technical factors and physical limitations may result in suboptimal images that can lead to
incorrect diagnoses and inaccurate counselling and prognostic information being given to parents. Previous
studies suggest that the addition of in utero magnetic resonance imaging (iuMRI) may improve diagnostic
accuracy for fetal brain abnormalities. These studies have limitations, including a lack of an outcome
reference diagnosis (ORD), which means that improvements could not be assessed accurately.
Objectives: To assess the diagnostic impact, acceptability and cost consequence of iuMRI among fetuses
with a suspected fetal brain abnormality.
Design: A pragmatic, prospective, multicentre, cohort study with a health economics analysis and a
sociological substudy.
Setting: Sixteen UK fetal medicine centres.
Participants: Pregnant women aged ≥ 16 years carrying a fetus (at least 18 weeks’ gestation) with a
suspected brain abnormality detected on ultrasonography.
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Interventions: Participants underwent iuMRI and the findings were reported to their referring fetal
medicine clinician.
Main outcome measures: Pregnancy outcome was followed up and an ORD from postnatal imaging
or postmortem autopsy/imaging collected when available. Developmental data from the Bayley Scales of
Infant Development and questionnaires were collected from the surviving infants aged 2–3 years. Data
on the management of the pregnancy before and after the iuMRI were collected to inform the economic
evaluation. Two surveys collected data on patient acceptability of iuMRI and qualitative interviews with
participants and health professionals were undertaken.
Results: The primary analysis consisted of 570 fetuses. The absolute diagnostic accuracies of ultrasonography
and iuMRI were 68% and 93%, respectively [a difference of 25%, 95% confidence interval (CI) 21% to
29%]. The difference between ultrasonography and iuMRI increased with gestational age. In the 18–23
weeks group, the figures were 70% for ultrasonography and 92% for iuMRI (difference of 23%, 95% CI
18% to 27%); in the ≥ 24 weeks group, the figures were 65% for ultrasonography and 94% for iuMRI
(difference of 29%, 95% CI 23% to 36%). Patient acceptability was high, with at least 95% of respondents
stating that they would have iuMRI again in a similar situation. Health professional interviews suggested that
iuMRI was acceptable to clinicians and that iuMRI was useful as an adjunct to ultrasonography, but not as a
replacement. Across a range of scenarios, iuMRI resulted in additional costs compared with ultrasonography
alone. The additional cost was consistently < £600 per patient and the cost per management decision
appropriately changed was always < £3000. There is potential for reporting bias from the referring clinicians
on the diagnostic and prognostic outcomes. Lower than anticipated follow-up rates at 3 years of age were
observed.
Conclusions: iuMRI as an adjunct to ultrasonography significantly improves the diagnostic accuracy
and confidence for the detection of fetal brain abnormalities. An evaluation of the use of iuMRI for cases
of isolated microcephaly and the diagnosis of fetal spine abnormalities is recommended. Longer-term
follow-up studies of children diagnosed with fetal brain abnormalities are required to fully assess the
functional significance of the diagnoses.
Trial registration: Current Controlled Trials ISRCTN27626961.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 49.
See the NIHR Journals Library website for further project information.
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Plain English summary
U ltrasonography is routine in pregnancy to check that the baby’s brain is developing as expected.However, no medical test is perfect and ultrasonography may miss some brain abnormalities, may
get some brain abnormalities wrong or may diagnose an abnormality that is not really present. Magnetic
resonance imaging (MRI) may help clarify difficult cases during pregnancy.
We wanted to find out if MRI was better than ultrasonography alone in making an accurate diagnosis.
We recruited pregnant women whose ultrasound scan, performed by an expert, suggested that their baby
had a brain abnormality, and referred them for a MRI scan. The results of the two tests were compared
with each other and to the final outcome of the pregnancy.
Our results showed that using MRI in addition to ultrasonography improved the accuracy of the diagnosis
in about one in four pregnancies. It changed the prediction of how the baby would develop in at least one
in five cases. In many cases, the pregnancy was managed differently because of the MRI result. The MRI
was acceptable to women, with 95% saying that they would have MRI again in a similar situation. Neither
MRI nor ultrasonography accurately identified children who went on to have delayed development at the
age of 2–3 years, but MRI was better than ultrasonography at ruling out developmental problems at this
age. The MRI cost more than ultrasonography alone; therefore, whether or not it is worthwhile depends
on the value placed on the decisions that changed as a result of its use.
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Scientific summary
Background
For many years, fetal imaging with ultrasonography has been the mainstay of antenatal screening
programmes in the UK. However, no imaging method is perfect and various technical factors and physical
limitations may result in suboptimal images. These may lead to incorrect diagnoses of structural abnormalities
and inaccurate counselling and prognostic information being given to parents. The fetal brain is a particular
area of concern because of the relatively high frequency of developmental abnormalities (approximately
3/1000 pregnancies), many of which are associated with serious clinical morbidities.
Previous studies have suggested that in utero magnetic resonance imaging (iuMRI) may be a powerful
adjunct to ultrasonography for detecting fetal brain abnormalities from 18 weeks’ gestational age. However,
the majority of these studies have a number of key limitations and, most notably, they lack an outcome
reference diagnosis (ORD), which means that improvements in diagnostic accuracy could not be assessed
accurately. Therefore, the extent of diagnostic improvement and the impact that this has on clinical
management and counselling remains unclear.
Aims and objectives
The aim of the research was to assess iuMRI to aid the prenatal diagnosis (PND) of fetal developmental
brain abnormalities among fetuses for which ultrasonography had suggested a brain abnormality.
The objectives were to:
l assess the diagnostic accuracy of iuMRI compared with antenatal ultrasonography using ORD as a comparator
l assess the clinical effectiveness of iuMRI through changes in clinical diagnostic confidence before and
after iuMRI and the effect on prenatal counselling and management decisions
l assess the acceptability of the clinical care package with the use of magnetic resonance imaging
(MRI) included
l conduct a health economics analysis to assess the cost consequences of the use of MRI.
Methods
Design
We conducted a pragmatic, prospective, multicentre, cohort study with a health economics analysis and a
qualitative substudy.
Recruitment and imaging examinations
Participants were pregnant women aged > 16 years and carrying a fetus with a suspected brain abnormality
on detailed ultrasonography as diagnosed by a fetal medicine consultant. They were recruited by 16 fetal
medicine centres and referred for iuMRI. There were no specific requirements made for the ultrasound
technique and details of suspected brain abnormalities were recorded along with a confidence rating of the
diagnosis. The iuMRI was completed at one of six collaborating centres where radiologists were required
to comment on each abnormality suspected by the ultrasonography and their confidence in the diagnosis.
The radiologist could add a diagnosis if appropriate, or use ‘diagnosis excluded’ if they disagreed with an
ultrasonography diagnosis. It was not possible to match protocols across all scanning centres because
of different MRI manufacturing systems; however, all scans were performed at 1.5 T and an absolute
requirement of imaging sequences was defined.
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Outcome reference diagnoses
This was defined as postnatal neuroimaging for continued pregnancies with a surviving child and autopsy
and/or postmortem MRI in cases of termination of pregnancy, stillbirth or neonatal death. Agreement
between ultrasonography, iuMRI and ORD was determined by a two-level review process including a
Multidisciplinary Independent Expert Panel.
Diagnostic accuracy
Participants who underwent iuMRI within 14 days of ultrasonography and for whom an ORD was available
were included in the primary analysis.
In cases with multiple anatomical diagnoses, all had to be reported accurately to be classified as ‘correct’.
We estimated the overall diagnostic accuracy, defined as:
(true positives)/total for ultrasonography and (true positives + true negatives)/total for iuMRI. (1)
This percentage is equivalent to the positive predictive value for ultrasonography. Diagnostic accuracy was
calculated for both gestational age groups (i.e. 18–23 weeks and ≥ 24 weeks) and overall using McNemar’s
paired binomial test.
Diagnostic confidence and clinical impact
Data on diagnostic confidence and the clinical impact of the iuMRI on the counselling and management of
pregnancies were also collected for analysis.
Economic evaluation
This determined whether or not the new intervention (iuMRI) represented good value for money compared
with current practice (ultrasonography alone). Information on participant resource use and outcomes
were analysed to estimate the total additional costs and change in outcomes associated with iuMRI in the
diagnosis of fetal brain abnormalities. In the base case, the economic analysis compares the costs and
outcomes associated with iuMRI with ultrasonography alone. In scenario analyses, iuMRI is compared with
repeat ultrasonography.
Sociological substudy
The aim of the patient and health professional perspectives substudy was to assess the acceptability of
the clinical care package including iuMRI using qualitative and quantitative methods. This substudy drew
on quantitative data from patients and qualitative data from patients and health professionals to assess
the acceptability of iuMRI in the PND for fetal brain abnormality. This mixed-method approach provided an
in-depth analysis of key issues and experiences that matter to those with first-hand knowledge of iuMRI
in practice.
Three data sets (i.e. women’s survey responses, women’s interviews and professionals’ interviews) were
used to explore service user and health professional experiences of engaging with the clinical study. Survey
1 was administered after the fetal medicine consultation following iuMRI (when a management plan had
been made), and survey 2 was administered 3–6 months after the pregnancy outcome. Participants who
responded to survey 2 formed the sampling frame for the qualitative interviews with women, and
purposive sampling identified the pool for health professional interviews.
Add-on study
Recruitment into the MERIDIAN study included only women with fetuses thought to have had brain
abnormalities on ultrasonography, which allowed us to assess the diagnostic accuracy of ultrasonography
and iuMRI in terms of the false-positive rate of detecting a fetal brain abnormality; however, the false-
negative rate cannot be estimated. The add-on study addressed this by recruiting pregnant women
carrying a fetus without any form of abnormality detected on detailed ultrasonography.
SCIENTIFIC SUMMARY
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Participants were recruited via the MERIDIAN study fetal medicine centres and local media advertisement.
Participants could either be referred directly or self-refer. Potential participants were initially screened by
telephone and, if deemed eligible, attended the unit for the iuMRI study where further screening took
place prior to obtaining written informed consent.
The 2- to 3-year follow-up study
Surviving infants were followed up at 2–3 years of age in order to assess three aims: (1) whether or not
additional diagnoses had become apparent, (2) what impact their diagnosis had on their neurodevelopment
(i.e. the accuracy of the prognosis following ultrasonography or iuMRI) and (3) the extent to which these
matter in the specific subgroup of isolated, mild ventriculomegaly (VM), which is the most frequent single
diagnosis. The issue of prognosis is particularly relevant because it is the functional significance of the
diagnosis that matters most to parents rather than the brain abnormality per se. Research has shown that
following the diagnosis of a fetal abnormality, parents want to hear all possible outcomes. Preparation for
the potential outcomes allows families to build a picture of what those difficulties would be like to live with
and helps them consider other aspects, such as the emotional impact and the implications for family life.
The surviving infants who underwent ultrasonography and iuMRI as part of the original study, and whose
families gave consent to be approached about future studies, were screened and the family was approached
to participate in the follow-up study. The first aim involved a review of the child’s medical case notes. This
review allowed us to refine our estimates of diagnostic accuracy based on more recent imaging of the
infant’s brain. We also collected information about follow-up care and life events that may have had an
impact on the child’s development.
For the second aim, parents were asked to complete the Ages and Stages Questionnaire and their children were
invited to participate in a developmental assessment, the Bayley Scales of Infant Development, Third Edition
(BSID3). The assessments were completed either in the local recruiting hospital or, when possible, in the child’s
home. The cognitive, language and motor components were completed.
In addition to the BSID3, or when a face-to-face appointment could not be arranged, a further two
questionnaires were completed: the Strengths and Difficulties Questionnaire and the MERIDIAN Gross
Motor Skills Questionnaire. Following these assessments, each child’s neurodevelopment was classified as
‘normal’, ‘at risk’ or ‘abnormal’.
The third objective was to assess outcomes of children diagnosed with an isolated, mild VM on either
ultrasonography or iuMRI.
Results
Between July 2011 and August 2014, 903 participants (911 fetuses) were recruited to the study. A total of
823 participants (829 fetuses) successfully underwent iuMRI. In total, 64% of all participants attended the
Academic Unit of Radiology at the University of Sheffield for their iuMRI, whereas the remaining 36% of
participants attended one of the five collaborating centres. An ORD was available for 638 out of 829 (77%)
fetuses; of these 638, 570 (89%) had the iuMRI performed within 2 weeks of the referral ultrasonography.
A total of 369 fetuses (65%) were in the 18–23 weeks group (110% of required participants) and 201
fetuses (35%) were in the ≥ 24 weeks group (120% of required participants). The three commonest
ultrasonography diagnoses were isolated VM (306/570, 54%), an abnormality restricted to the contents
of the posterior fossa (83/570, 15%) and failed commissuration (79/570, 14%).
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The overall diagnostic accuracies of ultrasonography and iuMRI were 68% and 93%, respectively, with a
difference of 25% [95% confidence interval (CI) 21% to 29%]. The difference between ultrasonography
and iuMRI increased with gestational age. In the 18–23 weeks group, the figures were 70% for
ultrasonography and 92% for iuMRI (difference of 23%, 95% CI 18% to 27%); in the ≥ 24 weeks group,
the figures were 65% for ultrasonography and 94% for iuMRI (difference of 29%, 95% CI 23% to 36%).
In 386 out of 570 cases (67.7%) both ultrasonography and iuMRI reports were correct, and in 144 out
of 570 cases (25.3%), the ultrasonography report was incorrect but the iuMRI report was correct. There
were two fetuses (0.4%) in whose cases the ultrasonography was correct and the iuMRI was incorrect,
and 38 fetuses (6.8%) in whose cases both the ultrasonography and iuMRI were incorrect.
In total, 198 participants (205 fetuses) were recruited to the add-on study and underwent iuMRI. Although the
results confirm the ability of both ultrasonography and iuMRI to correctly confirm when brain development
of the fetus is normal, there was one instance of a brain abnormality that ultrasonography had not detected
but which was apparent on iuMRI. This highlights the validity of ultrasonography as the primary screening
imaging method for pregnancy.
The 2- to 3-year follow-up study recruited 238 participants, 10 of whom had a new ORD available (five
previously had no ORD and another five had a diagnosis that differed from the original ORD). The overall
difference in diagnostic accuracy was revised to 24.8% (95% CI 21.0% to 28.5%; p < 0.0001), which
was very similar to the original difference of 24.9% and still statistically significant. Analysis of the
developmental data showed minimal difference between ultrasonography and iuMRI in prognosticating
abnormal development. However, iuMRI demonstrated a higher number of correct prognoses in surviving
infants who were developmentally assessed as ‘normal’ or ‘at risk’.
In total, 19 (22%) participants diagnosed with isolated, mild VM on ultrasonography had abnormal
neurodevelopment, with a further 12 (14%) participants being considered ‘at risk’. Among those with
a diagnosis of isolated, mild VM on iuMRI, the incidences were 18% (13/71 of patients) among those
with abnormal neurodevelopment and 13% (9/71 of patients) among those ‘at risk’. None of the children
had received a poor prognosis on either modality. The higher than expected incidence of abnormal
neurodevelopment in some of the children could be attributed to additional brain diagnoses (some of which
the iuMRI detected correctly) other (non-brain) diagnoses and life events (e.g. accidents) leading to delayed
development.
Health economic evaluation
The use of iuMRI resulted in additional costs compared with ultrasonography alone, owing to the cost
of iuMRI itself and the costs from the resulting management decisions. Across a range of scenarios,
the incremental cost was consistently < £600 per participant and the cost per management decision
appropriately changed was always < £3000.
Sociological substudy
Patient acceptability was high, with 97% of questionnaire 1 and 95% of questionnaire 2 respondents
stating that they would have iuMRI as part of their care if they were ever in a similar situation again.
In response to the question about whether or not iuMRI was undertaken at an acceptable time and place,
73% of questionnaire 1 and 68% of questionnaire 2 respondents strongly agreed or agreed. Interviews
suggested that participants were usually ‘information hungry’ and prepared to tolerate significant
discomfort to maximise information prior to decision-making about their pregnancy. Health professional
interviews suggested that iuMRI was broadly acceptable to clinicians and it was consistently noted that
iuMRI was useful as an adjunct to ultrasonography, but not as a replacement.
SCIENTIFIC SUMMARY
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Conclusions
Implications for health care
Our study provides robust data indicating that there would be significant benefits from the routine use of
iuMRI as an adjunct to ultrasonography in the diagnostic pathway for identifying fetal brain abnormalities.
The development of a service that includes iuMRI in the diagnostic pathway may consider providing the
service at a small number of supraregional centres and/or promoting collaboration between radiologists to
form expert panels for cases, provide formal training to improve radiologists’ knowledge base and having
the iuMRI study supervised by the radiologist and the images double reported.
Recommendations for research
l Evaluate the use of iuMRI for cases of isolated microcephaly identified on ultrasonography, as this is
often associated with other brain abnormalities and the severity correlates with the risk of poor outcome.
l Evaluate the use of iuMRI in the diagnosis of fetal spine abnormalities that, to date, have not been well
studied; however, there is a small body of research that suggests that iuMRI may have a role in the
diagnosis of these abnormalities.
l Longer-term follow-up studies of children diagnosed with fetal brain abnormalities to fully assess the
functional significance of the diagnoses.
Trial registration
This trial is registered as ISRCTN27626961.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific and clinical background
Ultrasonography and fetal screening
For many years, fetal imaging with ultrasonography has been the mainstay of antenatal screening
programmes in the UK. However, no imaging method is perfect and various technical factors and physical
limitations of ultrasonography may result in suboptimal images of the fetus being obtained. Suboptimal
images may lead to incorrect diagnoses of structural abnormalities and inaccurate counselling and prognostic
information being given to parents. The fetal brain is a particular area of concern because of the relatively
high frequency of developmental abnormalities (approximately 3/1000 pregnancies).1 A wide spectrum
of neuropathologies can be shown, many of which are associated with serious clinical morbidities.
Development of magnetic resonance imaging
Magnetic resonance imaging (MRI) technology has advanced over the years and because of significant
improvements in spatial and contrast resolution, highly reliable and accurate diagnoses of comparable
pathology can now be made for children. In the 1990s, MRI became a realistic clinical possibility because
of advances in hardware and software. The Academic Unit of Radiology at the University of Sheffield was
a pioneer in this field.2 Clinical magnetic resonance sequences have been developed that do not require
maternal sedation or fetal neuromuscular blockade, allowing several groups, including our own, to believe
that in utero magnetic resonance imaging (iuMRI) may be a powerful adjunct to ultrasonography for
detecting fetal brain abnormalities from 18 weeks’ gestational age.
Magnetic resonance imaging in the literature: diagnostic accuracy
Much of the early literature focused on describing the techniques required to perform iuMRI and relied
on anecdotal cases to compare the additional information provided with ultrasonography alone.3–8 A key
limitation of the majority of the literature was the lack of an outcome reference diagnosis (ORD), with
discrepancies between iuMRI and ultrasonography generally assumed as errors on the part of the latter.
Doing so inevitably leads to bias in favour of iuMRI, and fetal ultrasonography experts have criticised
these studies for the artificially high detection rates for iuMRI that resulted from biased patient selection,9,10
although the extent of this bias is unknown. One such study was published by our group;11 it was a study
of 100 singleton pregnancies in which a fetal brain abnormality was suspected on ultrasonography but for
which optimal diagnostic information had not been obtained. When iuMRI was used in conjunction with
ultrasonography, an increase in diagnostic accuracy of 48% was observed. Although these findings are
clearly prone to the aforementioned bias, they nevertheless demonstrate the potential for a significant
improvement in diagnoses based on ultrasonography and provide an upper limit on the improvement
attributable to the introduction of iuMRI.
Ventriculomegaly (VM) has been the focus of much research in the field of fetal neuroimaging with iuMRI
because of the high prevalence of the finding (1 or 2 out of 1000 pregnancies) following a screening
ultrasonography. In our more recent study, 147 fetuses were diagnosed with isolated VM on ultrasonography,
with high confidence and no technical limitations.12 When iuMRI was performed in these cases, additional
clinically important brain findings were detected in 17% of cases. In a second study of 61 fetuses with cerebral
VM, iuMRI was found to provide more information than ultrasonography in 33% of cases and was able to
identify the cause of the VM in 21% of cases.13 A further study of 185 fetuses with isolated VM in the third
trimester found that 11 out of 185 (5.94%) fetuses had other brain abnormalities.14 The use of iuMRI as an
adjunct to ultrasonography for detecting fetal brain abnormalities has been further supported by recent studies
and systematic reviews;15–18 however, the extent of diagnostic improvement remains unclear.
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Magnetic resonance imaging in the literature: clinical management
The literature on the clinical impact of iuMRI on the counselling and management of pregnancies
complicated by fetal brain abnormalities is limited. One prospective study of fetuses with a suspected central
nervous system abnormality observed that 24 out of 52 (46%) pregnancies were managed differently after
iuMRI,19 and a further prospective study found that the counselling and management of pregnancies were
changed after iuMRI in 49.7% and 13.5% of cases, respectively.20 Our study of fetuses with isolated VM
found significant changes in clinical management after iuMRI in the majority of cases when additional brain
abnormalities were identified. Changes in management more frequently happened between the gestational
ages of 20 and 24 weeks.12 Our group conducted a systematic review and meta-analysis18 including
34 studies, of which only 11 reported on the changes in counselling or management of pregnancies brought
about by the iuMRI. These 11 studies11,21–30 comprised 186 fetuses and changes were observed in 78 (41.9%)
cases. Our review concluded that the clinical impact of iuMRI through changes to the counselling and
management of pregnancies remains unclear owing to being reported in only a small proportion of studies.
It is important to recognise that iuMRI is unlikely to be incorporated as a routinely used diagnostic tool for
pregnancies. Constraints on resources, both financial and human, mean that iuMRI is likely to be used
selectively, in combination with ultrasonography and other tests, for fetuses that are considered to be at a
high risk of severe developmental abnormalities. The term ‘high risk’ can be interpreted in many different
ways and may legitimately incorporate genetic features and/or a previous pregnancy with a fetal abnormality,
but the most obvious risk factor is when the fetus has an abnormality diagnosed by the ultrasonography.
Therefore, the project set out to determine whether or not adding iuMRI to the usual diagnostic pathway
helps to improve the diagnosis and appropriate management of fetuses with a suspected brain abnormality
based on previous ultrasonography.
Rationale for the MERIDIAN study
In the light of the uncertainties surrounding the extent of improvement in diagnostic accuracy associated
with iuMRI as an adjunct to ultrasonography and its impact on clinical management and counselling,
a large prospective study with a representative population of fetal brain abnormalities was required to
inform clinical practice in the UK.
For a full evaluation of the use of iuMRI in clinical practice, it was essential that patient acceptability was
assessed. New technologies in fetal medicine can raise ethical and social dilemmas for the patients involved
and, therefore, the views of patients and their partners are important when considering the implementation
of iuMRI.31 A survey of 227 women who were not pregnant but underwent MRI suggests that it is perceived
positively in terms of comfort and impact on care;32 however, other studies have shown a potential
association between MRI and anxiety33,34 and that patients may find it less acceptable than ultrasonography.35
A study published in 2007 found that overall satisfaction with the prenatal diagnosis (PND) is high in women
carrying a fetus with a congenital abnormality.36 Satisfaction with prenatal care has been found to be
associated with the attitude of the medical staff,37,38 the amount of information provided38 and the patient’s
involvement in decision-making.37 Data on the use of MRI in fetomaternal medicine are limited but do
suggest that MRI may cause additional distress, especially in women for whom the prognosis for the fetus is
poor,39,40 and can lead to more anxiety than that of undergoing an ultrasonography.41
The research described in this report was a logical extension of our previous work and essential in
providing definitive data on the diagnostic accuracy, clinical impact and acceptability of iuMRI in clinical
practice in the UK.
Study aims and objectives
The aim of the research was to assess iuMRI as a technology to aid the PND of fetal developmental brain
abnormalities.
INTRODUCTION
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The objectives were to:
l assess diagnostic accuracy of iuMRI compared with antenatal ultrasonography through the –
¢ measurement of the diagnostic accuracy of antenatal ultrasonography alone (i.e. prior to iuMRI)
relative to an ORD (postnatal imaging or postmortem examination)
¢ measurement of the diagnostic accuracy of iuMRI (following antenatal ultrasonography) relative to
an ORD (postnatal imaging or postmortem examination).
l assess the clinical effectiveness of iuMRI through the –
¢ change in clinical diagnostic confidence before and after an iuMRI study
¢ effect of iuMRI on prenatal counselling and management intent.
l assess the acceptability of the clinical care package with the use of MRI included via quantitative and
qualitative psychosocial measures
l undertake an economic analysis to evaluate the cost consequence of the use of iuMRI scans.
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Chapter 2 Methods
This report is concordant with the Standards for the Reporting of Diagnostic Accuracy Studies (STARD)guidelines updated in 2015.42
Study design
The MERIDIAN study was a prospective, multicentre, observational cohort study.
Participants and eligibility criteria
Participants were pregnant women aged ≥ 16 years and carrying a fetus with a suspected brain abnormality
on detailed ultrasonography as diagnosed by a fetal medicine consultant. The potential participants were
screened against the following criteria.
Inclusion criteria
A participant was eligible for the trial if the following criteria were met:
l The participant had an ongoing singleton or multifetal pregnancy of ≥ 18+0 weeks’ gestation by
ultrasonography dating.
l The participant was thought to be carrying a fetus with a brain abnormality following detailed specialist
ultrasonography examination.
Exclusion criteria
A participant was excluded from the trial if any of the following criteria were met:
l The participant was unable to give informed consent.
l The participant had a cardiac pacemaker, had an intraorbital metallic foreign body or recently had
surgery with metallic sutures or an implant.
l The participant had previously experienced or is likely to suffer from severe anxiety or claustrophobia in
relation to a MRI examination.
l The participant was unable or unwilling to travel to Belfast, Birmingham, Leeds, Newcastle, Nottingham
or Sheffield for specialist MRI.
l The participant was unable to understand the English language (except where satisfactory translation
services were available).
l The participant was aged < 16 years.
Participant identification and recruitment
Potentially eligible participants were identified from 16 participating fetal medicine units that acted as
research sites. Following a detailed ultrasonography examination that confirmed the suspicion of a fetal
brain abnormality, consecutive patients were screened by the referring clinician or local research midwife
according to the inclusion and exclusion criteria listed above. Written informed consent was obtained after
the confirmation of eligibility and after the patient had been given the opportunity to consider participation
and ask any questions. Data collection and management provides details of the referral process once
consent had been obtained.
Test methods
Detailed ultrasonography
The protocol did not specify the exact requirements for the ultrasound technique. All ultrasonographies
were performed by fetal medicine consultants working within the UK NHS who reported the suspected fetal
brain abnormalities using nomenclature from the ViewPoint™ antenatal ultrasonography-reporting software
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(GE Healthcare, Chalfont St Giles, UK). Recruiting clinicians were asked to record their certainty of the
diagnosis alongside each brain abnormality using a five-point Likert scale43 as follows: very unsure (10%
certain), unsure (30% certain), equivocal (50% certain), confident (70% certain) and highly confident
(90% certain). Following the detailed ultrasonography, participants underwent iuMRI at one of the
six collaborating sites.
In utero magnetic resonance imaging
Magnetic resonance imaging protocols could not be matched exactly across all the scanning sites because
of the different manufacturers of MRI systems being used. However, all examinations were performed at
1.5 T and there was an absolute requirement to obtain T2-weighted images of the fetal brain in the three
orthogonal planes using the best, ultrafast method available (maximum slice thickness of 5 mm) and a
T1-weighted ultrafast sequence in at least one plane (usually axial).44 The attending radiologist could add
further sequences to the case as appropriate to obtain thorough diagnostic information. To reflect clinical
practice, the radiologist was aware of the diagnoses and the level of certainty made by the fetal medicine
consultant prior to the iuMRI being performed and had access to the full clinical ultrasonography report.
The radiologist was required to comment on each brain abnormality diagnosed by the ultrasonography.
If the radiologist did not agree with a diagnosis made by ultrasonography then ‘diagnosis excluded’ could
be used and an additional diagnosis could be added if appropriate. The radiologists were also required to
indicate their certainty for each diagnosis using the same five-point Likert scale43 as the ultrasonography
assessment.
Data collection and management
After the detailed ultrasonography performed by a fetal medicine consultant, participants were recruited
into the study and referred for an iuMRI scan at the Academic Unit of Radiology at the University of
Sheffield or at one of the five collaborating sites (Belfast, Birmingham, Leeds, Newcastle or Nottingham).
The referral form was completed by the referring clinician and a copy was sent to the MRI site through the
standard referral pathway. The referral form collected details of the type of brain abnormalities suspected,
confidence of diagnosis and the prognosis for the outcome of the pregnancy. It also collected data on whether
or not termination of pregnancy (TOP) was discussed or offered because the abnormalities on ultrasonography
were sufficient to consider that option under Ground E of the Abortion Act 1967 [section 1(1)(d) – substantial
risk of serious mental or physical disability].45
The reporting radiologist completed a similar iuMRI feedback form and was required to comment on all
suspected diagnoses along with their diagnostic confidence. Additional diagnoses could be added or
excluded when required, as detailed previously.
Following the iuMRI examination, the participant attended a follow-up appointment with the referring fetal
medicine consultant. The iuMRI report was available to the clinician at this appointment and the clinical
feedback form was completed. The purpose of the clinical feedback form was to assess the changes in
the clinical management and prognosis of the pregnancy after the iuMRI. In addition, further details of
diagnostic and prognostic information were collected, along with the management plan for the pregnancy.
From a diagnostic perspective, participants were asked if iuMRI had provided additional information and,
if so, if the ‘new’ pathology was visible when the clinician performed a follow-up ultrasonography. To assess
the prognosis, the clinicians were asked if iuMRI had changed the prognostic information given to the
patient and to regrade the prognosis in the light of the iuMRI information using the same five categories
used at referral. The clinicians also recorded whether or not TOP had been discussed or offered. Finally,
the clinicians were requested to state if the iuMRI had altered the counselling and management of the
pregnancy and, if so, what the degree of change was.
The pregnancy was then followed up for up to 6 months post delivery and data were collected on the
outcome of the pregnancy, as described in Statistical analysis. The outcome data form was used to collect
relevant information.
METHODS
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Statistical methods
Sample size
A recruitment target of 750 pregnant women was set, from whom we anticipated 504 fetuses would have
a complete ORD. It was assumed that 336 of these fetuses would be 18 to < 24 weeks’ gestation at the
time of iuMRI. A diagnostic accuracy of 70% in ultrasonography46–54 and 80% in iuMRI was assumed,
and it was further assumed that iuMRI would correctly contradict the ultrasonography in 20% of cases and
erroneously contradict the ultrasonography in 10% of cases. A sample size of 336 participants allowed the
confidence interval (CI) for the difference to be estimated to within a standard error of 3%, and ensured
that any improvement in diagnostic accuracy of < 5% with 90% power and at 85% confidence could be
ruled out. A change of 5% was deemed to be clinically important as it would lead to changes in fetal
prognostic information and management intent in ≈5% of all cases. A total recruitment target of
504 fetuses with complete ORDs was set, assuming that one woman with a fetus of > 24 weeks’ gestation
would be scanned for every two fetuses in the 18 to < 24 weeks’ gestation age group.
Statistical analysis
The diagnostic strategies are referred to as ultrasonography (diagnostic ultrasonography alone) and iuMRI
(iuMRI following diagnostic ultrasonography).
Statistical analysis was conducted using R version 3.3.3 (The R Foundation for Statistical Computing,
Vienna, Austria) and Stata® version 14 (StataCorp LP, College Station, TX, USA).
Analysis populations
Owing to the nature of the study, some outcomes were collected at the mother level (e.g. other diagnostic
tests, participant feedback). In some instances, more than one record was available for the same mother
because of repeat ultrasonography and/or MRI scans, multiple pregnancies or repeat pregnancies.
The denominator used is outlined throughout the methods and the results.
The primary analysis of diagnostic accuracy was undertaken on all fetuses for which a successful iuMRI
scan had been undertaken within 2 weeks of their diagnostic ultrasonography and for whom an ORD was
available. The 2-week time window was chosen so as to minimise the bias arising because of the evolving
brain and, in some cases, the evolving diagnosis. A long delay between scans may favour iuMRI because
diagnoses may become more apparent as the brain matures. Secondary analyses of diagnostic accuracy
were undertaken on fetuses:
l with successful ultrasonography and iuMRI scans (irrespective of their timing) and with ORD
l with successful ultrasonography and iuMRI scans undertaken within 2 weeks, with or without ORD
l with successful ultrasonography and iuMRI scans, irrespective of timing and availability of ORD.
For all these analysis populations, the analyses were based on the first diagnostic ultrasonography and
iuMRI scan unless otherwise stated. When groups were large enough, analyses were conducted on
different subsets (i.e. analysis populations) of the data. Details of which population was assessed for each
outcome are described in this section.
Within each of these populations, when appropriate, analyses were repeated on the following subgroups:
l first pregnancies (i.e. excluding any pregnancies subsequent to their first within the MERIDIAN study)
l singleton pregnancies
l first and singleton pregnancies
l repeat pregnancies
l repeat scans (i.e. second ultrasonography and iuMRI for the same pregnancy).
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Finally, analyses of diagnostic accuracy were intended to be undertaken separately for pregnancies at
< 22 weeks’, 22–24 weeks’ and > 24 weeks’ gestational age at the time that the MRI scan was performed.
However, these three categories were condensed to 18–24 weeks’ and > 24 weeks’ gestational age
because of small numbers in the first two subgroups.
Summaries and analyses of diagnostic confidence were undertaken on the primary analysis population and
on all fetuses undergoing scans. Summaries and analyses of changes in prognosis and management were
undertaken on all mothers undergoing both scans. Summaries of safety and adverse outcomes were
undertaken separately for all mothers undergoing a scan and all fetuses undergoing a scan.
Approach/consent
The number of mothers who were approached and consented is presented in the STARD flow diagram
(Figure 1). When given, the reasons for not offering iuMRI and reasons for not consenting to join the
study have been presented.
Potential participants
(n = 1101; 1109 fetuses)
Completed iuMRI
(n = 823; 829 fetuses)
Incomplete
(n = 191;a 191 fetuses)
Complete
(n = 633;a 638 fetuses)
> 2 weeks after referral
(n = 68; 68 fetuses)
• 2 – 3 weeks, n = 40
• 3 – 4 weeks, n = 12
• > 4 weeks, n = 16
• Incomplete/inadequate
   reference diagnosis available
   (n = 180) and losses to follow-up
(n = 9) (176 had iuMRI  
   < 2 weeks from referral)
• Withdrawals after iuMRI and
   before outcome data were
   collected, n = 2
Eligible participants
(n = 903; 911 fetuses)
Reference standard
(< 2 weeks from referral)
(n = 565; 570 fetuses)
Completed cases – fetal
medicine management
decision made
(Gestational age at time of iuMRI)
Ineligible/declined participants
(n = 198; 198 fetuses)
Did not complete iuMRI
(n = 80; 82 fetuses)
• 24 weeks, n  =  369
• ≥  24 weeks, n = 201
• iuMRI offered but declined, n = 112
• iuMRI not offered, n = 86
• iuMRI referrals/examinations
   cancelled, abandoned or
   incomplete, n = 46; 48 fetuses
• Withdrawals before iuMRI, n = 34
<
FIGURE 1 Flow diagram to show the pathway and recruitment numbers in the MERIDIAN study. a, One participant
carried two fetuses, only one of which had an ORD. Therefore, the participant is counted in both the incomplete
and complete participant groups.
METHODS
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Data completeness
The number of participants who completed data collection at each stage of the study is presented in the
STARD flow diagram (see Figure 1). This included the number of participants who completed iuMRI, the
number of those with a reference diagnosis available, the number of participants who withdrew or were lost
to follow-up, the number of complete cases and at what gestational age a management decision was made.
Characteristics
The following summaries were presented for all mothers who entered the trial:
l iuMRI centre
l maternal age
l gestational age at initial approach
l whether the pregnancy was single or multiple
l dominant diagnosis of brain abnormality based on screening ultrasonography.
The number and percentage in each category were presented for categorical variables and appropriate
summary statistics were presented for continuous variables. These figures were presented by population
groups 1–3 (i.e. primary, ORD unavailable and excluded).
Diagnostic accuracy
Diagnostic accuracy was defined as the percentage of true-positive diagnoses for ultrasonography and the
percentage of true-positive and true-negative diagnoses for iuMRI. This percentage is equivalent to the
positive predictive value (PPV) for ultrasonography screening.
Primary analysis (agreement)
For the purposes of our trial, the ORD was defined as follows:
l For delivered neonates, the reference used was the neuroanatomical diagnosis recorded in the child’s
clinical notes at 6 months of age, based on all available follow-up imaging (i.e. postnatal MRI,
computed tomography when performed for clinical purposes or postnatal transcranial ultrasonography).
The exceptions were (1) cases of isolated VM, for which a resolved diagnosis made via third trimester
ultrasonography was acceptable, and (2) isolated microcephaly, for which clinical examination was
sufficient.
l For terminated fetuses, the reference diagnosis was based on postmortem data (i.e. autopsy and/or
postmortem MRI when available).
Agreement between the PND and the reference diagnosis was determined by a two-level review process.
The first-level review was carried out by one of two neuroradiologists, who were not associated with the
MERIDIAN study. Their role was to determine whether or not a full review by the Multidisciplinary
Independent Expert Panel (MIEP), described below, was required, based on the ORD. A full review by the
MIEP was required unless the following criteria were met: (1) there was complete and unequivocal agreement
between the anatomical findings on ultrasonography, iuMRI and the ORD, or (2) VM was the only finding
described on both ultrasonography and iuMRI examinations, but the size of the ventricles had returned to
normal as shown on ultrasonography later in pregnancy or on neonatal imaging. The latter was counted as
agreement because the enlargement of ventricles can commonly resolve spontaneously during pregnancy.55
The second-level review (by the MIEP) consisted of three NHS consultants (i.e. a neuroradiologist, a fetal
and maternal medicine specialist and a paediatric neurologist) from a single centre, independent of the
MERIDIAN study. The MIEP was provided with the diagnostic results for each fetus and members were
blinded to knowing if it was an ultrasonography or iuMRI report. The MIEP was responsible for deciding
whether or not each report agreed completely with the ORD (all listed diagnoses correct) and, when it was
judged that there was disagreement between ultrasonography and iuMRI, which one indicated the more
severe pathology. The MIEP could request additional information if required to assess a case and could be
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given access to the full report. In the small number of cases when the full clinical report was required to
assess a case, blinding was no longer possible. The research team at the Sheffield Clinical Trials Research
Unit (CTRU) was able to unblind the results for the MIEP for analysis purposes.
The number of fetuses diagnosed, diagnostic accuracy (i.e. the proportion of fetuses correctly diagnosed)
and its 95% CIs were presented for ultrasonography and iuMRI in the primary analysis population by
gestational age (i.e. 18–23 weeks and ≥ 24 weeks). The differences in diagnostic accuracy between
ultrasonography and iuMRI and the 95% CIs were presented along with associated p-values calculated
using McNemar’s test.
Missing data
To examine the effect of missing data on the primary analysis, two sensitivity analyses were undertaken
on the subset of fetuses whose iuMRI was undertaken within 2 weeks of their ultrasonography. The first
sensitivity analysis was to assume that outcome data are missing at random,56 which means that the
reason for missing data can be predicted based on measurable covariates. A bivariate Probit analysis
was undertaken, in which the two outcomes (ultrasonography correct, iuMRI correct) were modelled with
the same covariates for both outcomes but with their coefficients allowed to differ. The covariates were
chosen based on their association with missingness and diagnostic accuracy. The predicted probabilities
of ultrasonography and iuMRI being correct, conditional on their covariates, were then derived for fetuses
both with and without ORD; these predictions are unbiased under the assumption of data missing at
random.57 The difference between ultrasonography and iuMRI was calculated as the difference between
the two predicted probabilities, with a 95% CI derived using bootstrap methods with 10,000 simulations.
The second sensitivity analysis estimated the impact of missing data worst-case assumptions about the
diagnostic ability of iuMRI. The differences in diagnostic accuracy between ultrasonography and iuMRI
were calculated under both assumptions.
Secondary analysis of agreement
Repeat in utero magnetic resonance imaging
The primary analysis was repeated using repeat iuMRI scans. When mothers had more than one repeat
scan, the latest iuMRI report was used.
Anatomical subgroup analysis
The primary analysis was repeated on three subgroups of the primary analysis population. These subgroups
were defined by the diagnosis at ultrasonography.
Definition of subgroups
Isolated ventriculomegaly
Cases were included in this group if they were diagnosed with isolated VM as the only finding on
ultrasonography. No other brain abnormality was diagnosed on ultrasonography in this subgroup.
These cases were further categorised into three types based on the largest trigone on ultrasonography:
mild (10–12 mm), moderate (13–15 mm) and severe (≥ 16 mm).
Posterior fossa
Cases were included in this group if they were diagnosed with abnormalities confined to the posterior
fossa (with or without associated VM) on ultrasonography. These cases were further divided into two
specific diagnosis categories: those involving the brain stem or cerebellum (i.e. parenchymal abnormalities
including Dandy–Walker spectrum malformations, Chiari II malformation and cerebellar hypoplasia) and
those involving cerebrospinal fluid (CSF)-containing lesions (i.e. enlarged cisterna magna, Blake’s pouch
cyst and arachnoid cysts). In the first ‘overall’ group, correctness was judged by the presence of any
diagnosis of isolated posterior fossa abnormality on ORD. For a diagnosis in the two subsequent groups
to be deemed correct, an ORD included the same specific diagnosis described above.
METHODS
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Failed commissuration
Fetuses were included in this group if they were diagnosed with either agenesis or hypogenesis of the
corpus callosum (CC) as the sole diagnosis or in conjunction with VM on ultrasonography only. These fetuses
were further categorised into their specific diagnosis category of ‘agenesis of the CC’ or ‘hypogenesis of the
CC’. In the first ‘overall’ group, correctness was judged only by either the presence of CC abnormality or
the absence of another brain lesion. For a diagnosis in the two subsequent groups to be deemed correct, an
ORD included the same specific diagnosis (i.e. ‘agenesis of the CC’ or ‘hypogenesis of the CC’), regardless of
any other brain lesion.
Subgroup analysis
Fetuses were categorised into one of the three anatomical subgroups described above if they were diagnosed
on ultrasonography. The number of fetuses diagnosed within these groups for whom the diagnoses were
correct on ORD were used to calculate the diagnostic accuracy of ultrasonography. The diagnostic accuracy
of iuMRI was calculated on the same subgroup as defined using ultrasonography diagnosis.
Diagnostic accuracy was also calculated for the subgroups within each of the three anatomical subgroups.
The number of incorrectly diagnosed cases on ultrasonography and iuMRI were presented along with the
difference in diagnostic accuracy and its associated 95% CI and p-value from McNemar’s paired test.
Diagnostic confidence
Diagnostic confidence was defined for each diagnosis on a five-point scale (10% = very unsure to
90% = highly confident) on ultrasonography. Diagnostic confidence by iuMRI is similar but has one
addition (‘diagnosis excluded’). Ultrasonographers were also asked which method of ultrasonography was
used and which factors contributed to low confidence in the diagnosis. High confidence was defined as a
score of 70% or 90% and low confidence was defined as a score of 10%, 30% or 50%.
The numbers of missed diagnoses (false negatives) have been presented by confidence category following
ultrasonography alone and ultrasonography plus MRI for the primary population. Changes in confidence
were categorised into five categories: no change, ultrasonography with more confidence by one category,
ultrasonography with more confidence by two or more categories, MRI with more confidence by one
category and MRI with more confidence by two or more categories. The number and percentage of fetuses
in each category were presented. A Wilcoxon signed-rank test was carried out to compare the difference
in confidence on ultrasonography with the difference in confidence on MRI.
Diagnostic accuracy and diagnostic confidence
A score-based weighted-average analysis was conducted58 that combined changes in diagnostic accuracy,
diagnostic confidence and management to provide a summary measure of the clinical impact attributable
to iuMRI. The scores were defined for each individual diagnosis by its presence/absence and the assigned
diagnostic confidence. The scores for the overall impact (i.e. at the level of the fetus rather than the
condition) were assigned by the expert panel on a case-by-case basis. The null hypothesis, that the impact
scores are zero (no impact), was tested by a one-sample t-test in the primary analysis population. The
mean, standard deviation (SD) and 95% CI of difference in confidence was presented overall and also by
anatomical subgroup.
Clinical impact
Change in prognosis
The prognosis was defined at the pregnancy (mother) level, rather than the fetal level. Following
ultrasonography, the prognosis was recorded by using a four-point scale of severity (i.e. poor, intermediate,
favourable and normal) and if the ultrasonographer was unable to offer a prognosis on the basis of the scan
this was recorded as not known. The same process was undertaken following iuMRI and the two were
compared in a 5 × 5 contingency table, with the number and percentage of pregnancies in each group
presented.
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When a fetus had a known prognosis for both ultrasonography and ultrasonography plus iuMRI, the
change in prognosis category was categorised as no change, more favourable with ultrasonography
by one category, more favourable with ultrasonography by two or more categories, more favourable
with iuMRI by one category or more favourable with iuMRI by two or more categories. The number and
percentage of fetuses in each of these categories were presented and their distribution compared using
a Wilcoxon signed-rank test.
When a prognosis was unknown on either ultrasonography or ultrasonography plus iuMRI, these fetuses were
presented separately and further grouped into nine categories: no change, not known to known (i.e. poor,
intermediate, favourable or normal) or known (poor, intermediate, favourable or normal) to not known.
Counselling and management of pregnancy
In 2012, the study opened to recruitment in Belfast. Under Northern Irish law, TOP is permissible only in very
specific circumstances that are more limited than in the rest of the UK or Western Europe. The incidence of
TOP and the grounds for it being performed are, therefore, likely to be very different between Belfast and
other centres, and findings in Belfast would not be expected to generalise to other study centres. Therefore,
the main summaries of counselling and management included all mothers who completed iuMRI but
excluded patients recruited from Belfast.
Following both ultrasonography and MRI, the clinician was asked to record if they discussed TOP with the
mother, offered TOP to the mother, or neither. If TOP was offered, the clinician recorded whether or not
this was due to there being a substantial risk of disability. The clinician was also asked whether or not MRI
changed their counselling from ultrasonography only to ultrasonography plus iuMRI. A cross-tabulation of
counselling categories (i.e. TOP not discussed, TOP discussed but not offered, TOP discussed and offered,
TOP offered based on substantial risk of disability) on ultrasonography and counselling on ultrasonography
plus iuMRI has been presented in Appendix 9.
Following iuMRI, the chosen management plan was recorded (i.e. continued pregnancy, continued
pregnancy with further imaging, fetal demise, termination, unable to decide). If further imaging was used,
the type was recorded (i.e. ultrasonography, iuMRI or both) and a rating of iuMRI’s contribution was
recorded (i.e. none, minor, significant, major, decisive). The number and percentage of mothers in each
category has been presented.
Magnetic resonance imaging errors
The number of iuMRI errors and the total number of scans were presented by central and non-central
reporters for the primary analysis population. The overall error rate (number of errors/total number
of scans) was calculated by central and non-central reporters along with the difference in error rate.
Errors were also assessed in relation to their chronological order within the study (i.e. errors within the
first 25 scans, errors in scans 26–50, errors in scans 51–75 and errors thereafter).
Patient acceptability
Participants were invited to complete two surveys to evaluate their satisfaction with the care received.
The methods and results relating to this are outlined in Chapter 4.
Patient outcomes
Outcome of pregnancy
The outcome of pregnancy was categorised and the number and percentage of fetuses that were
categorised as livebirth, perinatal, neonatal, infant death, stillbirth, spontaneous intrauterine fetal demise or
terminated have been presented by each of the four analysis populations described in Statistical analysis.
METHODS
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The Hospital Anxiety and Depression Scale questionnaire
The Hospital Anxiety and Depression Scale (HADS) questionnaire was used to measure anxiety and depression,
each being scored from 0 to 21, with higher scores indicating greater severity.59 Prorating was used for
partially answered questionnaires, provided that at least four of the seven questions within the domain had
been answered. The change from survey 1 to survey 2 was calculated among mothers who completed both
surveys and the difference was tested using the Wilcoxon signed-rank test.
Mothers were also classified separately for anxiety and depression as ‘in the normal range’ (0–7.5), ‘cause
for concern’ (7.51–10.5) or ‘probable clinical case’ (> 10.5). The change in response categorisations from
survey 1 to survey 2 was analysed using McNemar’s test generalised to a three-point scale (also known as
Bowker’s test for symmetry).
Mean, SD, median, interquartile range (IQR) and minimum and maximum values were presented for anxiety
and depression scores from each survey. The number and percentage of mothers in each category were
also presented. When mothers completed both surveys, the mean, SD, median and IQR of the difference
between scores was presented. The difference in the percentage by category for those completing both
surveys was also presented.
Additional tests and resource use
When additional tests were used, the number and percentage of each type of test was presented for the
whole cohort. The median and IQR of additional tests per mother were presented. The impact of these
additional tests was presented by category.
A summary of clinic visits has not been presented because of inconsistent reporting; however, full resource
use has been reported as part of the health economic evaluation.
Ultrasonography technical factors
The type of ultrasonography used was recorded (i.e. two or three dimensional) and the number and
percentage of mothers were presented. Technical factors affecting the confidence of the sonographer
(e.g. high body mass index of the patient, fetal position, oligohydramnios or other) were also reported.
Safety analysis
Adverse events (AEs) and serious adverse events (SAEs) were reported separately for all mothers and
fetuses.
The number and percentage of mothers and fetuses experiencing an AE have been presented separately.
Owing to the small number of AEs, they were reported descriptively by the participants. AEs related to
the iuMRI procedure were reported separately. The AEs have also been presented by the type of AE and
whether or not it was attributable to the procedure. The same summaries have been presented for SAEs.
Descriptions of all AEs and SAEs have been presented in Table 20.
Missing data
When data have not been recorded, ‘not reported’ has been included in relevant summary tables
throughout the report (see Tables 15 and 16).
Health economic methods
Background
Introducing iuMRI to diagnose fetal brain abnormalities during pregnancy will introduce additional direct
costs to the NHS. However, iuMRI may also lead to cost savings in other areas and may improve outcomes.
Therefore, there is a need for health economic analysis to assess the cost-effectiveness of iuMRI in the
diagnosis of fetal brain abnormalities.
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Overview
This section considers an economic evaluation based on data collected as part of the MERIDIAN study.
Information on resource use and outcomes is analysed for participants in the MERIDIAN study, to estimate
the total additional costs and the change in outcomes associated with iuMRI in the diagnosis of fetal brain
abnormalities.
A health economic analysis involves the comparison of two or more alternative courses of action. One of
the comparators should be usual care, so that it can be determined whether or not the new intervention
represents good value for money compared with current practice. The MERIDIAN study is not a randomised
controlled trial with an intervention and a comparator, but instead it reports the diagnostic accuracy of
iuMRI. In the base case, the economic analysis compares the costs and outcomes associated with iuMRI
with those of single ultrasonography. In scenario analyses, iuMRI is compared with repeat ultrasonography.
Costs
The base-case analysis considers the costs incurred until the end of pregnancy. This includes costs of
delivery for continued pregnancies and costs of termination for terminated pregnancies. Scenario analyses
consider the exclusion of costs of delivery and termination.
In the base-case analysis, resource use is calculated from the analysis of MERIDIAN study data. Costs in the
analyses include costs of ultrasonography scans, iuMRI scans, consultations, further investigations and TOP.
Resource use is multiplied by unit costs to calculate total costs. Unit costs considered in the base case are
shown in Appendix 1. All costs are reported for 2016; when necessary, costs were inflated using the Unit
Costs of Health and Social Care 2016 by Curtis and Burns.60
There are several NHS costs available for TOP.61 In almost all cases within the study (96.1%), gestational age
at termination was > 20 weeks, so ‘Medical or surgical termination of pregnancy, over 20 weeks’ gestation’
(MA20Z) appears to be the most appropriate classification. Clinicians advised that terminations would be
planned and so elective inpatient costs are appropriate. Clinicians further advised that the majority of women
would stay in hospital for 2 days, with 10% of women staying in hospital for longer and none staying
for < 2 days. The elective inpatient cost of £1232 per patient corresponds to an average length of stay of
1.26 days, so additional excess bed-days were included (costed at £277 per day), such that the total average
stay was 2.1 days, costing £1581 per patient. From the NHS costs it is unclear whether or not the total costs
include feticide, which clinicians advised would be required for gestational ages of > 21+6 weeks.61 Clinicians
advised that the cost of feticide would be similar to the cost of a specialised fetal diagnostic procedure,
which is £366 on average per procedure (NZ72Z). The NHS reference cost for an elective inpatient medical
termination at 14–20 weeks’ gestation (MA18D) would not include feticide and is £322 less than the
equivalent cost category for > 20 weeks’ gestation.61 This suggests that the cost for termination at > 20 weeks’
gestation already includes a feticide cost (at least for a proportion of admissions). Therefore, we used our
cost for termination at 20 weeks’ gestation for a 2.1-day stay for terminations that involved a feticide. For
validation, clinicians advised that this cost should be similar to the cost of a normal delivery, which costs
an average of £1643 per procedure (NZ30C0).61
For terminations that did not require feticide, we assumed that a 2.1-day stay cost for 14–20 weeks’
gestation was appropriate, which was calculated as £1136.
Scenario analysis additionally considers the inclusion of costs borne by participants, such as travel (valued
at £0.45 per mile as per UK Government expenses62) and time (valued using earnings by age taken from
the 2016 Annual Survey of Hours and Earnings63). A further scenario analysis includes the long-term costs
associated with caring for children born with disabilities.
Costs for the pathway with iuMRI and with ultrasonography alone are reported separately for participants
who had and for those who did not have TOP. Resource use differs for participants who have TOP, there is
the cost of TOP itself, and further imaging or consultation costs may differ. The proportion of participants
METHODS
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having a TOP is required to calculate the total cost of iuMRI and ultrasonography. The proportion of
participants having a TOP following iuMRI was observed, but because the MERIDIAN study was not a
comparative trial, the proportion of TOP for ultrasonography alone was not directly available and had to
be estimated (see Analyses).
Outcomes
Health economic analysis from an NHS perspective typically uses the quality-adjusted life-year (QALY) as
the measure of benefit. However, the relevance of the QALY in iuMRI is questionable as decision-makers
may be uncomfortable with the use of QALYs to reflect the value of an unborn child. Furthermore,
incorporating QALYs for unborn children may lead to the perverse situation whereby the intervention with
the lowest rate of true-negative detections maximises QALY gain.
In utero magnetic resonance imaging is intended to provide information, additional to ultrasonography,
that is of value to parents and treating clinicians. This additional information is of value only if it is both
accurate and leads to changes in the management of pregnancy. Therefore, the primary outcome selected
for the economic analysis is ‘appropriate management decisions’. The decision for an individual mother is
classified as appropriate if the revised decision is consistent with the presence or otherwise of neuro-
developmental abnormalities at birth or postmortem. Therefore, appropriate management decisions are:
l TOP advised following ultrasonography, continuation of pregnancy advised following iuMRI.
Continuation of pregnancy chosen and infant exhibits no abnormalities at birth.
l TOP advised following ultrasonography, continuation of pregnancy advised following iuMRI. TOP chosen
and the fetus exhibits no abnormalities at postmortem.
l Continuation of pregnancy advised following ultrasonography, TOP advised following iuMRI.
Continuation of pregnancy chosen and infant exhibits abnormalities at birth.
l Continuation of pregnancy advised following ultrasonography, TOP advised following iuMRI. TOP chosen
and the fetus exhibits abnormalities at postmortem.
In the base-case and scenario analyses, the reported cost-effectiveness estimate is the cost per management
decision appropriately revised. The proportion of management decisions appropriately revised is calculated
by cross-tabulating the number of cases in which iuMRI was correct with the number of cases in which
iuMRI changed the diagnosis. The proportion of management decisions appropriately revised is equal to the
number of cases in which iuMRI was correct and iuMRI changed the diagnosis, divided by the total number
of cases for which both outcomes were available.
Analyses
All analyses were conducted using Stata to calculate resource use and outcomes, and data were analysed in
Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) to calculate total costs and cost-effectiveness.
All analyses used completed cases with the exception of the imputed missing data, which used bootstrapping
in Stata. The analyses conducted are summarised in Table 1 and explained further in the sections that follow.
Base case, scenario 1 and scenario 2
The MERIDIAN study recorded if participants were offered a TOP following the ultrasonography, if participants
were offered a TOP following the iuMRI and if participants had a TOP. In the base-case analysis, the
proportion of participants who had a TOP is used for iuMRI and the proportion of participants who had a
TOP following ultrasonography alone is assumed to be equal to the proportion of participants who were
offered TOP following ultrasonography. This approach may overestimate the proportion of participants
having a TOP following ultrasonography alone. After iuMRI, 189 out of 537 participants were offered a
TOP but only 58 participants had a TOP. Therefore, two further scenarios are considered. In scenario 1,
the proportion of participants having TOP following iuMRI is assumed to be the proportion of participants
who were offered TOP following iuMRI. In scenario 2, the proportion of participants having TOP following
ultrasonography is the proportion of participants offered TOP following ultrasonography adjusted by the
proportion of those who were offered TOP following iuMRI who had a TOP.
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TABLE 1 Summary of analyses
Scenario Population iuMRI: proportion of TOP Ultrasonography: proportion of TOP Effectiveness data Costs included
Base case All women with
outcomes
Proportion of women who
had TOP
Proportion of women offered TOP after
ultrasonography
Proportion of cases for which iuMRI
was correct and changed the prognosis
NHS costs only
Scenario 1 Same as base case Proportion of women
offered TOP after iuMRI
Same as base case Same as base case Same as base case
Scenario 2 Same as base case Same as base case Proportion of women offered TOP after
ultrasonography, multiplied by the
proportion of women offered TOP after
iuMRI who had TOP
Same as base case Same as base case
Inclusion of participant-
borne costs 1
Same as base case Same as base case Same as base case Same as base case NHS costs plus costs for
time and mileage
Inclusion of participant-
borne costs 2
All women with
outcomes whose
total mileage was
< 40 miles
Same as base case Same as base case Same as base case NHS costs plus costs for
time and mileage
Gestational age at iuMRI
of < 22 weeks
Gestational age of
< 22 weeks
Same as base case Same as base case Same as base case Same as base case
Gestational age at iuMRI
of 22–24 weeks
Gestational age of
22–24 weeks
Same as base case Same as base case Same as base case Same as base case
Gestational age at iuMRI
of > 24 weeks
Gestational age of
> 24 weeks
Same as base case Same as base case Same as base case Same as base case
Comparison with the
second ultrasonography
All women with
outcomes
Same as base case Adjusted to account for a proportion of
cases in which ultrasonography identified
the same information as iuMRI, and a
proportion of cases for which TOP was
offered (after iuMRI) and occurred
Proportion of cases in which iuMRI was
correct and changed the prognosis,
multiplied by the proportion of cases
in which additional iuMRI provided
information that was not visible on
follow-up ultrasonography
Ultrasonography arm
patients: additional cost
for one two-dimensional
ultrasonography and one
subsequent consultation
Delivery costs excluded Base case, scenario 1
and scenario 2
Base case, scenario 1 and
scenario 2
Base case, scenario 1 and scenario 2 Base case, scenario 1 and scenario 2 Same as base case but
delivery costs excluded.
Termination costs included
Delivery and termination
costs excluded
Base case, scenario 1
and scenario 2
Base case, scenario 1 and
scenario 2
Base case, scenario 1 and scenario 2 Base case, scenario 1 and scenario 2 Same as base case but
delivery and termination
costs excluded
Increased cost for
termination
Base case, scenario 1
and scenario 2
Base case, scenario 1 and
scenario 2
Base case, scenario 1 and scenario 2 Base case, scenario 1 and scenario 2 Same as base case,
termination costs increased
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Deterministic analysis and probabilistic sensitivity analysis were conducted for the base case and for the
two scenarios. The deterministic analysis reports total costs, incremental cost and incremental cost per
management decision appropriately revised. The probabilistic sensitivity analysis samples each uncertain
value from its associated probability distribution (i.e. normal for mean costs, log-normal for resource
use, beta for proportions; see Appendix 2) simultaneously and reports the probabilistic mean cost per
management decision appropriately revised. Cost-effectiveness acceptability curves are presented for a
range of willingness-to-pay thresholds for appropriate management decisions. The cost-effectiveness
acceptability curves are calculated from the proportion of simulations for which the cost per management
decision is below each willingness-to-pay threshold and summarise the uncertainty associated with the
cost-effectiveness results. The expected value of perfect information (EVPI) analysis is conducted on a
per-person basis for varying willingness-to-pay thresholds. The EVPI is the price we would be willing to
pay for perfect information about all of the factors that determine which intervention is cost-effective.
This is calculated from the difference in monetary benefit when the choice between interventions is made
on current information and when the choice is made based on perfect information with no uncertainty.
EVPI is calculated at each willingness-to-pay threshold (per management decision appropriately changed,
from £0 to £10,000):
l Each uncertain parameter is sampled from its associated distribution – this is called ‘one run’.
l For each run, the following are calculated:
¢ the net benefit of iuMRI (appropriate management decisions are valued using the willingness-to-pay
threshold and the cost of the iuMRI strategy, for TOP and continued pregnancies)
¢ the net benefit of ultrasonography
¢ the net benefit with perfect information (the maximum of the net benefit of iuMRI and the net
benefit of ultrasonography).
l The mean over all the runs is calculated for:
¢ the net benefit of iuMRI
¢ the net benefit of ultrasonography
¢ the net benefit with perfect information.
l The expected outcome with current information is calculated as:
¢ the maximum of the mean net benefit of iuMRI and the mean net benefit of ultrasonography.
l The EVPI is calculated as:
¢ the difference between the mean net benefit with perfect information and the expected outcome
with current information.
Some participant records were missing data on some elements of resource use. In order to include as
many participants as possible in the analysis, imputed missing data were analysed. The imputation used
multivariate normal regression with 75 replicate data sets with age (years), distance from iuMRI unit,
the total number of fetal unit visits and gestational age at iuMRI as predictors of missing costs. Imputed
missing data are analysed for the base case, scenario 1 and scenario 2.
Inclusion of participant-borne costs
Two scenarios considered participant-borne costs, including costs for mileage and costs for participant
time to travel to and undergo an iuMRI procedure. The first analysis considered the whole population.
The second analysis considered only patients whose mileage was < 40 miles to estimate the potential
results of reconfiguring services so that iuMRI could be locally available. Outcome data were the same as
in the base case.
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Subgroups by gestational age
Subgroup analyses separately considered participants with a gestational age at iuMRI of < 22 weeks,
22–24 weeks and > 24 weeks. Total costs, the proportion of TOPs and the proportion of management
decisions correctly revised following iuMRI are analysed separately for the subgroups.
Comparison with second ultrasonography
This analysis compares iuMRI with repeat ultrasonography, as recommended by the Royal College of
Obstetricians and Gynaecologists (RCOG) pathway. In the RCOG pathway, if an abnormality is suspected,
the woman should be referred for a second opinion as soon as possible, ideally within 3 working days.64
As described in Data collection and management, after an iuMRI examination, participants attended a
follow-up appointment that included a follow-up ultrasonography to determine whether or not the
additional information from iuMRI was visible on follow-up ultrasound scans.
In this scenario, the proportion of management decisions appropriately revised following iuMRI is adjusted
to account for the improved diagnostic accuracy of a second ultrasonography. This downgrades the effect
of iuMRI to take into account the proportion of abnormalities that would have been detected by a repeat
ultrasonography. The proportion of management decisions appropriately revised is multiplied by the
proportion of cases in which the additional diagnostic information obtained from iuMRI was not visible
on follow-up ultrasonography. The proportion of participants having a TOP following a second
ultrasonography is calculated using the following approach:
1. Cross-tabulating the number of cases when TOP was offered following ultrasonography by the number
of cases when TOP was offered following iuMRI to calculate the number of cases in which the
management decisions agreed or disagreed.
2. Multiplying the number of cases when ultrasonography and iuMRI do not agree by the proportion of
cases when the new information from iuMRI was not visible on follow-up ultrasonography, to calculate
the proportion of cases when the second ultrasonography and iuMRI would agree or disagree.
3. Calculating the proportion of cases when TOP would be offered following the second ultrasonography.
4. Multiplying the proportion of cases when TOP would be offered following the second ultrasonography
by the proportion of cases for which TOP was offered following iuMRI in which TOP happened.
In this scenario, the same costs for the iuMRI and ultrasonography pathway (whether or not the participant
had a TOP) are used, but there is a cost for one additional two-dimensional ultrasonography and consultation
for all participants in the second ultrasonography pathway.
Longer time horizon
This scenario considers costs over a longer time period, to include the cost of additional care for children
born with disabilities. This analysis uses the proportions of children with abnormalities, borderline
abnormalities and no abnormalities from the follow-up study to estimate the long-term costs associated
with continued pregnancies. In the follow-up study, at 2–3 years, 31% of children had abnormalities,
14% of children had borderline abnormalities and 56% of children had no abnormalities (see Table 38).
A published study of the economic costs of childhood psychiatric disorders reports the mean public sector
costs over the previous year of life for children with and without psychiatric disorders by level of cognitive
impairment.65 The costs were estimated by collecting resource use data from parents when the child was
11 years of age. The annual costs for moderate and severe impairment without psychiatric disorders were
£5529 and £5842, respectively, inflated to 2016 prices.60 Our analysis assumed that these costs would be
applicable each year up until the age of 11 years, and so considered long-term cost for 11 years. Beyond
the age of 11 years, it is anticipated that the costs could change substantially as children enter adolescence
and their needs change. Children born with no abnormalities are assumed to incur no additional costs,
children with abnormalities incur the costs associated with severe cognitive impairment and children
with borderline abnormalities incur the costs associated with moderate cognitive impairment. Costs are
discounted at 3.5% per annum.66
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Costing scenarios
The following three scenarios consider changes to the costs included in the analysis. These were applied to
the base case, scenario 1 and scenario 2 to explore the sensitivity of the variation in results to the costing
assumptions.
Delivery costs excluded
This scenario considers the same costs as the base case, except that it excludes the costs for the delivery
of continued pregnancies.
Delivery and termination costs excluded
This scenario considers the same costs as the base case, except that it excludes the costs for TOP and the
costs for the delivery of continued pregnancies.
Increased termination cost
This scenario considers a higher cost of termination, assuming that the cost for termination at 20 weeks’
gestation for a 2.1-day stay did not involve feticide and that feticide would incur an additional cost of £366.
In this scenario, the cost for a termination without feticide was £1581 and the cost for a termination with
feticide was £1947.
Patient and public involvement
Representatives from Antenatal Results and Choices (ARC) and the Spina Bifida, Hydrocephalus, Information,
Networking, Equality (SHINE) charities were involved in the study oversight throughout the project through
the Trial Steering Committee (TSC). This included the review and development of the study protocol and
patient documents, monitoring the study progress and review and discussion of the final results of the study.
Feedback from the patient and public involvement (PPI) members informed our approach to potential
participants and the content of the participant information sheets. The PPI members also had input in the
content of the results summary/participant debrief letter and the method for disseminating results to
participants.
Study governance and management
Study governance
The study conduct was governed by a number of oversight committees: the Trial Management Group
(TMG), the TSC and the Data Monitoring and Ethics Committee (DMEC). The trial was conducted in
accordance with Sheffield CTRU standard operating procedures (SOPs) and the committees convened at
appropriate intervals as dictated by both study requirements and SOPs.
The TMG was composed of the chief investigator (chairperson), study collaborators and key staff within
the CTRU and Newcastle University. The TMG met monthly or bimonthly via teleconference during trial
recruitment and follow-up.
The TSC members were approved and appointed by the funder. The TSC was composed of a professor
of fetal and maternal medicine as the independent chairperson, an independent consultant in neuroradiology,
experts in antenatal screening and supporting families who provided expert advice and acted as PPI
representatives. The DMEC consisted of an independent statistician, a professor of health-care research
(chairperson) and a fetal medicine consultant. The TSC received formal recommendations from the DMEC.
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Ethics arrangements and regulatory approvals
The study and subsequent amendments were approved by the Yorkshire and The Humber – South
Yorkshire Research Ethics Committee (REC) (reference number 11/YH/0006). Each participating site gave
UK NHS Research and Development approval. The study was conducted in accordance with the principles
of good clinical practice.
Protocol amendments after study initiation
Details of substantial amendments submitted to the REC, which were important changes to trial
methodology, are listed below.
Multidisciplinary independent expert panel
The original protocol stated that agreement between the PND and the outcome diagnosis would be judged
independently by two fetal medicine experts and that a third expert would arbitrate if there was a discrepancy
in opinion. In June 2011, the protocol was revised to state that an independent expert panel would be
appointed to assess agreement rather than two independent experts. The independent expert panel was to
consist of a fetal medicine clinician, a paediatric neuroradiologist and a paediatric neurologist or neurosurgeon.
Outcome data collection
A number of measures were introduced to assist with the collection of follow-up data about the outcome
of the pregnancy. First, a data-collection sheet for handheld notes was developed; this sheet requested
basic details of where and when the participant delivered. This meant that the research midwife could be
notified of the delivery and could subsequently request the appropriate outcome data.
We also implemented the option of a postmortem MRI. When a woman opted for TOP, or when there
was a neonatal death, we aimed to gather the results of any postmortem autopsies performed for clinical
purposes. However, the offer of a postmortem is often declined; therefore, we introduced the option
of a non-invasive postmortem MRI examination that could be performed in addition to, or instead of,
a postmortem autopsy.
Following feedback from sites where, in some cases (e.g. mild VM that resolved during pregnancy), clinicians
did not advocate postnatal imaging, we modified our ORD to include a third-trimester ultrasonography in
cases of resolved VM.
Recruitment target
The recruitment target was changed on the advice of the DMEC and TSC from 750 participants to ‘at least
750 participants’ to ensure that the required 504 complete cases were obtained.
METHODS
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Chapter 3 Study results
Recruitment and participant flow
Between July 2011 and August 2014, 1101 women carrying 1109 fetuses were identified as potentially
eligible. Of those, 198 women (198 fetuses) were deemed to be ineligible on further screening or
declined participation, resulting in 903 participants (911 fetuses) being recruited. A total of 80 participants
(82 fetuses) did not complete ultrasonography and iuMRI (see Figure 1). A total of 64% of all participants
attended the Academic Unit of Radiology at the University of Sheffield for their iuMRI and the remaining
36% of participants attended one of the five collaborating centres. ORD was available in 638 out of 829
(77%) fetuses, of which 570 out of 638 (89%) had the iuMRI performed within 2 weeks of the referral
ultrasonography. A total of 369 fetuses (65%) were in the 18–23 weeks’ gestational age group (110%
of required) and 201 fetuses (35%) were in the ≤ 24 weeks’ gestational age group (120% of required).
The three commonest ultrasonography diagnoses were isolated VM (306/570, 54%), an abnormality
restricted to the contents of the posterior fossa (81/570, 14%) and failed commissuration (79/570, 14%).
Of the 1101 potential participants, 198 women were ineligible or declined participation. A total of 86 of
these potential participants were not asked to be part of the study. The most common reason for this was
that the consultant considered it to be clinically inappropriate or unhelpful (n = 50, 58%). A total of 112
potential participants were offered to participate but declined. There were several reasons for refusal that
were all reported with a similar frequency [i.e. decision had already been made (n = 18), unwilling to travel
(n = 13), does not want iuMRI (n = 28) and too upset or distressed (n = 11)]. A full summary of these
reasons can be found in Appendix 3.
Characteristics
Participant characteristics are shown in Table 2. The majority of participants completed their iuMRI in the
host institution (Sheffield, 67% of the ‘ORD available cohort’). Belfast had a large number of participants
who were excluded (n = 14, 17%) because of the time delay between the ultrasonography referral and the
iuMRI. The median maternal age of the ‘ORD available’ cohort was 29 years (IQR 24–33 years). The median
gestational age of the ‘ORD available’ cohort was 22.5 weeks (IQR 21.4–26.5 weeks). A total of 95% of
the ‘ORD available’ cohort were singleton pregnancies. The majority (56%) of this cohort had a dominant
diagnosis of VM.
Uptake of in utero magnetic resonance imaging
The iuMRI was successful in and diagnostic images were obtained from 823 participants (829 fetuses).
Second iuMRI studies were performed on 97 participants and seven of these had a third iuMRI study.
All follow-up studies were successful and useful diagnostic images were obtained.
Uptake of ultrasonography
A total of 681 mothers had two-dimensional ultrasonography and 140 mothers had both two-dimensional
and three-dimensional ultrasonography. Technical factors experienced during ultrasonography are summarised
in Appendix 4.
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Outcome of pregnancy
Of the 829 fetuses undergoing both ultrasonography and iuMRI, 642 (77%) were livebirths, 124 (15%)
underwent TOP and 53 (6.4%) were categorised as stillbirths, miscarriages, intrauterine demise or deaths
within the postnatal follow-up (Table 3). Data were not available for 10 (1.2%) fetuses.
Diagnostic source for outcome reference diagnosis
The most frequently used diagnostic source for ORD in the primary cohort was transcranial
ultrasonography (n = 261, 46%; Table 4). Postnatal MRI was used in one-quarter of cases (n = 144, 25%).
Agreement
Overall
The overall diagnostic accuracies of ultrasonography and iuMRI were 68.1% and 93.0%, respectively, with
a difference of 24.9% (95% CI 21.1% to 28.7%; Table 5). The difference between ultrasonography and
iuMRI increased with gestational age: in the 18–23 week group, the diagnostic accuracies were 69.9% for
ultrasonography and 92.4% for iuMRI (difference of 22.5%, 95% CI 17.8% to 27.2%); in the ≥ 24 week
group, the diagnostic accuracies were 64.7% for ultrasonography and 94.0% for iuMRI (difference of 29.3%,
95% CI 22.6% to 36.1%).
TABLE 2 Characteristics of mothers and fetuses who were recruited to the MERIDIAN study and included in the
primary analysis
Characteristic
ORD available
(N= 570)
ORD unavailable
(N= 175)
Excludeda
(N= 84)
iuMRI site, n (%)
Sheffield 380 (67.0) 120 (69.0) 31 (37.0)
Birmingham 75 (13.0) 34 (19.0) 15 (18.0)
Newcastle 66 (12.0) 6 (3.4) 9 (11.0)
Leeds 34 (6.0) 12 (6.9) 11 (13.0)
Nottingham 12 (2.1) 3 (1.7) 1 (1.2)
Belfast 3 (0.5) 0 (0.0) 17 (20.0)
Maternal age at approach (years), median (IQR) 29 (24–33) 28 (24–33) 30 (25–35)
Gestational age at iuMRI (weeks), median (IQR) 22.5 (21.4–26.5) 22.0 (21.2–24.7) 24.8 (23.1–28.5)
Singleton pregnancy, n (%) 539 (94.6) 165 (94.3) 80 (96.4)
Dominant diagnosis on ultrasonography, n (%)
Isolated VM 321 (56.0) 33 (19.0) 51 (63.0)
ACC 89 (16.0) 51 (29.0) 9 (11.0)
Posterior fossa 81 (14.0) 44 (25.0) 9 (11.0)
Other 79 (14.0) 47 (27.0) 12 (15.0)
ACC, agenesis of the corpus callosum.
a Includes participants who completed iuMRI > 2 weeks after referral and participants who were withdrawn after iuMRI.
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In 386 out of 570 cases (67.7%), both the ultrasonography and iuMRI reports were correct, and in 144
out of 570 cases (25.3%), the ultrasonography report was incorrect but the iuMRI report was correct.
There were two fetuses (0.4%) for whom the ultrasonography was correct and the iuMRI was incorrect
and 38 (6.7%) fetuses for which both the ultrasonography and the iuMRI were incorrect.
Missing data
Of the 175 fetuses with no ORD, ultrasonography and iuMRI agreed in 86 cases and disagreed in 89 cases.
In the most conservative assumption possible, ultrasonography would be correct in all 175 cases, with iuMRI
incorrect in all cases of disagreement, resulting in a diagnostic accuracy for ultrasonography of 76.6% and
for iuMRI of 82.7%. The difference of 7.1% (95% CI 3.0% to 11.2%), although vastly reduced, remains
highly statistically significant (p = 0.0007). The improved diagnostic accuracy of iuMRI over ultrasonography
was, therefore, not attributable to missing data.
TABLE 3 Outcome of pregnancy in 827 cases that completed iuMRI
Outcome of pregnancy
ORD available,
n (%) (N= 570)
ORD unavailable,
n (%) (N= 175)
Excluded,
n (%) (N= 84)
Overall,
n (%) (N= 829)
Livebirth 482 (84.6) 90 (51.4) 70 (83.3) 642 (77.4)
Stillbirth or miscarriage/fetal demise 20 (3.5) 27 (15.4) 6 (7.1) 53 (6.4)
Terminated 68 (11.9) 51 (29.2) 5 (6.0) 124 (15.0)
Not available 0 (0.0) 7 (4.0) 3 (3.6) 10 (1.2)
TABLE 4 Diagnostic source used for ORD in 570 cases in the primary analysis
Diagnostic source for ORD n (%)
Transcranial ultrasonography 261 (46.0)
Postnatal MRI 144 (25.0)
Postmortem autopsy 70 (12.0)
Third-trimester ultrasonography 63 (11.0)
Postnatal computed tomography 19 (3.3)
Abnormality visible on postnatal inspection 11 (1.9)
Postmortem MRI 2 (0.4)
TABLE 5 Diagnostic accuracy of ultrasonography and iuMRI by gestational age in the 570 cases in the primary
analysis population
Gestational age
Ultrasonography correct,
n (%)
iuMRI correct,
n (%)
Percentage difference
(95% CI) p-valuea
18–23 weeks (N = 369) 258 (69.9) 341 (92.4) 22.5 (17.8 to 27.2) < 0.0001
≥ 24 weeks (N = 201) 130 (64.7) 189 (94.0) 29.3 (22.6 to 36.1) < 0.0001
Combined (N = 570) 388 (68.1) 530 (93.0) 24.9 (21.1 to 28.7) < 0.0001
a McNemar’s test between ultrasonography and iuMRI.
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A less extreme method of handling a missing ORD was to assume that it was missing at random and then to
predict what the outcome would have been based on other, similar fetuses for which ORDs were available.
The prediction model took into account the relationship between diagnostic accuracy, the probability of
missing ORD data and the following characteristics: maternal age, fetal age (weeks) at time of iuMRI,
single/multiple pregnancy, outcome (TOP/no TOP) and prognosis.
A missing ORD was more commonly encountered among individuals with a normal, poor or unknown
prognosis, but was similar in relation to whether or not iuMRI changed the prognosis. The association of
missing data with a prognosis was similar regardless of whether the prognosis was based on ultrasonography
or iuMRI. As there were no missing data for the ultrasonography prognosis, it was used in the prediction
model. Missing data were also more commonly observed among individuals who underwent TOP, although
this was highly associated with the prognosis. Missing data were slightly more common among younger
fetuses but showed little association with maternal age or single/multiple pregnancy. Because gestational
age was associated with diagnostic accuracy (the diagnostic accuracy of ultrasonography was reduced in
those of older gestational age), this was retained in the prediction model along with the prognosis based on
ultrasonography.
Using the prediction model to predict missing outcomes (under the assumption of missing at random),
the diagnostic accuracy of ultrasonography was 66.9% and iuMRI was 92.8%, resulting in a slightly greater
difference of 25.9% (95% CI 22.3% to 29.7%).
All participants with outcome reference diagnosis
The primary analysis was repeated on all participants who had scans and an ORD (Table 6). Similar results to
the primary analysis were observed and the overall diagnostic accuracies of ultrasonography and iuMRI, at
68.8% and 92.3%, respectively, resulted in a difference of 23.5% (95% CI 20.0% to 27.1%; p < 0.0001).
Repeat in utero magnetic resonance imaging
There were 65 fetuses for which repeat ultrasonography and iuMRI were undertaken and an ORD was
obtained. As with the primary analysis, the majority (46/65) underwent iuMRI at the host institution.
The median gestational age was 31 weeks with just five fetuses under 24 weeks. The overall diagnostic
accuracies of ultrasonography and iuMRI were 67.7% and 87.7%, respectively, indicating a difference of
20.0% (95% CI 7.8% to 32.2%; p < 0.0001; Table 7).
A summary of the analysis repeated on first, single and repeat pregnancies can be found in Appendix 5.
TABLE 6 Diagnostic accuracy of ultrasonography and iuMRI by gestational age in the 638 cases who had scans and
ORDs
Gestational age
Ultrasonography
correct, n (%)
iuMRI correct,
n (%)
Percentage
difference (95% CI) p-valuea
18–23 weeks (N = 399) 279 (69.9) 365 (91.5) 21.6 (17.1 to 26.0) < 0.0001
≥ 24 weeks (N = 239) 160 (66.9) 224 (93.7) 26.8 (20.6 to 32.9) < 0.0001
Combined (N = 638) 439 (68.8) 589 (92.3) 23.5 (20.0 to 27.1) < 0.0001
a McNemar’s test between ultrasonography and iuMRI.
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Anatomical subgroup analysis
Isolated ventriculomegaly
Ventriculomegaly was the most common brain abnormality for referral to the MERIDIAN study.67 In 421
out of 570 (74%) fetuses, VM formed part of the ultrasonography diagnosis; in 306 out of 570 (54%)
fetuses, VM was the only brain abnormality diagnosed on ultrasonography. This analysis is based on the
306 cases with isolated VM on ultrasonography.
A total of 199 out of 306 (65%) cases were in the 18–23 weeks group at the time of iuMRI and 107 out
of 306 (35%) cases were in the ≥ 24 weeks group. The category of VM was determined by the largest
trigone measurement and were divided into mild (10–12 mm), moderate (13–15 mm) and severe (≥ 16 mm)
categories. Ultrasonography diagnosed mild VM in 244 out of 306 (80%) fetuses, moderate VM in 36 out
of 306 (12%) fetuses and severe VM in 26 out of 306 (8%) fetuses.
The ORD found additional brain abnormalities other than VM in 31 out of 306 fetuses (10.1%); 17 out of 199
(8.5%) of those were in the 18–23 weeks group and 14 out of 107 (13.1%) of those were in the ≥ 24 weeks
group. Of those fetuses, 5.7% (14/244) of those referred with mild VM had other brain abnormalities on
ORD, 19.4% (7/36) of those referred with moderate VM had other brain abnormalities and 38.5% (10/26)
of those referred with severe VM on ultrasonography showed other brain abnormalities on ORD (Table 8).
The other brain abnormalities identified were agenesis of the CC (ACC) or hypogenesis of the CC in 17 out
of 31 (55%) fetuses, encephalomalacia and/or intracranial haemorrhage in 8 out of 31 (26%) fetuses,
cortical formation abnormalities in 4 out of 31 (13%) fetuses and absent cavum septum pellucidum (CSP)
caused by septo-optic dysplasia in 2 out of 31 (6%) fetuses.
TABLE 7 Diagnostic accuracy of ultrasonography and iuMRI in 65 cases with complete outcome data for which
repeat iuMRI was used (the latest scan was used if more than two were completed)
Gestational age
Ultrasonography
correct, n (%)
iuMRI correct,
n (%)
Percentage
difference (95% CI) p-valuea
18–23 weeks (N = 5) 4.0 (80.0) 4.0 (80.0) 0.0 (20.0 to 20.0) N/A
≥ 24 weeks (N = 60) 40.0 (66.7) 53.0 (88.3) 21.6 (8.6 to 34.7) < 0.0001
Repeat MRI (N = 65) 44.0 (67.7) 57.0 (87.7) 20.0 (7.8 to 32.2) < 0.0001
N/A, not available.
a McNemar’s test between ultrasonography and iuMRI.
TABLE 8 Diagnostic accuracy of ultrasonography and iuMRI in cases diagnosed with isolated VM on ultrasonography
VM diagnosis N
Other brain
abnormality
on ORD (n)
Diagnostic
accuracy (%)
Other brain
abnormality
correct on
iuMRI (n)
Diagnostic
accuracy (%)
Difference
(95% CI) p-valuea
All cases of
isolated VM
306 31 89.9 27 98.7 8.8 (4.9 to 12.1) < 0.0001
Mild 244 14 94.3 12 99.2 4.9 (1.3 to 7.8) 0.0034
Moderate 36 7 80.6 7 100.0 19.4 (3.7 to 35.2) 0.0156
Severe 26 10 61.5 8 92.3 30.8 (9.2 to 52.4) 0.0078
a McNemar’s test between ultrasonography and iuMRI.
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The iuMRI was correct in 302 out of 306 cases when compared with the ORD. Of these 302 cases,
275 were correctly diagnosed with isolated VM and in 27 cases the iuMRI correctly identified additional
brain abnormalities. The iuMRI provided an incorrect diagnosis in 4 out of 306 fetuses (three cases of
hypogenesis of the CC and one case of absent CSP).
There were complete clinical impact data available for 295 out of 306 (96%) fetuses; of these, 29 fetuses
had additional brain abnormalities. Fetal medicine clinicians reported that iuMRI provided additional
information compared with ultrasonography in 106 out of 295 (35.9%) cases. Overall, there was a change
in the prognosis category after iuMRI in 69 out of 295 (23.4%) cases. This was a change to a worse
prognosis in 22 cases and to an improved prognosis in 47 cases.
Forty-two (14.2%) women were offered TOP based on the ultrasonography diagnosis alone and in eight of
those cases the offer of TOP was reversed after iuMRI. After iuMRI, an additional 14 women were offered
TOP based on the diagnosis of brain abnormalities other than VM. The decision to offer TOP, therefore,
was changed in 22 out of 295 (7.5%) fetuses after iuMRI and TOP was performed in 14 out of 295 (4.7%)
cases. The contribution of iuMRI to the final choice of management was rated by the fetal medicine expert
to be ‘of no value’ in 41 out of 295 (14%) cases, minor in 177 out of 295 (60%) cases, significant in
64 out of 295 (22%) cases, major in 12 out of 295 (4%) and decisive in one (0.3%) case.
For the 29 fetuses that had brain pathology other than VM confirmed on ORD, the prognosis was
considered worse in 13 out of 29 (44.8%) cases after the iuMRI and the effect of iuMRI on overall clinical
management was rated as ‘significant’, ‘major’ or ‘decisive’ in 15 out of 29 (51.7%) cases.
Failed commissuration
Ultrasonography reported some form of ‘failed commissuration’ abnormality in 92 out of 570 (16.1%)
referrals into the MERIDIAN study.68 Thirteen of those referrals also had additional brain pathology other
than VM identified on ultrasonography and were, therefore, not included in this subgroup analysis.
The remaining 79 cases form the basis of this analysis, 54 of which had associated VM. The iuMRI was
performed at 18–23 weeks of gestational age in 51 out of 79 (65%) fetuses and at ≥ 24 weeks of gestational
age in 28 out of 79 (35%) fetuses. In total, 24 out of 79 cases were diagnosed with hypogenesis of the CC
on ultrasonography and 55 out of 79 cases were diagnosed with ACC.
The diagnostic accuracy for ‘isolated failed commissuration’ as a whole group was 34.2% for ultrasonography,
compared with 94.9% for iuMRI (difference of 60.7%, 95% CI 47.6% to 73.9%; p < 0.0001) (Table 9).
Of the 52 fetuses whose diagnosis was incorrect on ultrasonography, the ORD recorded a normal CC in
46 fetuses and additional diagnoses not detected on ultrasonography in 12 fetuses (five fetuses had a normal
CC but additional diagnoses).
TABLE 9 Diagnostic accuracy of ultrasonography and iuMRI in cases diagnosed with either ACC or hypogenesis
of the CC on ultrasonography
Diagnosis N
Ultrasonography iuMRI
Difference (95% CI) p-valueaIncorrect (n)
Diagnostic
accuracy (%) Incorrect (n)
Diagnostic
accuracy (%)
Any malformation
of the CC
79 52 34.2 4 94.9 60.7 (47.6 to 73.9) < 0.0001
Hypogenesis
of the CC
24 22 8.3 3 87.5 79.2 (55.1 to 103.3) < 0.0001
ACC 55 33 40.0 4 92.7 52.7 (37.7 to 67.7) < 0.0001
a McNemar’s test between ultrasonography and iuMRI.
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The iuMRI had an error rate of 4 out of 79 fetuses; all four of these errors were in relation to the CC diagnosis.
All 12 other brain abnormalities shown on ORD were diagnosed correctly on iuMRI.
Further analysis looked at the diagnostic accuracy of ultrasonography and iuMRI in specifically diagnosing
hypogenesis of the CC or ACC as discrete abnormalities, irrespective of the presence of other brain
abnormalities (see Table 9).
Ultrasonography was shown to have a diagnostic accuracy of 8.3% for detecting hypogenesis of the CC.
In comparison, iuMRI demonstrated 87.5% accuracy (difference of 79.2%, 95% CI 55.1% to 100%;
p < 0.0001). The diagnostic accuracy for detecting ACC specifically was 40.0% for ultrasonography and
92.7% for iuMRI (difference of 52.7%, 95% CI 37.7% to 67.7%; p < 0.0001).
Ultrasonography correctly diagnosed hypogenesis of the CC in 2 out of 24 fetuses (8.3%). The majority of
ultrasonography errors (20/24) for hypogenesis of the CC occurred when the ORD showed a normal CC,
and in 2 out of 24 cases the ORD reported ACC.
Ultrasonography correctly diagnosed ACC in 22 out of 55 cases (40.0%). Of the remaining 33 cases,
which ultrasonography diagnosed with ACC, the ORD reported hypogenesis of the CC in seven cases and
a normal CC in 26 cases.
The iuMRI reported a normal CC in 45 out of 79 fetuses, 43 (95.5%) of which were subsequently confirmed
as normal on ORD; the other two fetuses were incorrectly diagnosed by iuMRI and were found to have
hypogenesis of the CC on ORD. In 8 out of 79 cases, the iuMRI reported hypogenesis of the CC, of which
6 (75%) were found to be correct. Finally, iuMRI diagnosed 26 cases of ACC, of which 23 (88.5%) were
subsequently found to be correct.
Posterior fossa abnormalities
Ultrasonography reported some form of abnormality in the posterior fossa in 81 out of 570 (14.2%)
fetuses.69 The iuMRI was performed at 18–23 weeks of gestational age in 57 out of 81 (70%) fetuses
and at ≥ 24 weeks of gestational age in 24 out of 81 (30%) fetuses. A total of 67 out of 81 cases were
diagnosed with a parenchymal abnormality confined to the posterior fossa on ultrasonography and
14 out of 81 cases were diagnosed with a CSF-containing abnormality. Associated VM was found on
ultrasonography in 25 out of 81 (31%) cases overall and in 3 out of 15 (20%) fetuses with cerebellar
hypoplasia, 6 out of 21 (29%) fetuses with Dandy–Walker spectrum abnormalities and 11 out of 21 (52%)
fetuses with Chiari type II malformations.
The overall diagnostic accuracy of ultrasonography was 65.4%. A normal brain was reported on ORD in
18 out of 28 of the ultrasonography errors and other supratentorial brain abnormalities were reported
on in 10 out of 28 of the ultrasonography errors (the other brain abnormalities consisted of six ACC or
hypogenesis of the CC cases, two cortical formation abnormalities and two acquired pathologies). The
iuMRI gave a diagnostic accuracy of 87.7%, showing an improvement in diagnostic accuracy of 22.3%
(95% CI 14.0% to 30.5%; p < 0.0001) over ultrasonography.
In the 10 iuMRI errors, eight were cases in which the ORD was normal and two were cases in which iuMRI
failed to detect an abnormality of the CC shown on the ORD.
The specific diagnoses of parenchymal abnormalities on ultrasonography were:
l cerebellar hypoplasia in 25 out of 67 (38%) fetuses – vermian hypoplasia in 15 fetuses and hypoplasia
of the cerebellar hemispheres in 10 fetuses
l Dandy–Walker spectrum abnormalities in 21 out of 67 (31%) fetuses
l Chiari type II malformation in 21 out of 67 (31%) fetuses.
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The label ‘parenchymal abnormality’ in Table 10 requires the exact pathological diagnosis of the posterior
fossa abnormality to be correct when compared with the ORD and ignores the presence or absence of other
brain abnormalities. The correct specific diagnosis was made by ultrasonography in 54 out of 67 fetuses,
demonstrating a diagnostic accuracy of 80.6%. The iuMRI correctly diagnosed 64 out of 67 fetuses,
demonstrating a diagnostic accuracy of 95.5%. The difference in diagnostic accuracy was 14.9% (95% CI
5.7% to 24.1%; p = 0.002) in favour of iuMRI.
The CSF-containing abnormalities made up 14 out of 81 of the diagnoses on ultrasonography. Eight fetuses
had an enlarged CM and six fetuses had abnormal cystic structures (four arachnoid cysts and two unspecified).
In total, 3 out of 14 cases with an ultrasonography diagnosis of a CSF abnormality were correct (diagnostic
accuracy of 21.4%). In the 11 out of 14 cases of incorrect diagnoses on ultrasonography, the ORD consisted
of ‘no brain abnormality’ in eight fetuses, failed commissuration in two fetuses and durovenous thrombosis
with ectasia70 in one fetus. The iuMRI was correct in 8 out of 14 of those cases (diagnostic accuracy of 57.1%),
with a difference of 35.7% (95% CI –1.6% to 73.0%; p = 0.0625) in favour of iuMRI. All of the iuMRI errors
were cases in which iuMRI reported a CSF-containing abnormality but this was not confirmed on ORD,
although in one case a CC abnormality was also missed.
Diagnostic confidence
The assessment of the effect of iuMRI on diagnostic confidence is based on the confidence of which the
dominant diagnosis was reported. The dominant diagnosis is defined as the one most likely to influence the
prognosis and for each case was decided on by the independent panels. Overall, iuMRI reported the dominant
diagnosis with high confidence (70% or 90% confidence) in 13% more cases than ultrasonography, with
iuMRI reporting 544 out of 570 (95%) cases with high confidence compared with ultrasonography reporting
465 out of 570 (82%) cases (Table 11). There were 122 cases that were diagnosed with high confidence
on ultrasonography but were subsequently found to be incorrect on ORD (22% of the overall population),
compared with 32 (6%) cases on iuMRI. Diagnoses were reported with low confidence (≤ 50% confidence)
in 105 out of 570 (18%) cases on ultrasonography and in 26 out of 570 (5%) cases on iuMRI. Eighteen
(3% of all cases) cases reported with low confidence on iuMRI were found to be correct on ORD, compared
with 45 (8%) correct on ultrasonography.44
The majority of diagnoses showed no change in confidence from ultrasonography to iuMRI (n = 331, 58%;
Table 12). When confidence did change, most diagnoses were more confident with iuMRI by one (n = 91,
16%) or two categories (n = 93, 16%). This paired difference between confidence on ultrasonography and
iuMRI was found to be statistically significant (p < 0.0001).
TABLE 10 Diagnostic accuracy of ultrasonography and iuMRI in cases diagnosed with abnormalities of the posterior
fossa on ultrasonography
Diagnosis N
Ultrasonography iuMRI
Difference (95% CI) p-valueaIncorrect (n)
Diagnostic
accuracy (%) Incorrect (n)
Diagnostic
accuracy (%)
Any abnormality of
the posterior fossa
81 28 65.4 10 87.7 22.3 (14.0 to 30.5) < 0.0001
CSF abnormality 67 13 80.6 3 95.5 14.9 (5.7 to 24.1) 0.002
Parenchymal
abnormality
14 11 21.4 6 57.1 35.7 (–1.6 to 73.0) 0.0625
a McNemar’s test between ultrasonography and iuMRI.
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Table 13 shows three approaches to assessing the changes brought about in the diagnostic confidence
using iuMRI. The simple (conventional without correction) approach is to subtract the ultrasonography
confidence from the iuMRI confidence; the estimated difference of 0.44 points indicates an average
increase of almost half a point on the 5-point scale of confidence. Although intuitive, this difference
takes no account of whether or not the increase in confidence is appropriate. The corrected conventional
method penalises ultrasonography (but not iuMRI) confidence in cases when the two diagnoses differ but
the ultrasonography diagnosis is made with high confidence. The Ng and Palmer58 method also combines
diagnostic confidence and accuracy but uses the ORD as the benchmark for the latter. The iuMRI was
found to be preferable to ultrasonography, with an average improvement of 0.75 points (95% CI 0.63 to
0.83 points; p < 0.0001) on the ± 4-point scale.
TABLE 12 Difference in diagnostic confidence on ultrasonography alone and ultrasonography with iuMRI in the
primary analysis population (n= 570)
Difference between ultrasonography alone and ultrasonography with iuMRI ORD available, n (%) (N= 570)
No change 331 (58.0)
Ultrasonography more confident, one category 38 (6.7)
Ultrasonography more confident, two or more categories 17 (3.0)
iuMRI more confident, one category 91 (16.0)
iuMRI more confident, two or more categories 93 (16.0)
p-valuea < 0.0001
a Wilcoxon signed-rank test between ultrasonography alone and ultrasonography with iuMRI.
TABLE 13 Difference in diagnostic confidence on ultrasonography and iuMRI in the primary analysis population
(n= 570)
Method
Difference in
confidence, mean (SD) 95% CI Test statistic (t) p-value
Score-based method 0.75 (1.5) 0.63 to 0.88 12.0 < 0.0001
Conventional analysis without correction 0.44 (1.2) 0.35 to 0.54 8.9 < 0.0001
Conventional analysis with correction 1.1 (1.57) 0.97 to 1.23 16.8 < 0.0001
TABLE 11 Diagnostic confidence categories on ultrasonography and iuMRI in the primary analysis population
(n= 570)
Diagnostic
confidence (%)
Ultrasonography, n (%) iuMRI, n (%)
Overall (N= 570)
Incorrect diagnoses
(N= 182) Overall (N= 570)
Incorrect diagnoses
(N= 40)
10 18 (3.2) 12 (6.6) 6 (1.1) 3 (7.5)
30 25 (4.4) 18 (9.9) 5 (0.9) 2 (5.0)
50 62 (11.0) 30 (17.0) 15 (2.6) 3 (7.5)
70 102 (18.0) 27 (15.0) 51 (8.9) 7 (18.0)
90 363 (64.0) 95 (52.0) 493 (87.0) 25 (62.0)
DOI: 10.3310/hta23490 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 49
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Griffiths et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
Clinical impact
Prognosis
Clinical feedback was available for 783 out of 823 pregnancies. Of the remaining 40 pregnancies, there
were 26 participants for whom no follow-up took place, 13 participants for whom the clinical feedback
form was not fully completed and one participant who withdrew from the study after the iuMRI but before
the clinical feedback visit. The ORD was available for 545 pregnancies but was not a requisite for this
analysis, meaning that the analysis was based on 783 mothers. A full summary of prognosis categories on
ultrasonography and iuMRI can be found in Appendices 6 and 7.
Fetal medicine clinicians reported that the iuMRI provided additional diagnostic information in 387 out of
783 (49%) cases. In 201 out of 387 (52%) cases, the ‘new’ fetal brain abnormalities identified by iuMRI
were visible on follow-up ultrasonography.
In 189 out of 783 (24%) cases, referring clinicians answered ‘yes’ to the question ‘Did iuMR change your
prognosis?’. In 138 out of 189 cases, additional non-neuroimaging investigations, such as karyotyping,
fetal cardiac echo and infection screening, were performed in conjunction with the iuMRI examination.
The results of such tests were considered to have a major influence on the prognosis in 32 of those cases.
Therefore, we estimate that iuMRI per se changed the prognostic information in at least 157 out of
783 cases (20%). Although 24% of clinicians reported that iuMRI changed their prognosis, the actual
prognostic information was modified in 342 out of 783 (44%) participants. The changes were primarily
shifting away from ‘intermediate’ and ‘unknown’ to ‘normal’, ‘favourable’ or ‘poor’. The most frequent
change in prognosis was from ‘unknown’ on ultrasonography to a quotable risk category after iuMRI
(113/783, 14% of cases). Conversely, on 33 occasions (4%) after iuMRI the prognosis was changed
from a quotable known risk to ‘unknown’. A full summary of these changes can be found in Appendix 8.
The prognosis was quotable after both scanning methods in 77% of cases; of these, the prognosis was
improved after iuMRI in 102 out of 783 (13%) cases and worsened in 94 (12%) cases (Table 14). Most
participants showed no change in prognosis (n = 409, 68%).
Counselling and management
Termination of pregnancy was discussed in 51% of consultations before iuMRI and in 49% of consultations
after iuMRI. However, the rate of TOP being offered increased from 25% before iuMRI to 36% after iuMRI,
with an additional 84 (11%) cases in which TOP was offered after iuMRI (Table 15). A higher proportion of
cases had TOP offered based on substantial risk of disability following iuMRI than ultrasonography (33%
following iuMRI and 23% following ultrasonography alone). There were also fewer cases when TOP was
discussed but not offered following iuMRI (12% following iuMRI and 25% following ultrasonography alone).
TABLE 14 Change in prognosis from ultrasonography to iuMRI, by category, for mothers who have a known
prognosis on both modalities
Change in prognosis n (%)
Number of fetuses 605
No change 409 (68.0)
More favourable with ultrasonography, one category 83 (14.0)
More favourable with ultrasonography, two or more categories 11 (1.8)
More favourable with iuMRI, one category 89 (15.0)
More favourable with iuMRI, two or more categories 13 (2.1)
p-valuea 0.543
a Wilcoxon signed-rank test.
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In response to the question ‘Did iuMR change your counselling in this case?’ the referring clinician reported no
influence on counselling in 172 out of 783 (22%) cases, minor influence in 496 out of 783 (63%) cases and
major influence in 115 out of 783 (15%) cases. The contribution of iuMRI to the final choice of management
was felt to be of ‘no value’ in 95 out of 783 (12%) cases, a ‘minor influence’ in 419 out of 783 (53%) cases,
‘significant’ in 201 out of 783 (26%) cases, a ‘major influence’ in 49 out of 783 (6%) cases and ‘decisive’
in 19 out of 783 (3%) cases (Table 16).44 The contribution of iuMRI was rated particularly highly among
those participants whose chosen management plan was TOP (Table 17). A total of 31 out of 103 (30%)
participants said that it was ‘significant’, 9 out of 103 (8.8%) participants said that it was ‘major’ and
12 out of 103 (12%) participants said that it was ‘decisive’.
TABLE 15 Counselling based on ultrasonography alone and iuMRI for all mothers who completed iuMRI
Counselling Overall, n (%) (N= 810)
Ultrasonography alone
TOP not discussed 400 (49.0)
TOP discussed but not offered 203 (25.0)
TOP offered based on substantial disability risk 184 (23.0)
TOP discussed and offered, other reason 23 (2.8)
iuMRI
TOP not discussed 393 (49.0)
TOP discussed but not offered 98 (12.0)
TOP offered based on substantial disability risk 270 (33.0)
TOP discussed and offered, other reason 14 (1.7)
Not reported 35 (4.3)
Note
Belfast participants (n = 17) have been excluded from this table. A paired comparison of ultrasonography and iuMRI
counselling can be found in Appendix 9.
TABLE 16 Management of pregnancy following iuMRI in 783 cases with complete clinical feedback data
Rating of iuMRI contribution Overall, n (%) (N= 783)
Chosen management plan
Continued pregnancy 213 (27.0)
Continued pregnancy, further imaging 465 (59.0)
TOP 102 (13.0)
Unable to decide 3 (0.4)
Further imaging
Ultrasonography 368 (47.0)
iuMRI 16 (2.0)
Both 81 (10.0)
Not reported 318 (41.0)
Rating of iuMRI contribution
None 95 (12.0)
Minor 419 (54.0)
Significant 201 (26)
Major 49 (6.3)
Decisive 19 (2.4)
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Additional tests/resource use
In the 821 mothers who had complete scan data, 924 additional tests were carried out with 559 mothers
having at least one additional investigation (Table 18). The most common of these was ‘infection screen’
(n = 395, 48%). The median number of additional investigations was one (IQR 0–1). Table 19 shows that
three-dimensional ultrasonography and karyotyping were more likely to have an influence on prognosis and
counselling (27% and 25% of referring clinicians said that the test changed prognosis and counselling).
TABLE 17 Management of pregnancy by iuMRI contribution in 783 cases with complete data
Rating of iuMRI
contribution
Overall, n (%)
(N= 783)
Management, n (%)
Continued with
pregnancy
(N= 213)
Continued with
pregnancy with
further imaging
(N= 465)
Termination
(N= 102)
Unable to
decide (N= 3)
None 95 (12.0) 35 (16.0) 51 (11.0) 8 (7.8) 1 (33.0)
Minor 419 (54.0) 118 (55.0) 259 (56.0) 42 (41.0) 0 (0.0)
Significant 201 (26.0) 48 (23.0) 121 (26.0) 31 (30.0) 1 (33.0)
Major 49 (6.3) 10 (4.7) 29 (6.2) 9 (8.8) 1 (33.0)
Decisive 19 (2.4) 2 (0.9) 5 (1.1) 12 (12.0) 0 (0.0)
TABLE 18 Summary of additional investigations performed in the 821 mothers who completed iuMRI
Investigation and clinical impact Overall
Mothers with at least one additional test performed 559
Investigation, n (%)
Karyotype 235 (29.0)
Echocardiography 128 (16.0)
Infection screen 395 (48.0)
Three-dimensional ultrasonography 145 (18.0)
Other NAIT 17 (2.1)
Other 4 (0.5)
Median number of additional investigations (IQR) 1 (0–1)
Additional investigation changed prognosis and counselling, n (%) 190 (21.0)
Major factor in choice of management, n (%) 144 (16.0)
Abnormal finding, n (%) 45 (6.0)
Three-dimensional ultrasonography, n (%)
Prior to iuMRI 120 (85.0)
Volume saved offline and interpreted by expert 56 (39.0)
Modified existing diagnosis 37 (26.0)
Provided same diagnostic information as iuMRI 82 (58.0)
Modified confidence from two-dimensional ultrasonography, n (%)
No change 85 (60.0)
Increased 56 (39.0)
Decreased 1 (0.7)
NAIT, neonatal alloimmune thrombocytopenia.
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There was a similar result when the clinicians were asked about whether or not the test was a major factor
in the choice of management (three-dimensional ultrasonography at 22.8% and karyotyping at 21%).
Abnormal findings were not shown in many of these additional tests (45/924 tests).
Safety
There were 214 SAEs in total, all of which were defined as expected in the study protocol. There were
138 preterm deliveries (defined as a delivery before 37 weeks’ gestational age), 33 cases of spontaneous
intrauterine fetal demise or stillbirth, 29 neonatal or infant deaths and 14 cases in which the iuMRI
diagnosis differed from the ORD and a TOP had been performed.
All of the above were reviewed by a nominated fetal medicine specialist and the DMEC, who did not have
any concerns regarding the rate of events.
A full case review was instigated for the 14 participants for whom the iuMRI diagnosis differed from the ORD
and a TOP was performed. In all cases, the TOP was judged to have been performed because of the severity
of a brain abnormality confirmed on iuMRI, another abnormality not related to the study diagnosis (e.g. a
cardiac abnormality or a diagnosis of a chromosomal disorder) or the case underwent a full multidisciplinary
team (MDT) review during which it was concluded that the ORD was incomplete (e.g. no autopsy) or incorrect
and an addendum to the ORD was issued.
There were 130 AEs reported during iuMRI scanning, with 123 (15%) participants experiencing at least one AE
(Table 20). The most common reason associated with this was persistent fetal movement (n = 104 AEs, 80%).
In utero magnetic resonance imaging errors
In the primary analysis population (n = 570 participants), there were 40 iuMRI errors overall, resulting in
an overall error rate of 7% (Table 21). When summarising by central and non-central reporters, 12 out of
40 (30%) errors were attributed to the central reporter and 28 out of 40 (70%) errors were attributed to
the non-central reporters. The overall error rate was higher in non-central reporters (11%) than in the
central reporter (3.8%), with a difference of 7.2% (95% CI 2.5% to 12.0%).71
TABLE 19 Additional investigative tests and their impact on the prognosis in 559 mothers who received them
Investigative test N
Impact, n (%)
Did the test change
the prognosis and
counselling?
Was the test a major
factor in the choice of
management? Abnormal finding
Karyotype 235 59 (25.0) 50 (21.0) 10 (4.3)
Echo 128 28 (22.0) 17 (13.0) 23 (18.0)
Infection screen 395 64 (16.0) 43 (11.0) 12 (3.1)
Three-dimensional
ultrasonography
145 39 (27.0) 33 (23.0) 0 (0.0)
Other NAIT 17 0 (0.0) 1 (6.2) 0 (0.0)
Other 4 0 (0.0) 0 (0.0) 0 (0.0)
NAIT, neonatal alloimmune thrombocytopenia.
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When further categorised by previous experience, radiologists with less previous experience had a higher
error rate (12% and 12%) than radiologists with more previous experience (8.5% and 3.8%). Radiologists
with > 150 previous scans had a consistently low error rate (< 10%) and the central reporter had an error
rate that was consistently < 5%. However, the data are limited by the small number of radiologists in each
category.
Hospital Anxiety and Depression Scale
The HADS questionnaire was used to assess anxiety and depression among study participants, both during
their pregnancy (survey 1) and postnatally (survey 2). In total, 414 participants completed survey 1 and
274 participants completed survey 2, with 194 participants completing both. High rates of anxiety were
apparent during pregnancy, with over one-third of participants reporting scores in the range of ‘probable
case’; a total of 15% of study participants were in the ‘probable case’ range for depression (Table 22).
The mean anxiety score was lower in survey 2 than in survey 1 (paired difference of –3 points; p < 0.0001)
for those participants who responded to both surveys. This trend was also observed in depression scores
(paired difference of –2.2 points; p < 0.0001). There were also more participants in the ‘normal’ anxiety
category in survey 2 than in survey 1 (39% of participants in survey 1, 64% of participants in survey 2),
with fewer participants in the ‘cause for concern’ and ‘probable clinical case’ categories in survey 2.
Although not as strong, a similar trend was observed in the depression categories.
TABLE 21 Error rates in relation to the experience category of the reporting radiologist71
Experience category
(number of
radiologists)
Number of
cases reported
in the MERIDIAN
study (overall
error rate %)
Error rate (%) in the radiologists’ reports
First 25 reports Reports 26–50 Reports 51–75 Reports ≥ 76
Non-central reporter;
0–50 iuMRI studies (3)
95 (12.0) 13.0 (of 54 cases) 16.0 (of 25 cases) 0.0 (of 16 cases) Not performed
Non-central reporter;
50–150 iuMRI studies (4)
138 (12.0) 14.0 (of 87 cases) 11.0 (of 37 cases) 7.1 (of 14 cases) Not performed
Non-central reporter;
150–300 iuMRI studies (4)
71 (8.5) 9.4 (of 64 cases) 0.0 (of 7 cases) Not performed Not performed
Central reporter; > 1000
iuMRI studies (1)
316 (3.8) 4.0 (of 25 cases) 0.0 (of 25 cases) 0.0 (of 25 cases) 4.6 (of 241 cases)
TABLE 20 Adverse events during iuMRI that occurred during the MERIDIAN study
Adverse events
Mothers in the MERIDIAN
cohort (N= 823), n (%)
Mothers with incomplete scans
(not part of the MERIDIAN cohort), n (%)
Total iuMRI-related AEs 130 7
Mothers experiencing at least one AE 123 (15.0) 6 (13.0)
Type of AE
Persistent fetal movement 104 (80.0) 1 (14.0)
Anxiety/claustrophobia 12 (9.0) 4 (57.0)
MRI equipment or software failure 5 (3.8) 0 (0.0)
Skin heating/other sensory effects 1 (0.8) 0 (0.0)
Other AE 17 (13.0) 2 (29.0)
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Health economic results
Outcomes
A total of 570 women were part of the primary analysis set, had outcomes recorded and had iuMRI within
2 weeks of the ultrasonography. Information on whether or not iuMRI changed the prognosis was missing
for 19 women. Table 23 shows whether or not iuMRI was correct and if it changed the prognosis for the
remaining 551 women.
TABLE 22 Summary statistics of the HADS questionnaire completed as part of surveys 1 and 2
HADS category Survey 1 Survey 2 Difference
HADS: anxiety
N 414 274 194
Mean (SD) 9 (4.7) 6.5 (4.7) –3 (4.5)
Median (IQR) 9 (5 to 12) 6 (3 to 9) –3 (–6 to 0)
Minimum to maximum 0 to 21 0 to 19 –15 to 14
p-value ≤ 0.0001a
Anxiety category, n (%)
Normal range (≤ 7.5) 160 (39) 176 (64) –25%
Cause for concern (> 7.5–10.5) 102 (25) 42 (15) 10%
Probable clinical case (> 10.5) 152 (37) 56 (20) 17%
p-value ≤ 0.0001b
HADS: depression
N 414 274 194
Mean (SD) 5.7 (4.4) 3.7 (3.8) –2.2 (3.9)
Median (IQR) 5 (2 to 9) 3 (1 to 5) –1 (–4 to 0)
Minimum to maximum 0 to 21 0 to 21 –18 to 7
p-value ≤ 0.0001a
Depression category, n (%)
Normal range (≤ 7.5) 289 (70.0) 229 (84.0) –14%
Cause for concern (> 7.5–10.5) 65 (16.0) 29 (11.0) 5%
Probable clinical case (> 10.5) 60 (15.0) 16 (5.8) 9.2%
p-value ≤ 0.0001b
a Paired Wilcoxon signed-rank test between survey 1 and survey 2.
b McNemar’s test between survey 1 and survey 2.
TABLE 23 ‘Was iuMR correct?’ by ‘Did iuMR change the prognosis?’
Was iuMRI correct?
Did iuMRI change the prognosis?
TotalNo Yes
No 30 10 40
Yes 391 120 511
Total 421 130 551
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Of the 570 women in the primary analysis set, information on whether or not TOP was offered after
ultrasonography was missing in 23 women and information on whether or not TOP was offered after
iuMRI was missing in 33 women.
Of the 570 women with information on whether or not TOP happened, 68 (11.93%) women had a TOP.
Of the 547 women with information on whether or not TOP was offered after ultrasonography,
135 (24.68%) women were offered TOP after ultrasonography.
Of the 537 women with information on whether or not TOP was offered after iuMRI, 189 (35.20%) women
were offered TOP. A total of 58 of the 189 (30.69%) women offered TOP after iuMRI had a TOP (Table 24).
Costs
Disaggregated and total costs for iuMRI resulting in TOP, iuMRI not resulting in TOP, ultrasonography
resulting in TOP and ultrasonography not resulting in TOP for complete cases are shown in Table 25.
Base case, scenario 1 and scenario 2
Results for the base case, scenario 1 and scenario 2 analyses are shown in Table 26.
Cost-effectiveness
In the base case, 21.78% (120/551) of decisions were appropriately revised following iuMRI. The incremental
cost per management decision appropriately revised is therefore £2203.
TABLE 24 ‘Did TOP happen?’ by ‘Was TOP offered after iuMR?’
Did TOP happen?
Was TOP offered after iuMRI?
TotalNo Yes
No 348 131 479
Yes 0 58 58
Total 348 189 537
TABLE 25 Disaggregated and total costs
Costs (£)
iuMRI no
TOP
iuMRI followed
by TOP
Ultrasonography
without TOP
Ultrasonography
followed by TOP
Mileage 26 37
Patient-reported personal
costs
51 69
Ultrasonography 271 269 271 269
iuMRI 264 264
Investigation 206 243 206 243
Further imaging 336 285 336 285
Further consultations 140 12 140 12
Cost of TOP 0 1098 0 1098
Cost of delivery 2647 0 2647 0
Total cost (NHS) 3864 2170 3600 1907
Total cost (all) 3941 2277 3600 1907
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TABLE 26 Deterministic results, imputed missing cost data results and probabilistic results
Cost type
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
Deterministic Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 3864 2170 3600 1907
Total cost (£) 3662 3182 480 21.8 2203
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.2 75.3 24.7
Cost (£) 3864 2170 3600 1907
Total cost (£) 3268 3182 86 21.8 394
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted
by the proportion of patients offered TOP after iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 3864 2170 3600 1907
Total cost (£) 3662 3472 190 21.8 873
Imputed missing cost data Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients who were offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 3848 2143 3584 1879
Total cost (£) 3645 3163 481 21.8 2210
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.2 75.3 24.7
Cost (£) 3848 2143 3584 1879
Total cost (£) 3248 3163 85 21.8 389
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TABLE 26 Deterministic results, imputed missing cost data results and probabilistic results (continued )
Cost type
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted
by the proportion of patients offered TOP after iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 3848 2143 3584 1879
Total cost (£) 3645 3455 190 21.8 871
Probabilistic sensitivity
analysis
Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.8
Cost (£) 3876 2329 3612 2065
Total cost (£) 3690 3232 458 21.8 2102
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.3 75.3 24.6
Cost (£) 3881 2318 3617 2054
Total cost (£) 3333 3230 103 21.8 470
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted
by the proportion of patients offered TOP after iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 3878 2337 3614 2073
Total cost (£) 3693 3497 195 21.8 899
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For scenario 1, if we assumed that each woman offered TOP after iuMRI had a TOP, then the average
cost to the NHS of iuMRI would be £3268. The cost of ultrasonography is unchanged from the base case.
The incremental cost is therefore £396 and the incremental cost per management decision appropriately
revised is £394.
For scenario 2, if we assumed that 30.69% of women offered TOP after ultrasonography had a TOP, then
7.57% of women who underwent ultrasonography would have had a TOP. The average cost to the NHS
of ultrasonography would be £3472. The cost of iuMRI is unchanged from the base case. The incremental
cost is therefore £301 and the incremental cost per management decision appropriately revised is £873.
The cost of a delivery is higher than the cost of a termination. In the base case, iuMRI leads to fewer TOPs
than ultrasonography; together with the additional cost for iuMRI, this means that the total cost is higher
for iuMRI than for ultrasonography. In scenarios 1 and 2, the proportion of TOPs for iuMRI and ultrasonography
is more similar than in the base case. In scenarios 1 and 2, iuMRI leads to more TOPs than ultrasonography,
so the costs are more comparable, although the cost of iuMRI means that the total cost is higher for iuMRI than
for ultrasonography but the incremental cost is lower than the base case.
Imputed missing data
When costs were analysed to impute missing data, the total cost to the NHS for iuMRI was £3848 without
TOP and £2143 with TOP. The total cost for ultrasonography was £3584 without TOP and £1879 with
TOP. Results for the base case, scenario 1 and scenario 2 using imputed missing data for costs are shown
in Table 26.
Probabilistic sensitivity analysis
Mean results from 1000 probabilistic simulations are shown in Table 26.
Cost-effectiveness acceptability curves are presented for the base case, scenario 1 and scenario 2 in Figure 2.
For the base-case analysis, if we are willing to pay ≥ £4000 for an appropriate management decision, iuMRI
has a probability of 100% of being the most cost-effective option. For scenarios 2 and 3, we can be certain
that iuMRI imaging is the most cost-effective option.
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FIGURE 2 Cost-effectiveness acceptability curve.
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Graphs for the per-person EVPI at varying willingness-to-pay thresholds are presented in Figure 3. The EVPI peaks
at the willingness-to-pay threshold at which there is most uncertainty about whether iuMRI or ultrasonography is
the most cost-effective technique. The maximum EVPI is relatively low (£14–30), indicating that there is little
value in conducting further research on the parameters in this short-term analysis.
Scenario analyses
Inclusion of participant-borne costs
If we include personal costs (i.e. mileage costs and time to travel to and undergo iuMRI) as well as NHS
costs, the average cost of iuMRI increases and the cost of ultrasonography stays the same. This reflects the
additional costs incurred by the participants to travel to and undergo a iuMRI scan. If we limit the distance
travelled to 40 miles and include personal costs (i.e. mileage costs and time to travel to and undergo
iuMRI) as well as NHS costs, all of the costs change slightly as different data are being analysed. Results
including personal costs are shown in Table 27.
Subgroup analyses
Results are presented for gestational ages of < 22 weeks, 22–24 weeks and > 24 weeks at iuMRI scan in
Table 28.
Comparison with repeat ultrasonography
A comparison of iuMRI with repeat ultrasonography is shown in Table 29. In this analysis, the incremental
cost is negative, meaning that iuMRI is cost-saving compared with repeat ultrasonography. The incremental
effectiveness of iuMRI over repeat ultrasonography is reduced.
Different costing scenarios
Results excluding delivery costs only, excluding delivery and termination costs, and increasing termination
costs are shown in Table 30.
When only delivery costs are excluded, TOP becomes more costly than continuation of pregnancy. In the
base case, there are more TOPs for ultrasonography than for iuMRI, but these costs are offset somewhat
by the cost of iuMRI itself. However, the incremental cost is much less than when delivery costs are
included (deterministic results in Table 26) and, therefore, the cost per management decision appropriately
revised decreases. In scenarios 1 and 2, the incremental costs have increased (compared with deterministic
results in Table 26) because there are more TOPs for iuMRI than for ultrasonography, which lead the cost
per management decision appropriately revised to increase. The estimates of cost-effectiveness for the
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TABLE 27 Scenario analyses including personal costs
Scenario
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
All participants
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 3941 2277 3600 1907
Total cost (£) 3743 3182 561 21.8 2574
Mileage (< 40 miles)
Proportion (%) 88.9 11.2 73.5 26.5
Cost (£) 3880 1987 3570 1682
Total cost (£) 3669 3070 599 21.8 2753
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TABLE 29 Scenario analysis comparing iuMRI with repeat ultrasonography
Scenario
iuMRI
Repeat
ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
Proportion (%) 88.1 11.9 90.7 9.3
Cost (£) 3864 2170 3827 2134
Total cost (£) 3662 3670 –8 10.6 Cost saving
TABLE 28 Subgroup analyses by gestational age at iuMRI
Gestational age (weeks)
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
< 22
Proportion (%) 79.8 20.2 71.0 29.0
Cost (£) 3851 2213 3587 1949
Total cost (£) 3520 3112 408 20.5 1993
22–24
Proportion (%) 88.6 11.4 75.5 24.5
Cost (£) 3883 1815 3619 1551
Total cost (£) 3646 3112 535 18.8 2851
> 24
Proportion (%) 96.0 4.0 79.5 20.5
Cost (£) 3857 2284 3593 2020
Total cost (£) 3794 3270 524 25.7 2043
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TABLE 30 Different costing scenarios
Scenario
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
Excluding delivery costs
Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 1217 2170 953 1907
Total cost (£) 1331 1188 142 21.8 654
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.2 75.3 24.7
Cost (£) 1217 2170 953 1907
Total cost (£) 1553 1188 364 21.8 1672
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted by the proportion of patients offered TOP after
iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 1217 2170 953 1907
Total cost (£) 1331 1025 305 21.8 1403
Excluding delivery and termination costs
Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients who were offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 1217 1072 953 809
Total cost (£) 1200 917 282 21.8 1297
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.2 75.3 24.7
Cost (£) 1217 1072 953 809
Total cost (£) 1166 917 249 21.8 1142
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TABLE 30 Different costing scenarios (continued )
Scenario
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted by the proportion of patients offered TOP after
iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 1217 1072 953 809
Total cost (£) 1200 942 258 21.8 1183
Increased termination costs
Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients who were offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 3864 2459 3600 2196
Total cost (£) 3696 3253 443 21.8 2034
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.2 75.3 24.7
Cost (£) 3864 2459 3600 2196
Total cost (£) 3370 3253 116 21.8 534
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted by the proportion of patients offered TOP after
iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 3864 2459 3600 2196
Total cost (£) 3696 3494 203 21.8 931
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base case, scenario 1 and scenario 2 are closer together, because the incremental cost of iuMRI itself,
which is the same between the scenarios, is a bigger driver of costs.
When delivery and termination costs are excluded, the incremental costs for the base case, scenario 1 and
scenario 2 are very similar to each other, as the only differences in the costs are the cost of the iuMRI and
the differences in investigations and further imaging.
When the cost of termination increases, it becomes closer to the cost of delivery. Therefore, there is less
difference in the costs for people with and without TOP. The incremental costs for the base case, scenario
1 and scenario 2 become closer to each other than they were in the deterministic results in Table 26,
but the difference between them is still larger than when termination and delivery costs are excluded.
Longer-term horizon
In this scenario (Table 31), the cost of a continued pregnancy becomes much higher than the cost of a
termination, and iuMRI becomes much more costly than ultrasonography when it results in fewer TOPs
(as in the base case) and becomes cost-saving when it results in more TOPs (as in scenarios 1 and 2). This
analysis demonstrates the uncertainty in the longer-term economic evaluation. Longer-term follow-up
studies of children diagnosed with fetal brain abnormalities would be required to address this uncertainty.
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TABLE 31 Long-term scenario
Scenario
iuMRI Ultrasonography
Incremental cost (£)
Proportion of management
decisions appropriately
revised following iuMRI (%)
Cost-effectiveness
(per management decision
appropriately revised
following iuMRI) (£)No TOP TOP No TOP TOP
Base case. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 88.1 11.9 75.3 24.7
Cost (£) 27,527 2170 27,264 1907
Total cost (£) 24,502 21,005 3497 21.8 16,057
Scenario 1. iuMRI: proportion of patients offered TOP after iuMRI; ultrasonography: proportion of patients offered TOP after ultrasonography
Proportion (%) 64.8 35.2 75.3 24.7
Cost (£) 27,527 2170 27,264 1907
Total cost (£) 18,603 21,005 –2402 21.8 Cost saving
Scenario 2. iuMRI: proportion of patients who had TOP; ultrasonography: proportion of patients offered TOP after ultrasonography, adjusted by the proportion of patients
offered TOP after iuMRI who had TOP
Proportion (%) 88.1 11.9 92.4 7.6
Cost (£) 27,527 2170 27,264 1907
Total cost (£) 24,502 25,343 –841 21.8 Cost saving
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Chapter 4 Qualitative substudy
Introduction
The aim of the patient and health professional perspectives substudy was to assess the acceptability of the
clinical care package including iuMRI using qualitative and quantitative methods. This aim encompassed
three objectives: (1) describing, exploring and understanding women’s views about the acceptability of iuMRI
in service user perspectives of the PND for brain abnormality; (2) describing, exploring and understanding the
acceptability of iuMRI in the PND for brain abnormality from a service provider perspective; and (3) drawing
on health professionals’ views about potential barriers to and facilitators of developing policy and provision
should the study outcomes suggest that there is a case for enhancing UK service provision.
Existing research on women’s experiences of iuMRI in the PND pathway is relatively limited. Evidence
suggests that women are accepting of the procedure, but that including iuMRI can be associated with
higher levels of psychological distress.72 Existing sociological work suggests that including iuMRI can help
manage the uncertainty associated with the PND.73 Understanding women’s perceptions of the PND for
brain abnormality, including iuMRI, is important in two ways. First, MRI techniques are poorly understood
in non-professional domains.74,75 Second, social scientists have noted that applying innovative health
technologies can have unintended social effects, so early assessment of service user perspectives could help
understand the impact of introducing new technologies in particular social and cultural contexts.31 Research
on health professionals’ views of iuMRI is limited but suggests that iuMRI can function as a bridge for
clinicians working across specialties.76 Diagnosis in particular can be conceptualised as a ‘powerful social
tool’,77 therefore understanding health professionals’ perspectives on innovation within the PND process
is an important part of understanding its impact, and can offer insights to facilitate future developments.
Well-informed policy development is crucial to enhance experiences of the PND for brain abnormality
(often with uncertain outcomes).
This substudy drew on quantitative data from women and qualitative data from women and health
professionals to assess the acceptability of iuMRI in the PND for fetal brain abnormality. This mixed-method
approach provided an in-depth analysis of key issues and experiences that matter to those with first-hand
knowledge of iuMRI in practice.
Recruitment, sampling and data-collection methods
The three data sets (i.e. women’s survey responses, women’s interviews and health professionals’ interviews)
were used to explore service users’ and health professionals’ experiences of engaging with the clinical study.
The three elements are outlined as separate activities but are considered together in informing the discussion
of the findings, providing triangulation in data interpretation. The surveys also collected qualitative data to
enhance the interpretation of the main data sets.
Questionnaire surveys
Women who were approached about the sociological study (after recruitment into the study) were provided
with a site-specific information pack. Survey 1 was administered after the fetal medicine consultation during
which the iuMRI findings were discussed and a provisional management plan was made. Survey 2 was
administered 3–6 months post pregnancy outcome (either birth or TOP). Both surveys included questions
to evaluate (1) the overall satisfaction with care, (2) the practical utility of results from iuMRI to inform
understanding and decision-making and (3) to what extent participants’ experiences were influenced
by their situation (e.g. psychological state) at the time of iuMRI. This last objective utilised the HADS
questionnaire data at the end of each survey.
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Survey 1 differed slightly from survey 2. Both surveys comprised questions on age, marital status, education
and questions on the impact of practical issues on the acceptability of the care package related to referral
pathways (e.g. travel times). Survey 2 included (1) an open-text question that allowed participants to raise
issues they felt were important to evaluating their health-care experience and (2) a filter question with an
expression of interest (EOI) form for an in-depth interview. Follow-up letters and survey forms were sent to
participants who had not responded after a certain time (Figure 4), improving returns by 4% (survey 1) and
6% (survey 2).
iuMRI scan, consultation and decision about pregnancy
6 months (24 weeks) from
iuMRI: survey 2 ‘overdue’
Possible outcomes
• Fetal demise
• TOP/feticide
• Stillbirth
• Early neonatal death
• Livebirth
4 weeks from iuMRI:
survey 1 ‘overdue’
Survey 1 given/posted
Survey 2 sent out:
3 – 6 months (12 – 24 weeks)
after outcome
30 – 60 days from iuMRI:
if survey 1 not received,
contact midwives to send
reminder and survey 1
(repeat)
90 days from iuMRI:
survey 1 (repeat) not
received or if outcome
over, enter survey as
‘unavailable’
4 – 7 months after outcome
(10 months from iuMRI): if survey 2
not received, contact midwife to
send reminder and survey 2
After 1 year from iuMRI:
if no survey 2 (repeat)
received, enter survey
as ‘unavailable’
Screening and recruitment
FIGURE 4 Substudy survey flow chart. Black, MERIDIAN database; green, site fetal medicine unit clinicians;
blue, substudy researchers.
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The primary focus of the survey was the quantitative data collected, but there were also a small number
of open-text responses in survey 2 and marginalia. Content analysis using NVivo 10 (QSR International,
Warrington, UK) was employed to code these textual data that were then used, when appropriate,
to inform the analytic process.
Qualitative interviews with women
Survey respondents who completed an EOI form in survey 2 formed the sampling frame for the qualitative
interviews with women. This approach facilitated the use of background characteristics, diagnostic category
and pregnancy outcome alongside fetal medicine unit and iuMRI centre in the purposive sampling for
maximum variation.78 Women were contacted using information provided in EOI forms. Following the
verification of the agreement to be interviewed, they were sent a study pack with information about the
interview phase (including a reply slip and information on how a partner/relative/friend could participate in
the woman’s interview if she desired).
Following written consent, interviews were conducted in participants’ homes and recorded on an encrypted
digital voice recorder. A narrative approach to interviewing allowed participants to develop their own
account of their ‘story’. The topic guide prompted participants to describe their feelings on learning about
the abnormality, undergoing the iuMRI and decision-making about pregnancy management. The topic
guide also explored perceived differences between ultrasonography and iuMRI, information-seeking
behaviour and the formal and informal support received.
Qualitative interviews with health professionals
Health professional participants were recruited from an identified pool of 42 health professionals associated
with the clinical study, including 10 sites that were recruited in a suitable time frame for inclusion. Purposive
sampling ensured that the participant group was sufficiently diverse (1) to cover a range of clinical sites,
(2) to cover a range of professionals (e.g. fetal medicine specialists, radiology specialists), (3) in gender and
(4) in length of service in the field. Potential participants were contacted by post with a study information
pack, including an information sheet and a reply slip. On receipt of a reply agreeing to take part, the
interviewer made contact using the details provided by the potential participant.
Interviews were carried out at two time points. The first round of interviews took place during the first year
of clinical recruitment at the participant’s site, and the second round of interviews took place during the
third year of recruitment at that site (originally the final year of recruitment, prior to the extension of the
clinical study). Whenever possible, participants interviewed in the first round were reinterviewed in in
the second round, but this was not possible in all cases. In the second round of interviews, participants
were offered a telephone or face-to-face interview and additional participants were included. Face-to-face
interviews were held at the participants’ place of work. The topic guide included prompts on key issues,
including experiences of the clinical project, perceived value of iuMRI in the PND and potential barriers to
and facilitators of future policy implementation.
Qualitative data management
Interviews continued until data saturation was reached (i.e. we achieved a sufficiently diverse sample
with no new themes emerging in the ongoing thematic analysis, leading to a stable descriptive coding
framework). All digital sound files were stored on a password-secure server and deleted from the digital
recorders. The interviews were transcribed, edited for accuracy, anonymised and entered into a qualitative
data-management software for indexing and retrieval, ATLAS.ti version 7 (ATLAS.ti Scientific Software
Development GmbH, Berlin, Germany).
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Data analysis
Data analysis approach for survey data
Responses to the four key questions were investigated using multiple logistic regression. For the purpose of
these analyses, responses were recategorised into ‘positive’ and ‘negative’ binary variables as follows:
l For Likert scale questions – 1 if the response was ‘strongly agree’ or ‘agree’, 0 for everything else.
l For rating scale questions – 1 if the response was ‘excellent’ or ‘very good’, 0 for everything else.
A variable selection approach was used with variables that were selected for use in the final model if
they had a p-value of < 0.1. The following models were calculated for each of the four outcomes in
questionnaires 1 and 2:
l background – maternal age, gestational age, level of education
l service – Sheffield versus non-Sheffield MRI centres, journey length
l prognosis on iuMRI
l diagnosis on iuMRI
l change from ultrasonography after iuMRI – change in counselling, change in prognosis.
A further model was produced for questionnaire 2:
l outcome – outcome for pregnancy, agreement between ultrasonography and iuMRI.
Odds ratios (ORs) with CIs and corresponding p-values were calculated. Only complete cases were included
(i.e. those mothers who had a value for the outcome and each of the covariates were included in the
model). Model fit was assessed for each of the models by the Hosmer–Lemeshow goodness-of-fit test.
All 49 questionnaire 2 responders who underwent TOP strongly agreed or agreed, meaning that the model
could not be estimated owing to separation; therefore, TOP was removed.
Data analysis for qualitative interview data
For the service user and the health professional interview data analyses, anonymised interview transcripts
(primary documents) constituted the formal data. Service users’ transcripts were coded separately from
health professionals’ transcripts. The health professionals’ transcripts were initially subdivided by round.
When a high degree of similarity in the data from the two data-collection periods became clear, the health
professionals’ transcripts were analysed as one set of primary documents. In both the service user and the
health professional interview data analyses, a generative thematic approach was used, incorporating a
multistage process similar to that described by Braun and Clarke79,80 (Table 32). Our approach to generative
thematic analysis is informed by Silverman81,82 and shares some principles with grounded theory approaches,83
for example the identification of themes that emerge from the data.84 However, we did not follow any specific
grounded theory protocol. Initial coding frames were developed by each lead analyst and with coding samples
reviewed by the co-analyst, providing a qualitative equivalent to inter-rater reliability, enhancing consistency
and theme refinement. The final theme content was then condensed and further refined by the lead analyst,
with input from the other two members of the substudy team.
The sensitive topic area meant that interviews were sometimes emotional for service user participants, but
still generated rich, in-depth narratives. In most cases, the presence of a partner or relative was supportive
and their participation gave an added dimension to the interviews. Field notes were written for unusual
cases (e.g. when family circumstances were difficult).
To guard against the fragmentation of data through the ‘code and retrieve’ method of analysis, synopses of
each woman’s interview were composed by the research associate, providing an overview of all interview
cases and read by the qualitative lead. A composite case study was produced to highlight the difficulties
faced by patients (see Appendix 10).
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Interviews with health professionals were, on occasion, challenging for pragmatic reasons. Participants
were usually interviewed at work, where they were busy and often interrupted. However, even the most
fragmented interviews retained a coherent narrative structure and detailed discussion, producing a rich,
complex data set. The interviews included transparent discussion of the context leading to the interview
and field notes were produced only as needed (e.g. when disruption had been experienced).
TABLE 32 Summary of stages of thematic analysis. Stages are drawn from Braun and Clarke’s79 sixfold typology of
the phases of qualitative thematic analysis
Stages of thematic
analysis Project activities Clinician data Patient data
1. Familiarisation with
the data
Initial reading of transcripts to
identify possible key themes
RG all, ML sample ML all, RG sample
Data meeting to discuss
provisional themes to guide
coding
RG, ML ML, RG
2. Coding the data Coding of transcripts RG ML
Refining of codes to (1) clarify
meaning, (2) remove overlaps
and (3) integrate very small
codes
ML, RG ML, RG
3. Searching for themes Mapping of codes to themes RG with detailed feedback
from ML
ML
4. Reviewing themes Initial refinement of themes in
relation to coded data
RG ML
Team review of themes
emerging from the data
RG, ML, SCR ML, RG, SCR
5. Defining and naming
themes
Data meetings to consolidate
the review of the thematic
framework
RG, ML, SCR
Includes some feedback from
dissemination workshops
(various participants)
ML, RG, SCR
Includes data meeting
feedback (ML, RG and SCR
with MERIDIAN study
members, including the
statisticians)
Further reduction of themed
data and adjustment of
subthemes
RG, ML ML, RG
Final content review of
themed data, refine when
necessary
Initially RG, ML and SCR, then
the full MERIDIAN study team,
particularly GM and CM
ML
Contrast findings with existing
literature to draw out and
develop discussion points
RG, with input from ML and
SCR
ML, RG
6. Reporting the data Extract key themes for the
Health Technology
Assessment report
RG ML
Finalise report chapter and
discussion of themes across
data sets
RG in collaboration with ML,
SCR and the wider MERIDIAN
team
ML in collaboration with RG,
SCR and the MERIDIAN study
statisticians
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Results
Service user substudy participants
The questionnaire survey was conducted between September 2011 and August 2014 and included the
first 681 participants recruited to the MERIDIAN study (questionnaire 1) and 630 participants who were
eligible for the follow-up questionnaire (questionnaire 2). The response rate was higher for questionnaire 1
(428/681, 62.8%) than for questionnaire 2 (284/630, 45.1%) (p = 0.005). A total of 206 participants
completed both questionnaires. Respondents’ characteristics are shown in Table 33. The proportion of
respondents to questionnaire 1 who opted for TOP was 18%, in contrast to the 11% of questionnaire 2
respondents who opted for TOP.
In total, 104 EOI forms were returned with survey 2. Of these, 10 respondents were not contactable and
49 respondents were withdrawn because their forms were returned after recruitment was completed.
Those eligible for the qualitative interview phase were contacted by telephone. Three respondents subsequently
declined and data from one interview was prematurely deleted, leaving data from 41 participants available
for analysis (39% of EOIs returned, 14% of surveys for questionnaire 2 completed).
TABLE 33 Characteristics of substudy patient respondents
Characteristics
Questionnaire 1
(N= 428)
Questionnaire 2
(N= 284)
Questionnaire 1 +
questionnaire 2
(N= 206)
Interview
(N= 41)
Age (years), mean (SD) 29.3 (6.0) 29.8 (6.0) 30.1 (5.9) 31.3 (6.0)
Education (highest qualification), n (%)
GCSE 172 (40.2) 121 (42.6) 91 (44.2) 4 (9.8)
A level/NVQ 167 (39.0) 119 (41.9) 84 (40.8) 17 (41.5)
Degree/N/A 42 (9.8) 32 (11.3) 25 (12.1) 19 (46.3)
Gestation at iuMRI (weeks),
mean (SD)
24.2 (4.1) 24.5 (4.4) 24.1 (4.2) 23.4 (4.6)
MRI centre, n (%)
Host institution 280 (65.4) 192 (67.6) 139 (67.5) 27 (65.9)
Other sites 148 (34.6) 92 (32.4) 67 (32.5) 14 (34.1)
Diagnosis,a n (%)
Isolated VM 195 (45.8) 120 (42.4) 98 (47.8) 20 (49.0)
VM and other pathology 93 (21.8) 75 (26.5) 42 (20.5) 13 (32.0)
Pathology not including
VM
138 (32.4) 88 (31.1) 65 (31.7) 8 (20.0)
Pregnancy outcome,b n (%)
Livebirth 359 (84.5) 220 (77.7) 175 (85.5) 30 (73.0)
Death 20 (4.7) 12 (4.2) 6 (2.9) 4 (10.0)
TOP 44 (10.4) 50 (17.7) 23 (11.2) 7 (17.0)
A level, advanced level; GCSE, General Certificate of Secondary Education; N/A, not available; NVQ, National Vocational
Qualification.
a Missing data: Q1 (n = 2), Q2 (n = 1), Q1 + Q2 (n = 1).
b Missing data: Q1 (n = 5), Q2 (n = 2), Q1 + Q2 (n = 1).
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Patient survey findings
A total of 97% of questionnaire 1 respondents and 95% of questionnaire 2 respondents would choose to
have iuMRI as part of their care if they were ever in a similar situation again. In response to the question
about whether or not iuMRI was undertaken at an acceptable time and place, 73% of questionnaire 1
respondents and 68% of questionnaire 2 respondents strongly agreed or agreed. Only 3% of respondents
in both groups strongly disagreed and 9% of questionnaire 1 respondents and 11% of questionnaire 2
respondents disagreed. The following open-text responses in the survey are illustrative:
We didn’t mind travelling a long distance there, but the return journey was extremely difficult after
being told such heart-breaking news.
ID239
. . . we had to stay overnight in a hotel with a 7-year-old, hours away from home. It would be very
helpful if this test was more widely available.
ID125
Responses to questions about the impact of iuMRI on understanding and decision-making are shown in
Figure 5. Overall, 83% of respondents to questionnaire 1 and 80% of respondents to questionnaire 2
gave positive responses to the statement ‘The information from the iuMRI scan helped me to understand
the baby’s problem’. Positive responses were more likely if the iuMRI was performed at Sheffield compared
with non-Sheffield sites [questionnaire 1 (OR 2.22, 95% CI 1.28 to 3.86; p = 0.005) and questionnaire 2
(OR 3.41, 95% CI 1.82 to 6.48; p < 0.001)] and less likely if the iuMRI had been performed after 24 weeks
of pregnancy [questionnaire 1 (OR 0.52, 95% CI 0.29 to 0.91; p = 0.022) and questionnaire 2 (OR 0.39,
95% CI 0.20 to 0.750; p = 0.005)].
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FIGURE 5 Responses to questions about the impact of iuMRI on understanding and decision-making in questionnaire 1
(black) and questionnaire 2 (green). (a) Responses to the question ‘The information from theMRI helpedme to understand
the baby’s problem’; (b) responses to the question ‘The information from theMRI helpedme to understand how the
baby’s problem could affect his/her future quality of life’; and (c) responses to the question ‘The information on theMRI
scanwas useful tomewhen I made the decision about whether or not to continuewith the pregnancy’. Of the 206
womenwho responded to both surveys, the proportion of those who either strongly agreed or agreed to (a) were 73%
(Q1) and 68% (Q2), to (b) were 73% (Q1) and 68% (Q2), and to (c) were 76% (Q1) and 72% (Q2). (continued)
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A total of 69% of respondents to questionnaire 1 and 71% of respondents to questionnaire 2 gave
positive responses to the statement ‘The information from the iuMRI scan helped me to understand how
the baby’s problem could affect his/her future quality of life’. Positive responses to questionnaire 1 were
more likely when the prognosis was graded as poor (i.e. < 50% chance of a normal outcome) (OR 4.20,
95% CI 1.64 to 11.10; p = 0.003). Positive responses to questionnaire 2 were more likely if iuMRI was
performed at the Sheffield site (OR 1.96, 95% CI 1.15 to 3.35; p = 0.013).
Of the questionnaire 1 respondents who answered either one of the previous two questions (see Figure 5a
and 5b), 37% of them did not respond to the statement ‘The information from the iuMRI scan was useful
to me when I made the decision about whether or not to continue with the pregnancy’ (see Figure 5c).
In total, 71% of the remaining respondents gave positive responses to the statement. None of the factors
included in the model influenced the response to questionnaire 1. Of the questionnaire 2 respondents who
answered either one of the two previous questions, 27% did not respond to the same statement but 74%
of the remaining questionnaire 2 respondents responded positively.
Women who were not faced with the dilemma of whether to have a termination because the condition
was ‘mild’ or were going to continue regardless of what the iuMRI scan revealed might have opted to leave
the question blank because it was not ‘relevant or appropriate’. The only factor that influenced the response
to the statement about whether or not the iuMRI scan was useful in decision-making was gestational
age at iuMRI; fewer mothers who were scanned at ≥ 34 weeks of pregnancy gave positive responses
(OR 0.11, 95% CI 0.02 to 0.47; p = 0.007).
Overall, 90% of questionnaire 1 respondents rated their care as ‘excellent’ or ‘very good’, 9% of respondents
rated their care as ‘good’ and only 1% of respondents rated their care as ‘fair’. Responses to questionnaire 1
did not appear to be influenced by any of the factors examined and responses were consistently positive
across groups. Overall, 88% of questionnaire 2 respondents rated their care as ‘excellent’ or ‘very good’,
9% of respondents rated their care as ‘good’ and 3% of respondents rated their care as ‘fair’. Only one
respondent to questionnaire 2 rated their care as ‘poor’. Responses to questionnaire 2 were only influenced
by journey length; positive responses were less likely if the journey length was 2–4 hours (OR 0.38, 95% CI
0.13 to 0.99; p = 0.05).
Patient qualitative interview findings
The sample of 41 women interviewed included experiences from three of the six iuMRI sites. A total of
18 family members were included: 16 family members were in joint interviews and two were individually
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FIGURE 5 Responses to questions about the impact of iuMRI on understanding and decision-making in questionnaire 1
(black) and questionnaire 2 (green). (a) Responses to the question ‘The information from theMRI helpedme to understand
the baby’s problem’; (b) responses to the question ‘The information from theMRI helpedme to understand how the
baby’s problem could affect his/her future quality of life’; and (c) responses to the question ‘The information on theMRI
scanwas useful tomewhen I made the decision about whether or not to continue with the pregnancy’. Of the 206
womenwho responded to both surveys, the proportion of those who either strongly agreed or agreed to (a) were 73%
(Q1) and 68% (Q2), to (b) were 73% (Q1) and 68% (Q2), and to (c) were 76% (Q1) and 72% (Q2).
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interviewed after their partners. Four of the women’s relatives were their mothers. Interviews were carried
out between July 2012 and December 2013, 4–12 months post pregnancy outcome and with the majority
> 7 months post outcome. Interviews lasted between 21 minutes (with a family member only) and 146 minutes
(with the participant). The average length of the interviews was 69 minutes. Four key themes were
identified from the data.
Theme 1: diagnosis of a fetal brain abnormality
The most common fetal brain abnormality was VM. The diagnosis had an impact on patient experience
because fetuses with VM often had more frequent ultrasonography monitoring of ventricle size (some
patients had an additional iuMRI scan). For most parents, the iuMRI scan was only one appointment
among many others along the care pathway:
. . . when it was diagnosed it was 10 and a half and 12 and a half or something like that [ML: that’s
not too] you know one was mild and one was moderate [ML: ‘yes, yes’] erm so the next time one was
moderate and one was heading towards severe you know it was [ML: ‘uhuh’] and when, we went
once and it was they were both over 15 [both left and right] both left and right were both over 15
and I was, I cried at that one because I knew that, that was severe and it wasn’t decreasing it was
getting worse . . .
P9
In cases in which the fetus had other pathologies, there were referrals to other specialists to clarify the
infant’s future quality of life with the condition. Many such cases were serious brain abnormalities involving
structural defects that often led to a TOP or a continuation of pregnancy expecting a non-surviving infant
or an infant with disability. The data suggested that iuMRI could help parents adjust and prepare for the
probable outcome, but uncertainties about prognoses could be disappointing for those who had hoped
that the new technology could provide more definite answers:
When we went . . . to the MRI scanner they still weren’t sure what they [cysts] meant [Family member:
‘no’] so they found the corpus callosum on the, on the MRI which just confirmed that it really hadn’t
disappeared which was good . . .
P25
The interview accounts show that participants benefited from clear explanations from consultants who drew
on different resources in communicating the diagnosis (e.g. analogies, drawings, textbooks, models and
scan images). The iuMRI images were seen as a useful source of information and explanation, but much
depended on how image interpretation was communicated to the women and families. At the Sheffield
site, parents could view the iuMRI images with the radiologist after the scan and found this process to be
beneficial. Other patients who were unable to view the images did not express much dissatisfaction; a small
number of patients were concerned about the waiting time or results.
Theme 2: experiences of in utero magnetic resonance imaging technology
A majority of iuMRI scans were conducted at the Sheffield site (27/41), but experiences of the technology
varied between and within sites. Scans took between 30 minutes and > 1 hour, depending on how well
the individual woman tolerated the scan and on fetal activity. Women understood the point of undergoing
iuMRI and for many it was an especially anxious time. In most women’s accounts, their discomfort seemed
to stem from being pregnant more than from the noise, heat and the confined space in the machine.
Those who described negative experiences in the machine were mostly those patients in advanced stages
of pregnancy or with a high body mass index:
I mean I was like 30-odd weeks pregnant and I was massive and I got, I got crushed in there so when I
come out I was crying . . .
P23
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Larger patient size led to more discomfort and could result in panic attacks. Most women tried their best
to keep as still as possible to try to settle the fetus for the scan to be completed. Many described resisting
urges to come out and tolerated any discomfort or pain to avoid delaying the process. The noise from
the machine was experienced as particularly loud and some women worried about their baby’s hearing.
In general, women were willing to undergo discomfort because of their concern for their baby.
Women appreciated being made comfortable and properly briefed about the procedure before and during
the scan via headphones. Several spoke about the support from their partner’s presence during the scan.
Those women and family members who were able to view the iuMRI images after the scan reported
positive reactions and some experienced surprise and, in one case, shock. Most women gave accounts
that expressed amazement and fascination at the image clarity compared with ultrasonography images.
Participants felt that the iuMRI images facilitated detailed explanations about the fetal brain abnormality
at follow-up. Those who had the opportunity to view the iuMRI images as a video clip found it incredible
and some described it as ‘surreal’. The possibility of seeing the video clip was also a turning point for those
parents facing an unexpected ‘reality’:
. . . like seeing that video when they put the frames together [ML: yeah] was just so amazing it really
made you feel like actually there is a real little baby in there . . . it’s not just . . . the ventriculomegaly . . .
P38
Theme 3: decision-making about a pregnancy at risk
Before considering the iuMRI, many participants experienced amniocentesis as a major crossroads, and
some participants decided to terminate the pregnancy after a trisomy 21 diagnosis. For other participants
continuing with pregnancies affected by trisomy 21, iuMRI images provided more detail of the brain and
assisted in the decision-making. Women who had had the amniocentesis and had normal results and
those who refused seemed more reliant on the iuMRI imaging than other patients:
. . . it would be MRI we got told it was all, he was all fully formed sort of and everything seemed to be
developing [F: yeah], sort of as much as it should be for that stage of pregnancy, we decided not to
[F: so we decided it (amniocentesis) wasn’t worth the risk] . . .
P11
Following the identification of a developmental brain abnormality, most participants experienced an
anxiety-ridden journey of abnormality monitoring. In VM cases, definitions of abnormality hinged on
ventricle measurements; iuMRI could be quite significant in parents’ decision-making in relation to what
the measurements meant. The clarity and detail provided in iuMRI images were particularly significant for
parents facing complex abnormalities that they could not quite comprehend. Viewing the iuMRI images
helped parents feel that they understood the abnormality and its possible consequences and helped them
come to terms with their baby’s condition. This feeling of enhanced understanding seemed to have a
strong impact on parental decision-making about their ‘at-risk’ pregnancy.
The timing of abnormality identification coinciding with fetal movements made it particularly difficult for
some mothers, heightening their desire for swift iuMRI results. Parents contemplating termination worried
about their baby’s future quality of life. In cases when disability would likely result from the brain abnormality,
the degree of severity was important. In these instances, iuMRI appeared important in influencing the tipping
point of parental decision-making. Some accounts suggested that iuMRI added to parents’ understanding of
the structural features of the brain:
. . . the clarity that, that the MRI scans can show is just and the detail, the level of detail they can see
is amazing it really is . . . I think it really hit it home for us because you could literally you know he
showed us the pictures of the brain and you could just see this big section missing, you know and he
showed us where it should be and what it should look like.
P41
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Theme 4: assessing the added value of in utero magnetic resonance imaging
In functional terms, participants understood that iuMRI technology could capture hundreds of images in
one scan session from various angles regardless of fetal position. The technology was also understood as
capable of scanning women with a higher body mass index. Participants saw iuMRI as producing clearer
images, representing comprehensive visualisations of the abnormality (compared with ultrasonography).
For this reason, many parents felt that iuMRI could provide additional information to ultrasonography.
Because parents recognised the importance of minute change in measurements, especially in VM, they
appreciated what they perceived as the greater accuracy and reliability of the information provided by
iuMRI. Nevertheless, some participants acknowledged the value of ultrasonography in identifying initial
problems and viewed these different technologies as being complementary.
For some parents, the perceived clarity and precision of iuMRI images reinforced their trust in the
patient–doctor relationship. Seeing structural defects with such clarity and establishing severity prepared
(or helped) them to think through either ending the pregnancy or facing the continuing pregnancy and
the possibilities at and beyond birth. However, parents who felt that the iuMRI had insufficiently prepared
them spoke of the shock of discovering an abnormality (or a more severe abnormality). This mother had
not felt prepared when her baby was born with trisomy 21:
ML: And do you think it’s all worth it going through all that?
P12: No not really cos we didn’t get anything found out. We didn’t, we don’t, we didn’t find what’s
wrong with him . . . it were a bit like a false sense really that everything’s going to be all right, cos I,
by this point I was like, he’s going to be all right.
The following response from the open-text section of a survey response also expresses a more negative
view of iuMRI:
The MRI scan showed additional problems that the ultrasound did not show – problems with the
cerebellum. I went for the MRI scan hoping for reassurance, but all I got was bad news. Problems with
the brain cannot be ‘fixed’ – therefore it should have been made clear that if we weren’t intending
to terminate then we shouldn’t have the scan, as nothing could be done except us worry.
ID100
Some parents felt that iuMRI merely confirmed/disconfirmed the ultrasonography findings, but some did
report relief and reassurance from the iuMRI findings. Those expecting a baby with a disability were
reassured when the extent of the disability was less serious than expected; others found that the iuMRI
images confirmed severity and so had greater confidence in their decision to end the pregnancy. Women’s
accounts reported that clinicians made it clear that expectations of the technology should be tempered
with caution.
Health professional participant characteristics
From 30 health professional recruitment packs, 23 (77%) returned a reply slip, of which 21 (70%) health
professionals were willing to be interviewed (50% of the originally identified sample). In round 1, 11 were
interviewed between March and August 2013. In round 2, 19 were interviewed [six face to face, 12 over
the telephone and one via Skype™ (Microsoft Corporation, Redmond, WA, USA)] between July 2014 and
March 2015. In round 1, interviews lasted between 41 and 89 minutes (average length of 63 minutes).
In round 2, interviews lasted between 26 and 62 minutes (average length of 44 minutes).
A total of 21 health professionals were recruited and interviewed at least once. Two participants were
interviewed in round 1 only, seven participants in round 2 only and nine participants were interviewed
in both. Participants’ characteristics are described in Table 34. Sites have not been included to protect
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participant anonymity in this close-knit professional field. However, participant recruitment covered
10 clinical sites and included sites with diverse provision structure (tertiary and non-tertiary care, those
providing iuMRI on site and those referring elsewhere).
Most participants fell within the fetal medicine and radiology specialties, but a number of participants were
in other categories (e.g. midwifery, radiography) or did not fit neatly into one category. To ensure the
confidentiality of participants in smaller subgroups, some specific categories are not identified.
Health professional qualitative interview findings
Theme 1: in utero magnetic resonance imaging in the health-care context
Health professionals using imaging techniques often enjoyed the intellectual challenge of imaging, and
the threshold competency for image interpretation is high. Producing and interpreting fetal images was
described as intuitive, especially in ultrasonography. Understanding the skill and experience involved in
TABLE 34 Characteristics of substudy health professional participants
Study ID Gender Specialism Site type Round 1 Round 2
HP01 Male Fetal medicine Tertiary Yes Yes
HP02 Male Rad Tertiary Yes Yes
HP03 Male Fetal medicine Tertiary Yes Yes
HP04 Male Fetal medicine Tertiary Yes Yes
HP05 Male Fetal medicine Tertiary Yes Yes
HP06 Male Fetal medicine Tertiary Yes Yes
HP07 Male Rad Tertiary Yes Yes
HP08 Male Rad Tertiary Yes Yes
HP09 Female Obstetrics/fetal medicine Non-tertiary Yes Yes
HP10 Female Rad Non-tertiary Yes Dropped out
HP11 Female Fetal medicine Non-tertiary Yes Not approached
HP12 Male Fetal medicine Tertiary Not approached Yes
HP13 Male Obstetrics/fetal medicine Non-tertiary Not approached Yes
HP14 Female Obstetrics/fetal medicine Non-tertiary Not approached Yes
HP15 Female Other Non-tertiary Not approached Yes
HP18 Male Rad Tertiary Not approached Yes
HP20 Female Rad Tertiary Not approached Yes
HP21 Female Fetal medicine Tertiary Not approached Yes
HP22 Male Other Tertiary Not approached Yes
HP23 Female Other Tertiary Not approached Yes
HP24 Female Rad Tertiary Not approached Yes
n = 21 12 male,
nine female
Eight fetal medicine only,
seven Rad only, six other
and obstetrics/fetal medicine
15 tertiary and
six non-tertiary
n = 11 n = 19
Rad, radiography/radiology.
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imaging was seen as important in highlighting the consequences of lack of expertise for both individuals
and newly emerged fields. Lack of expertise was considered problematic:
The harm is the misinterpretation both ways, so misinterpreting abnormal as normal but
misinterpreting normal as abnormal.
HP10, R1
Participants drew distinctions between radiologists’ interest in the clarity of anatomical structure compared
with fetal medicine specialists’ interest in images to understand fetal development. Radiologists in our
sample had regular patient contact but not all radiologists do. In other contexts, participants felt that this
could cause problems in MDT working when a radiology clinician ‘says no’ to a MRI request (to the treating
doctor, not to the patient). Radiology services face consistently increasing demand for MRI from other
medical specialties. Although there has been some increase in capacity, it has not kept pace with growing
demand.
Fetal medicine provision is primarily within specialist centres staffed by subspecialists, but some obstetricians
with specialist ultrasonography training provide high-risk work beyond specialist centres. Clinical practice is
therefore dependent on effective referral networks. Referral practices had implications for how (and where)
iuMRI was integrated in clinical pathways. Further layers of specialisation were apparent within established
fetal medicine centres. Views on the level of specialist knowledge needed for PND work varied, often
reflecting participants’ current role; those participants with subspecialty training felt that fetal medicine was
poorly understood by those outside the subspecialism.
Clinicians saw iuMRI as useful in PND, partly because of what could be ‘seen’ (e.g. symmetry of iuMRI
images compared with fetal ultrasonography). However, clinicians mainly noted the impact on counselling.
Both fetal medicine and radiology clinicians felt that iuMRI affirmed (rather than changed) provisional
ultrasonography diagnoses. Caveats to iuMRI utility included movement artefact and moving body parts
(e.g. the heart).
Interviewees compared past developments in fetal ultrasonography with more recent developments in
iuMRI. The expansion of fetal ultrasonography (and the migration of fetal imaging expertise from radiology
to fetal medicine) was described as a period of expansion and transition:
. . . very rapidly during [the late 1980s] it became apparent that obstetricians were learning obstetric
ultrasound and radiologists were beginning not to . . .
HP07, R1
Participants’ views about contemporary fetal ultrasonography provision drew on understandings of fetal
ultrasonography as an established but dynamic practice. Some clinicians felt that ultrasonography quality
had improved because of iuMRI feedback, whereas others worried that the ‘value added’ of iuMRI
reflected, in part, decreasing expertise in ultrasonography.
Most clinicians described incremental change in the context of iuMRI, including the more commonplace
lay experience of MRI, increasing data capture speed (shortening scan times) and image generation
developments. The significance of technological change in data capture and image processing was less
clear for clinical practice and patient experience in PND.
Developments in iuMRI practice reflected two key influences: (1) evidence-based policy and (2) managing
uncertainty. Formal research evidence was crucial, with clinical conferences providing a conduit for sharing
up-to-date information. Participants’ comments on evidence referred to concerns about uncertainty in
developing new practices given the impact that findings may have on women’s decision-making about
pregnancy. More material concerns included the funding of iuMRI provision and the timing of provision
for service users. Service development was conceptualised as incremental. In geographical terms, iuMRI
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provision had developed where there was sufficient demand, goodwill, professional interest and collaborative
working. Trust developed in teams providing care for parents making ‘high stakes’ decisions about a
pregnancy. This trust-building process centred on the reliability of interpretation:
. . . I don’t know of any case where [name] has made a diagnosis that’s been subsequently proved to
be wrong.
HP21, R2
Theme 2: in utero magnetic resonance imaging as added value in the prenatal diagnosis
for brain abnormality
Clinicians responsible for patient counselling saw specific advantages in iuMRI (e.g. improved imaging
of structures like the CC and for patients with a higher body mass index). Most comments related to the
perceived impact on counselling patients, sometimes because iuMRI confirmed the absence of additional
problems, improving confidence in the ultrasonography diagnosis. Alternatively, iuMRI information differed
from ultrasonography findings, clarifying either fetal normality or abnormality. Clinicians also saw significant
limitations, some of which were practical (e.g. inability to fit in the scanner, additional appointments, more
travelling). There were concerns that the possibility of iuMRI might create demand even when clinically
unnecessary. Participants consistently noted that iuMRI was useful, but as an adjunct to, not a replacement
for, ultrasonography.
Clinical decisions about management options were considered more straightforward for severe abnormalities
but more difficult when fetal abnormality lay close to the bounds of normality. Clinicians finalising the
diagnosis and the counselling of parents took reassurance from iuMRI as a second opinion (either from the
radiologist reporting the images or the modality). Perceived benefits included increased patient confidence,
increased clinician confidence/learning and reduced clinician isolation:
. . . I think if you’re making decisions based on life or death . . . you want to make sure you’re making,
you feel much, much, much, much, much happier making those recommendations or those choices
knowing that, that, that you’re not in isolation. Making those decisions before MRI I think er, was a
quite an isolating and lonely place.
HP4, R2
The uncertain risk associated with some anomalies made the lack of follow-up data on prognosis problematic,
but most clinicians saw iuMRI as helpful in refining diagnoses (if not prognoses). Limiting possible outcomes
was seen as helpful.
Clinicians compared the views of the brain offered by the two modalities and the physical processing
underpinning the imaging. Some felt that iuMRI was better than ultrasonography for viewing some specific
structural brain abnormalities. Participant HP06 (R1) offered a threefold typology of utility: (1) ultrasonography
suggests an abnormality but iuMRI finds none, (2) iuMRI gives additional information about an ultrasonography-
identified abnormality and (3) iuMRI identifies an abnormality not seen on ultrasonography (e.g. polymicrogyria).
Imager–interpreter relationships were also compared. Ultrasonography interpreters look at the image
while producing it; in iuMRI, the imager–interpreter relationship can be distant. This had an impact on
participants’ conceptualisations of quality and clinical applicability. Some felt that ultrasonography’s
interpreter-as-imager model improved quality, whereas others felt that double reporting (common in MRI)
was important. Modality also had an impact on clinician–patient relationships; some clinicians felt that
iuMRI images were more understandable to parents and others felt that ultrasonography’s ‘real-time’
image was better than an in utero magnetic resonance image ‘snapshot’. Participants discussed advantages
and disadvantages of ultrasonography’s perceived role in building rapport with pregnant women and
perceptions of safety and cost. Physical safety was seen as relatively clear for iuMRI, but cost was more
problematic. Economic viability required ongoing dominance of ultrasonography, with iuMRI as an adjunct.
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Fetal medicine specialists utilised iuMRI in different ways. Digital magnetic resonance images are transportable,
but many clinicians focus on only the textual report. Those with MDT experience generally found MDT
discussion helpful. Some clinicians felt that iuMRI reports could be more transparent about normality:
So just as you would have an ultrasound scan of a baby with a checklist of things that you say look
normal or don’t look normal, to have that for MRI would be very useful. So an MRI report that says
‘brain appearance is normal’ you think OK fine but that wouldn’t cut it with an ultrasound . . .
HP03, R2
Some clinicians providing fetal medicine counselling did not use the full details, instead looking for the
‘nitty gritty towards the end of the report’ (HP09, R2), whereas most clinicians saw value in structured
reporting to raise standards and as the basis of effective dialogue between clinicians:
. . . [the iuMRI team] have a very open approach in terms of getting hold of people that could explain
things better before I can explain it to the patient.
HP09, R1
Some clinician–patient encounters involved viewing images, but most fetal medicine specialists focused on
the iuMRI report to inform counselling. The iuMRI images were seen as potentially useful but not essential
and potentially problematic owing to lack of training in image interpretation. Participants identified the
ongoing and developing dialogue between radiology and fetal medicine as crucial for good-quality care.
Similar discussions were developing in other areas of fetal imaging (e.g. placenta) where cross-specialty
discussion of images was considered productive.
Theme 3: acceptable practice in providing in utero magnetic resonance imaging
Participants identified accessibility of services and perceived patient acceptability as key issues in acceptable
professional practice.
One aspect of accessibility is the location of the iuMRI scanner relative to the counselling site (same site,
local or regional/national travel). Participants reported that most women would travel but some would not
because of cost, inconvenience or wanting to be near home. Distance was balanced against service quality
and added value. Local provision was often considered more ‘ideal’, but some clinicians noted that this
might increase referral rates.
Accessibility of expertise was important. Time pressures in PND require swift access to specialised provision
(both image production and interpretation). Avoidable delay was considered highly problematic:
. . . pregnancy is very time sensitive and there’s decisions that parents make they need to have all the
information to make the decisions . . . some patients had to wait for, in my opinion, for too long to
get the MRI.
HP23, R2
Key indicators of acceptability for iuMRI included lay demand and ease of recruitment to the study.
Increased demand for iuMRI was seen as reflecting an increased demand for MRI in general. Expectations
sometimes required management, especially when women requested iuMRI when it was considered not
clinically justified. For some, the social characteristics of the population, or remote location, meant that
acceptability was less straightforward. Most professionals felt that their patients were accepting of MRI
technology, but some patients had reservations about the scanning process because of claustrophobia or
being pregnant and uncomfortable. Clinicians felt that patients appreciated the additional information,
with hunger for information driving patient demand.
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High-quality provision featured strongly in clinicians’ accounts of iuMRI in the PND for brain abnormality.
Acceptability was seen as underpinned by pragmatic and standards issues. Pragmatic issues often included
(in)adequate funding structures and (in)sufficient work volume to develop image interpretation expertise.
Clinicians sharing experience and standardised reporting were seen as important in raising technical
standards. Similarly, double reporting was considered beneficial in managing the uncertainties that might
stem from imaging or from variation in clinicians’ reporting experience. Lone provision was problematic
(e.g. annual leave, illness) and collaborative working was strongly endorsed:
. . . the worst thing that can happen is that the patient comes along, has the scan, you just reporting
it, it disappears off in to the nowhere [RG: yeah] with no knowledge of who’s receiving that whether
anyone’s bothered to read it.
HP17, R2
Standardisation was important, but clinicians explained that some variation in practice is inevitable and
acceptable in good-quality care at the individual level (e.g. relative levels of consultant–patient contact) or
at the unit level (e.g. referral practices). Variations in ultrasonography practice were framed around skill
levels (e.g. routine vs. specialist ultrasonography). Most comments about iuMRI variation centred on how
reports were written:
. . . the reporting length we get say from [specific site] even if it’s just telling us lots of things are
normal just feels much more reassuring to us as clinicians than the very brief summary we sometimes
get from our own units . . .
HP03, R2
Theme 4: enablers for future service development
Magnetic resonance imaging is just one option for radiology specialists, and iuMRI is one small element of
MRI activity. In a similarly niche area of fetal imaging, some participants noted that the low volume of
placental iuMRI did not justify funding a specific post (HP18, R1). Specialisation recurred in professionals’
accounts, suggesting a complex map of perceived authority to speak: ‘I think you should always stick to
what you’re good at and not dabble’ (HP10, R1). Clinicians understood their work in terms of specialist
training, highlighting the advantages of team working. Notions of expertise featured in fetal medicine and
radiology accounts, but as expertise in fetal imaging is more peripheral in radiology, regulated pathways to
expertise in fetal imaging were less developed. The lack of clear accreditation pathways to train the next
cohort of highly specialised fetal imagers was considered problematic. More informally, networks featured
strongly in clinicians’ accounts of iuMRI developments. Professional reputation really counted in this
network; one clinician noted that ‘. . . you learn which people often don’t get it right’ (HP21, R2). Trust
and reputation were crucial in professionals’ accounts; knowing who you were referring your patients to
(or receiving information from) was vital to good-quality provision:
. . . most clinicians the first thing they’ll do in a radiology is, who’s that, written the report . . . you can
automate a lot of things can’t you but you can’t automate that professionalism.
HP24, R2
Future iuMRI provision was discussed in terms of barriers to growth and influences on policy implementation,
with appropriate expertise and resourcing as common concerns. Participants saw a future for iuMRI
provision, but barriers to growth centred on difficulties securing sufficient staff with sufficient expertise,
adequate resourcing and infrastructure development. Several interviewees commented on recruitment
difficulties for radiology consultant posts.
Most clinicians linked problems associated with expanding provision to competing pressures for NHS
resource, and the possible outsourcing of iuMRI image interpretation was a significant concern. Three
key influences on policy change were identifiable in the data: (1) will professionals comply with new
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expectations, (2) how can collaborative working be promoted and (3) what is the best balance between
centralisation, geographical accessibility and value for money?
For changes in policy and provision to work, this demands engaged and willing clinicians. Guidelines and
funding mechanisms were seen as a way of facilitating and encouraging clinicians to work with the
evidence. Credible guidelines were seen as requiring meaningful consultation with clinician groups.
Fetal imaging in the PND for brain abnormality draws from both fetal medicine and radiology. Some clinicians
saw it as inevitable that radiologists would learn more fetal medicine, others that fetal medicine specialists
would learn iuMRI skills. However, training time for iuMRI is time not available for other aspects of
subspecialist training. MDT working was commonly seen as a positive development, but much depended
on getting the ‘right’ people in the room and confidence in the information presented. Working across
specialty boundaries was evident but challenging; sharing information between organisations remained
problematic (e.g. information transfer between NHS trusts). Most participants described a growing gap
between radiology and fetal medicine. Some saw iuMRI as signalling the need to reinvigorate this interface.
Collaborative working was seen as beneficial, but views differed on how this could be done. Some found
communication via the iuMRI report effective on its own, others suggested that collaborative working
needed more dialogue:
. . . it would be helpful if all the imagers could sit down together and learn exactly where we measure
say the ventricles . . . their atlas of normality is slightly different from our atlas of normality . . .
HP24, R2
Service user demand for imaging technology was seen as a key component of future policy developments.
Clinicians, aware of the need for cost-effective use of limited NHS funds, were mindful that cost-effectiveness
is balanced with quality control and professional acceptability. Provision of iuMRI on a larger scale (e.g. available
routinely for fetal brain abnormality diagnosis) required local interest and goodwill. Participants suggested that
resolving key capacity issues would be critical if the MERIDIAN study prompted expectations of UK-wide
provision. Capacity issues are not solely concerned with funds to pay for equipment and staff, but also
the time lag in training sufficient additional specialised clinicians. Generating additional posts (and trained
specialists to fill them) was a key concern for those thinking about how iuMRI should be developed in the UK.
The envisaged clinical groups needed to provide a good-quality service varied. Some felt that the primary
responsibility for the provision of iuMRI would remain with the radiology community, whereas others felt
that the expertise might migrate into fetal medicine. Future planning and investment for provision was
seen as important. The bottom line for participants was avoiding the dangers of adopting a new technique
in PND with a steep learning curve:
. . . there’s gonna be the people around the country that are doing it . . . or there’s going to be lots
of people trying to do it from ground zero and making all the mistakes that you make in your first
100, 150 cases erm. And that’s how you get a new technique a bad name.
P08, R2
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Chapter 5 The 2- to 3-year follow-up study
Introduction
Background
Although the main study demonstrated improved diagnostic accuracy and clinical impact of iuMRI, further
considerations must be addressed to fully answer whether or not iuMRI should be embedded in routine
clinical practice. First, the number of cases without an ORD was noted; a likely consequence of this is
that some diagnoses will not have been picked up and will only become clinically apparent as the child
develops. It is also possible that some incorrect diagnoses have been made. Thus, the 6-month follow-up
used in the original study may include diagnoses that differ from the confirmed diagnosis later in life.
Perhaps more importantly, the main study focused purely on the diagnosis, whereas to parents the
functional significance (i.e. motor, cognitive and behavioural) of the brain abnormality is of a greater interest.
The increased diagnostic accuracy only partially addresses the question of whether or not MRI improves
outcomes for the child and the family; outcomes in this context are very wide-ranging and include more
timely medical interventions, such as appropriate specialist referrals or the early involvement of therapists,
as well as improved understanding/knowledge, impacts on quality of life and parental anxiety. Following the
diagnosis of a fetal abnormality, parents often want to hear all the possible outcomes85 in order to build a
picture of what those difficulties would be like to live with. Aspects such as the emotional impact of caring
for a child with potentially serious disabilities and the implications for family life (financial and logistical)
affect their perceived ability to be able to provide for the child’s possible needs.86 The follow-up study was
intended to address these concerns by examining the predictive validity of antenatal diagnosis of a brain
abnormality for longer-term functional outcomes over the course of life. Specifically, we evaluated whether
or not a prognosis based on iuMRI offers an improvement on those prognoses made by ultrasonography
alone through a longer-term follow-up of our cohort.
Study aims and objectives
There were three distinct projects within the follow-up study, the aims and objectives of which are detailed
below.
Project 1
To estimate the diagnostic accuracy of ultrasonography and iuMRI using diagnoses collected over a 2- to
3-year time frame.
Project 2
To estimate the extent to which prognoses based on ultrasonography and iuMRI predict a neurodevelopmental
outcome at 2–3 years.
Project 3
To assess the clinical significance of isolated, mild VM and whether or not prognoses that incorporate iuMRI
are superior to those based on ultrasonography.
Methods
Participants and eligibility criteria
Study participants had undergone ultrasonography and iuMRI as part of the original MERIDIAN study
during their pregnancy. During the original consent process, women were asked whether or not they were
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happy to be contacted by the research team for future studies about their child’s development. Participants
were eligible if they:
l participated in the MERIDIAN study and had a surviving child aged ≥ 2 years
l underwent both ultrasonography and iuMRI during pregnancy as part of the MERIDIAN study
l consented to be contacted by the research team about future studies related to their
child’s development.
For children who were no longer alive, the date of death and the cause of death were obtained when
possible. No contact was made with the family.
Children who were aged > 42 months (term corrected) were not eligible for an assessment with the Bayley
Scales of Infant and Toddler Development, Third Edition (BSID3), because there is a ceiling for the upper
age at which a child can be tested using this tool, but they did complete an age-appropriate Ages and
Stages Questionnaire-3 (ASQ-3); the medical case notes were reviewed for additional diagnoses up until
the child was 42 months of age.
Participants were excluded from the study if any of the following criteria were met:
l if the child born to a participant in the MERIDIAN study was no longer alive
l if the child was no longer in the care of the biological mother who consented to participate in the
original MERIDIAN study
l the parent or guardian was unable to give informed consent
l the parent or guardian was unable to understand English (except in situations when another parent/
guardian of the child could translate and provide consent)
l if the participant was withdrawn at any stage of the MERIDIAN study.
Participant tracking and recruitment
To assess eligibility prior to contacting the participant for the follow-up study, the research team completed
a consent form audit to identify those participants who had consented to be approached about future
studies regarding their child’s development (optional question 7 in the original consent form). Of those
who had consented, medical notes and available NHS systems were checked to assess eligibility and
suitability for the study.
Section 251 Confidentiality Advisory Group approval (reference 15/CAG/0155) was obtained to allow the
central research team to check that the child was still alive using, when applicable, the Health and Social
Care Information Centre (now NHS Digital) Patient Tracking system.
Once participants were screened and deemed eligible, they were sent a letter of invitation and a consent
form/reply form to the most recent known address. The ASQ-3 was posted out along with the consent form.
Outcome measures and assessments
Project 1
Once written informed consent was received, a review of the participant’s medical case notes was
completed. We collected information about any further aetiological tests performed and diagnosis made,
as well as any follow-up care of the child and life events that may have had an impact on the child’s
development.
Project 2
For project 2, the MERIDIAN study children were invited to participate in a developmental assessment;
the BSID3 comprises cognitive, language and motor components. This is a standardised developmental
assessment tool validated in large numbers of children in both the USA and UK, and for which population-
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normative values are described. It provides details on cognitive, motor and communication skills and is
considered the best tool for assessing development in young children. The assessments were completed
either in the local recruiting hospital or, when possible, in the child’s home.
In addition to the BSID3, the Strengths and Difficulties Questionnaire (SDQ) and the MERIDIAN Gross
Motor Skills Questionnaire, which is based on the Gross Motor Function Classification Score (GMFCS),87
were completed. If a face-to-face appointment was not possible, then these two questionnaires were
completed via post or telephone. In some cases, the case review undertaken within project 1 provided
information about the child’s development that could be used in place of an assessment.
Two paediatricians independently reviewed the data. The first step involved looking at individual assessments
and their developmental domains. Each domain was categorised as ‘normal’, ‘borderline’ or ‘abnormal’. For
the BSID3, we considered that a composite score in any domain of > 85 (within 1 SD of the population mean)
was normal, 70–85 (between 1 and 2 SDs below the population mean) was borderline and < 70 (2 SDs
below the population mean) was abnormal. For the ASQ-3, a score in any domain in the ‘above the cut-off
point’ category (within 1 SD of the population mean) was normal, ‘near the cut-off point’ (between 1 and
2 SDs below the population mean) was borderline and ‘below the cut-off point’ (2 SDs below the population
mean) was abnormal. For the SDQ, normal was 0–12, borderline was 12–15 and abnormal was ≥ 16.
The paediatricians independently reviewed all of the data from the developmental assessment and
categorised each child’s overall developmental outcome as ‘normal’, ‘at risk’ or ‘abnormal’. Because the
ASQ-3 is a screening tool with a well-described false-positive rate, whereas the BSID3 is a formal hands-on
assessment, more weight was given to the BSID3. Therefore, a child who was below the cut-off line on the
ASQ-3 but had abilities in the normal range in the BSID3 was considered normal. The data from the SDQ
were used primarily when children were considered borderline between classifications. Therefore, when a
child showed a normal outcome on ASQ-3 and BSID3 but the SDQ was raised, the child was categorised
as having a normal outcome.
A child was classified as having an abnormal outcome when:
l the child’s development was abnormal in one or more domain on the BSID3
l the child’s development was abnormal in two or more domains on the ASQ-3 and no BSID3 data
were present
l the child’s development was abnormal in one domain and borderline in two or more other
developmental domains on the ASQ-3 and no additional BSID3 data were available.
A child with cerebral palsy was not automatically classified as being abnormal because a spectrum of
functional abilities and quality of life is possible for individuals with this diagnosis. When BSID3 or ASQ-3
scores for motor abilities were ≥ 2 SDs below the mean, or the GMFCS was ≥ 2, the child was categorised
as ‘abnormal’. When the child’s motor skills were within 2 SDs of the population mean, GMFCS was 1 and
there were no concerns on the SDQ, the child was categorised as ‘at risk’. This decision was made because
during antenatal counselling families want clinicians to build a picture of their child’s likely functional
abilities, and a diagnostic label associated with a broad spectrum of outcomes is not helpful in clinical
practice.
A child was categorised as ‘at risk’ if the child:
l was borderline in any developmental domain on the BSID3 (79–85)
l was borderline in two or more domains on the ASQ-3
l had a diagnosis of cerebral palsy but motor abilities on the BSID3 and/or ASQ-3 were normal and the
GMFCS was 0 or 1.
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The choice of words was important; it is possible that a child in the ‘at-risk’ group in our study could be in
either the normal or the abnormal group later in life. The implications of developmental outcome data in
antenatal counselling are that clinicians and women will use the data to make decisions on whether or not
to continue the pregnancy. In this situation, it was inappropriate to label children as ‘abnormal’ when their
scores fell into the normal population range and when they may have normal development in the future.
For the purpose of this study, participants who were ‘normal’ or ‘at risk’ were combined into a single
group.
All reviews were undertaken blind to diagnoses as obtained from ultrasonography, iuMRI or ORD. Any
cases for which there was disagreement were discussed by the clinicians at a panel review meeting and a
final decision was made by consensus.
The following were assessed using the outcome classifications:
l The prognosis as reported by antenatal ultrasonography alone (i.e. prior to iuMRI) relative to the
neurological development classifications calculated above.
l The prognosis as reported by iuMRI (following antenatal ultrasonography) relative to the neurological
development classifications calculated above.
l The prognosis as reported by antenatal ultrasonography alone (i.e. prior to iuMRI) relative to individual
components of neurological development.
l The prognosis as reported by iuMRI (following antenatal ultrasonography) relative to individual
components of neurological development.
Project 3
The primary outcome of project 3 was the developmental outcome at 2–3 years (i.e. ‘normal’, ‘at risk’ or
‘abnormal’) as defined in project 2 for participants diagnosed on iuMRI with an isolated mild VM.
Sample size
The sample size was constrained by the number of MERIDIAN study participants consenting to further
study. This did not affect project 1 for which the 6-month gestational age-corrected diagnosis was used
if no follow-up was available, meaning that the original sample size calculation remained applicable.
The sample size for project 2 was informed by the fact that there were almost 200 instances when the
prognosis changed as a result of iuMRI, of which 38 are now classified as the poorest prognosis. It was
also assumed that there would be approximately 400 surviving infants. Scaling these prevalences down,
400 cases would have a 90% power to detect a 20% increase in sensitivity and a 10% increase in
specificity using the tests outlined above at a two-sided significance level of 5%.
Project 3
With approximately 140 cases and assuming the prevalence of poor outcome is indeed less than 10%,
we will be able to estimate the prevalence to within a standard error of 2.5%.
Statistical methods
In project 1, the diagnostic accuracy was analysed as per the main MERIDIAN study, with the most recent
diagnosis (original MERIDIAN study diagnosis or subsequent) used as the ORD.
For project 2, the sensitivity, specificity, PPVs and negative predictive values (NPVs) of iuMRI and of
ultrasonography were reported. The sensitivity of each test was calculated for surviving children and
also for non-surviving children who had died because of reasons other than TOP. For surviving children,
the sensitivity was defined as the:
l number of participants with abnormal development and a prognosis of ‘poor’
l number of participants with abnormal development and a non-missing prognosis.
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The ability of ultrasonography and iuMRI to detect abnormalities associated with non-survival was defined
as the:
l number of non-surviving infants and a prognosis of ‘poor’
l number of non-surviving infants and a non-missing prognosis.
In order to provide an overall sensitivity averaged across both surviving and non-surviving infants, an
adjustment was required to ensure that surviving and deceased infants were represented proportionately
to their incidence. By definition, all deceased infants may be considered to have an ‘abnormal’ outcome
and, therefore, a response rate of 1. Defining the overall uptake of project 2 among surviving infants by p,
the sensitivity was therefore:
ns + p × nd, (1)
Ns + p × Nd, (2)
in which Ns infants were classified as having an abnormal prognosis and of whom ns had received a poor
prognosis; the total number of deceased infants at 2–3 years was Nd, of whom nd were classified as poor
prognosis.
The specificity was calculated for surviving children and was defined as the:
l number of infants with normal development and a prognosis of either ‘favourable’ or ‘normal’
l number of infants with normal development and a non-missing prognosis.
The relative prognostic accuracy of ultrasonography and iuMRI was compared by calculating the difference
in their respective sensitivities and specificities using McNemar’s paired-sample chi-squared test. CIs were
calculated using the Wilson method for simple proportions.88
The analyses were repeated with children classified as ‘abnormal’ and ‘at-risk’ neurodevelopment
considered as poor outcomes. Developmental scores (BSID3, GMFCS, SDQ and ASQ-3) were summarised
using box plots.
To further understand the characteristics of those recruited to the study compared with the original cohort,
specifically in relation to the prognosis on ultrasonography and iuMRI, simple bar charts were produced.
The number of infants who were not approached, who had died within the original study, who were
approached but did not consent and those who consented were presented by ultrasonography and iuMRI
prognosis category. Waffle charts comparing the proportion within each prognosis category in the original
cohort with those recruited into each project were produced. The number and type of deaths were also
presented by prognosis in a bar chart.
Owing to the small numbers who had completed developmental assessment, no further subgroup analysis
was conducted.
Analysis of project 3
Using the categories detailed in project 2 (i.e. ‘normal’, ‘at risk’ or ‘abnormal’), the prevalence of severe
and non-severe impairments was calculated together with exact binomial CIs. When the prognosis
changed as a result of iuMRI, we assessed whether or not this was attributable to the iuMRI identifying
further abnormalities.
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Additional analyses
Ages and Stages Questionnaire versus Bayley Scales of Infant and Toddler Development,
Third Edition
As an exploratory analysis, we assessed the diagnostic accuracy of the ASQ-3 in diagnosing neurodevelopmental
impairment. The PPV, NPV, sensitivity and specificity were calculated using the BSID3 assessment as the
‘reference standard’ and ‘abnormal’ development or not as the binary classification. Sensitivity and specificity
were presented with 95% exact binomial CIs.
Protocol amendments after study initiation
Details of substantial amendments submitted to the REC, which were important changes to trial
methodology, are listed below.
Contacting participants
A barrier to recruitment was being able to make contact with potential participants; therefore, a number
of amendments were implemented after reviewing recruitment throughout the study. First, the protocol
was updated to allow the research team to attempt to make contact through text messages when a
research mobile phone was available and to make a face-to-face approach if it was identified that the
potential participant was attending a clinic appointment.
A further amendment was then implemented to allow the research team to include the consent forms in
the initial invitation pack. The invitation letter was updated to clearly explain that the participant could
contact the research team if they wished to ask any questions prior to completing the consent form.
This approach was advised by the TSC to help improve the recruitment rate and reduce the burden on
participants.
Child age ranges for outcome measures
During the study, the initial cut-off age for offering a participant a BSID3 assessment was increased
from 38 to 42 months. The age for being eligible for an ASQ-3 was also increased from 42 months to
60 months to capture data on as many of the cohort as possible.
Results
Participant flow
Of the 829 participants from the MERIDIAN study who had both ultrasonography and iuMRI, 214 could
not be approached (Figure 6). A total of 615 participants were screened and 39 were found to be ineligible
at screening owing to the following: not wanting to be contacted (n = 12), being unable to confirm if the
child was alive (n = 3), the child was no longer in the care of the mother (n = 12) and it was deemed to
be inappropriate to contact (n = 12). A further 22 participants were excluded because a correct address
could not be found to which an invitation letter could be sent. A total of 554 invitation letters were sent;
196 participants did not respond and 41 declined to enter the study. A total of 317 participants agreed
to initial consent. Of these, 79 participants did not agree to formal consent.
Eight participants were screened in error as they did not complete iuMRI; two of these participants
completed consent and a developmental assessment despite being ineligible. For simplicity, these cases
have been excluded from the flow diagrams.
A total of 238 participants formally consented to project 1 (Figure 7); of these participants, medical
case note review could not be undertaken for 28 children. Medical case note review was undertaken in
210 children and updated imaging was found in 81 cases. Of those with updated imaging, five cases
had imaging that changed the original ORD and five had an ORD when they had not had one previously.
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When combined with the original MERIDIAN study data, 574 cases were included in the primary analysis
and 643 cases were included in the secondary analysis.
A total of 132 participants formally consented to project 2 (Figure 8); 127 of these completed at least one
type of developmental assessment. A further 52 participants completed the ASQ-3 as part of project 1.
When combined, a total of 179 participants completed at least one developmental assessment. Eleven
participants had relevant information in their medical case note review as part of project 1 that could be
used by clinicians to provide an overall assessment of development. A total of 190 participants completed
the clinicians’ review. The primary analysis was carried out on these 190 cases and on 78 children who had
died. Fifty-three children had died during the original MERIDIAN study and a further 25 children were
known to have died since the end of the MERIDIAN study.
  Did not consent
                        (n = 79)
• Not enough time, n = 2
• Consent form not received, n = 53
• No reason given, n = 10
• Not contacted, n = 13
• Other, n = 1
The MERIDIAN study
cohort with scans
(n = 829)
Number screened
(n = 615)
Number eligible
(n = 576)
Number sent
invitation letter
(n = 554)
Number agreed to
initial consent
(n = 317)
Number consented to
project 1
(n = 238)
Number consented to
project 2
(n = 132)
         Did not respond/no contact
          (n = 196)
   Declined entry
           (n = 41)
• No time, n = 6
• Not interested, n = 2
• Did not want to be contacted, n = 18
• Other, n = 15
Invitation letter could not be sent
        (n = 22)
• No address, n = 22
   Ineligible at screening
               (n = 39)
• Did not want to be contacted, n = 12
• Unable to confirm if child alive, n = 3
• Child no longer in care of mother, n = 12
• Inappropriate to contact, n = 12
                    Pre screening
    Could not be approached
    (n = 214)
• Died in original study, n = 177
• Died since the MERIDIAN study, n = 25
• Child outcome unknown, n = 8
• Withdrew from original study, n = 2
• Not screened reason unknown, n = 2
FIGURE 6 Participant flow in the MERIDIAN follow-on study.
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Consented to medical note review
(n = 238)
Medical note review completed
(n = 210)
Updated or new imaging available
(n = 81)
Medical note review
not undertaken
(n = 28)
• No access to notes, n = 22
• Consent returned too late,
   n = 6
No updated imaging
(n = 129)
Updated imaging did not
change the ORD
(n = 71)
Updated imaging changed the ORD
(n = 5)
New ORD available
(n = 5a)
Number included in primary analysis
(n = 574)
Number included in secondary analysis
(n = 643)
Number included in original
primary analysis
(n = 570)
Number included in original
secondary analysis
(n = 638)
FIGURE 7 Participant flow in the project 1 component of the follow-on study.
Number consented to project 2
(n = 132)
Did not complete
assessment or assessment
incomplete
(n = 4)
Completed clinician review
(n = 190)
Consented to project 1 and
completed ASQ-3
(n = 52)
Medical case note data from project 1
(n = 11)
Included in primary analysis
(n = 268)
Completed at least one
developmental assessment
(n = 179)
• BSID3, n = 88
• ASQ-3, n = 175
• GMFCs, n = 31
• SDQ, n = 102
Deaths within the MERIDIAN study
(n = 53)
Deaths since the MERIDIAN study
(n = 25)
• Unlikely to be fetal brain related, n = 2
• Brain sufficiently abnormal that might
   have caused death, n = 14
• Syndromic-type diagnosis likely to be
   associated with short lifespan where
   brain abnormality was a marker of a
   more widespread problem, n = 3
• Could not code, n = 6
FIGURE 8 Participant flow in the project 2 component of the follow-on study.
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Participant characteristics
Participants in projects 1 and 2 appear to be fairly representative of the overall MERIDIAN study cohort
(Table 35). Compared with the original cohort, a lower proportion of participants with a poor prognosis on
ultrasonography or iuMRI were recruited into project 1 or 2. A high proportion (55% on ultrasonography
and 62% on iuMRI) of participants with a poor prognosis died within the original MERIDIAN study
follow-up period (Figure 9). This can also be seen in Figure 10, demonstrating that a high proportion
of non-surviving infants had a poor or intermediate prognosis. Additional tables and figures summarising
the participants recruited in the study in comparison with the original cohort can be found in Appendix 11.
TABLE 35 Participant characteristics at entry to the MERIDIAN study
Characteristics
Overall
(N= 829)
Project 1
and project 2
(N= 194)
Project 1
only (N= 45)
Not
approached
(N= 274)
Approached,
not consented
(N= 316)
iuMRI site, n (%)
Sheffield 531 (64.0) 138 (71.0) 25 (56.0) 177 (65.0) 191 (60.0)
Birmingham 124 (15.0) 27 (14.0) 17 (38.0) 40 (15.0) 40 (13.0)
Newcastle 81 (10.0) 12 (6.2) 2 (4.4) 24 (8.8) 43 (14.0)
Leeds 57 (6.9) 5 (2.6) 1 (2.2) 21 (7.7) 30 (9.5)
Nottingham 16 (1.9) 2 (1.0) 0 (0.0) 5 (1.8) 9 (2.8)
Belfast 20 (2.4) 10 (5.2) 0 (0.0) 7 (2.6) 3 (0.9)
Maternal age (years) at approach,
median (IQR)
29 (24–33) 3 (26–35) 32 (25–34) 29 (24–33) 28 (24–32)
Single/multiple pregnancy, n (%)
Multiple 44 (5.3) 10 (5.2) 7 (16.0) 10 (3.7) 17 (5.4)
Single 784 (95.0) 184 (95.0) 38 (84.0) 263 (96.0) 299 (95.0)
Gestational age (weeks) at iuMRI,
median (IQR)
23 (21– 26) 23 (22–29) 22 (22–24) 22 (21–25) 23 (22–284)
Gestational age at iuMRI (weeks), n (%)
≤ 24 531 (64.0) 116 (60.0) 34 (76.0) 195 (71.0) 186 (59.0)
> 24 298 (36.0) 78 (40.0) 11 (24.0) 79 (29.0) 130 (41.0)
Diagnosis on iuMRI, n (%)
VM 405 (49.0) 106 (55.0) 30 (67.0) 89 (33.0) 180 (57.0)
CC 149 (18.0) 34 (18.0) 7 (16.0) 60 (22.0) 48 (15.0)
Posterior fossa 134 (16.0) 29 (15.0) 4 (8.9) 62 (23.0) 39 (12.0)
Other 138 (17.0) 25 (13.0) 4 (8.9) 60 (22.0) 49 (16.0)
Outcome of pregnancy, n (%)
Death 53 (6.5) 0 (0.0) 0 (0.0) 53 (20.0) 0 (0.0)
Livebirth 642 (78.0) 194 (100.0) 45 (100.0) 87 (33.0) 316 (100.0)
Termination 124 (15.0) 0 (0.0) 0 (0.0) 124 (47.0) 0 (0.0)
The MERIDIAN study analysis population, n (%)
ORD available 570 (69.0) 145 (75.0) 33 (73.0) 144 (53.0) 248 (79.0)
ORD unavailable 175 (21.0) 22 (11.0) 7 (16.0) 106 (39.0) 40 (13.0)
Excluded 84 (10.0) 27 (14.0) 5 (11.0) 24 (8.8) 28 (8.9)
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FIGURE 9 Bar chart showing the MERIDIAN study cohort (n= 829), by prognosis on (a) ultrasonography and (b) iuMRI for project 2. a, Death within original MERIDIAN include
terminations, stillbirths, fetal deaths and deaths within 6 months of birth.
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FIGURE 10 Bar chart showing the non-surviving infants in the MERIDIAN study cohort, by prognosis on (a) ultrasonography and (b) iuMRI (n= 202).
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Project 1
Primary analysis project 1: diagnostic accuracy
Consent was obtained for 238 infants, of whom 81 had undergone further imaging since the original
MERIDIAN study. As a result of this, 10 infants had an updated ORD. Five participants had updated imaging
that did not show the same pathology as the previous ORD and the additional pathologies seen had not
been acquired since birth. Of these five, the original ORD agreed with the ultrasonography in two cases
and with the iuMRI in five cases; the revised outcome for all five participants was discrepant with both
ultrasonography and iuMRI. Outcome data were obtained for a further five participants for whom there had
been no previous ORD.
The primary analysis (comprising fetuses undergoing iuMRI within 14 days of ultrasonography) included
four children with a revised ORD and four children who previously had no ORD. Table 36 shows the
updated diagnostic accuracy using updated imaging. The overall difference in diagnostic accuracy was
24.8% (95% CI 21.0% to 28.5%; p < 0.0001), which is very similar to the original difference of 24.9%
and still statistically significant.
When including all participants with an ORD, regardless of the timing of the iuMRI (Table 37), there was
still a significant difference of 23.3% (95% CI 19.8% to 26.9%; p < 0.0001).
Project 2
Developmental assessment scores and categories
Box plots showing the distribution of BSID3 scores appear to show very little difference between an
ultrasonography prognosis and an iuMRI prognosis (Figure 11). Median BSID3 composite scores are fairly
similar in those patients with a normal or favourable prognosis on ultrasonography and those with the
same prognosis on iuMRI. There is a small difference between ultrasonography and iuMRI in median
composite scores in those patients with a poor or an intermediate prognosis. iuMRI demonstrates slightly
lower medians in each of the composite subscale scores. Lower scores indicate lower developmental
ability. Box plots of ASQ-3 and SDQ can be found in Appendix 12.
TABLE 37 Diagnostic accuracy of ultrasonography and iuMRI by age of fetus in 643 cases with ORDs, using updated
and new ORDs. A total of 638 cases had previously had an ORD and a further five cases had a new ORD at 2–3 years
Fetal age
Ultrasonography
correct, n (%)
iuMRI correct,
n (%)
Percentage difference
(95% CI) p-valuea
18–23 weeks (N = 403) 277 (68.7) 362 (89.8) 21.1 (16.7 to 25.5) < 0.0001
≥ 24 weeks (N = 240) 160 (66.7) 225 (93.8) 27.1 (20.9 to 33.2) < 0.0001
Combined (N = 643) 437 (68) 587 (91.3) 23.3 (19.8 to 26.9) < 0.0001
a McNemar’s test between ultrasonography and iuMRI.
TABLE 36 Diagnostic accuracy of ultrasonography and iuMRI by age of fetus in the 574 cases with ORD, using
updated ORD (n= 5) and new ORD (n = 4) for participants who completed iuMRI within 2 weeks
Fetal age
Ultrasonography
correct, n (%)
iuMRI correct,
n (%)
Percentage difference
(95% CI) p-valuea
18–23 weeks (N = 372) 257 (69.1) 339 (91.1) 22.0 (17.4 to 26.7) < 0.0001
≥ 24 weeks (N = 202) 130 (64.4) 190 (94.1) 29.7 (22.9 to 36.5) < 0.0001
Combined (N = 574) 387 (67.4) 529 (92.2) 24.8 (21.0 to 28.5) < 0.0001
a McNemar’s test between ultrasonography and iuMRI.
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FIGURE 11 Box plots of BSID3 subscale composite scores, by ultrasonography and iuMRI prognosis in the MERIDIAN
study. (a) Cognitive index; (b) language index; and (c) motor index.
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The majority of participants (106/190) who were followed up were assessed as normal (Table 38). A total
of 58 out of 190 (31%) participants were assessed as abnormal. Descriptive statistics tables for the
developmental scores are presented in Appendix 13.
Primary analysis: project 2
Our primary analysis of project 2 (Table 39) indicates that there is no difference between ultrasonography
and iuMRI in prognosticating abnormal development in the surviving infants (difference of 5%, 95% CI
–7% to 18%; p = 0.505). This observed result is likely to be influenced by the small number of infants
from the original cohort with a poor prognosis being recruited into the study. A high proportion of these
infants died.
In utero magnetic resonance imaging demonstrated a higher number of correct prognoses in surviving infants
who were developmentally assessed as ‘normal’ or ‘at risk’ than did ultrasonography (ultrasonography, 51%;
iuMRI, 70%). This difference was statistically significant (difference of 19%, 95% CI 10% to 30%; p = 0.0004).
TABLE 38 Number and percentage of participants in each development category overall and according to each
individual assessment tool
Development tool (N= 190) n (%)
Overall development category
Abnormal 58 (31.0)
Borderline 26 (14.0)
Normal 106 (56.0)
BSID3 category
Abnormal (< 70) 21 (24.0)
Borderline (70 to < 85) 12 (14.0)
Normal (≥ 85) 55 (63.0)
ASQ-3 category
Abnormal 49 (29.0)
Borderline 24 (14.0)
Normal 98 (57.0)
SDQ category
Abnormal (≥ 16) 17 (17.0)
Borderline (13–15) 5 (5.0)
Normal (0–12) 79 (78.0)
GMFCS level
I 26 (84.0)
II 2 (6.5)
III 1 (3.2)
IV 2 (6.5)
V 0 (0.0)
Cerebral palsy
Yes 4 (2.1)
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When including non-surviving infants (Table 40), iuMRI was slightly better at correctly classifying a prognosis
(difference of 11%, 95% CI –3% to 21%). However, with the weighting applied to the non-surviving cases
this difference decreased and was not statistically significant (difference of 8.37%, 95% CI –4% to 17%;
p = 0.2717).
A further sensitivity analysis was conducted for which ‘normal’ and ‘at-risk’ cases were grouped together
(Table 41). In this analysis, the difference in sensitivity was 6% (95% CI –1% to 21%; p = 0.099), which is
greater than the difference in sensitivity shown in Table 6. The difference in specificity was 20% (95% CI
9% to 31%; p = 0.0005).
A breakdown of ultrasonography and iuMRI prognoses in abnormal, normal and borderline cases and a
visual summary of Table 39 can be seen in Appendix 14.
Ages and Stages Questionnaire, Third Edition, and Bayley Scales of Infant and Toddler
Development, Third Edition
In total, ASQ-3 categorised 25 cases as abnormal, of which 17 cases were in agreement with BSID3,
providing a PPV of 68% (Table 42). The ASQ-3 categorised 47 cases as normal and 12 cases as borderline.
The BSID3 was in agreement with 57 out of 59 of these cases, providing a NPV of 97%.
The ASQ-3 correctly categorised 17 out of 19 abnormal cases (Table 43). This corresponds to a sensitivity
of 90% (95% CI 67% to 99%). A total of 43 out of 52 normal cases were correctly categorised by the
ASQ-3, providing a specificity of 83% (95% CI 70% to 92%).
Although the numbers are small, this provides some limited evidence that the ASQ-3 performs fairly well in
categorising developmental impairment when compared with BSID3; however, the ASQ-3 had a relatively
low PPV owing to eight false positives.
TABLE 39 Primary analysis of project 2: prognosis on ultrasonography and iuMRI compared with the
neurodevelopmental category at 2- to 3-year follow-up in surviving infants only
Prognosis Abnormal development Normal/at-risk development
Prognosis on ultrasonography, n (%) N = 58 N = 132
Poor 11 (19.0) 5 (3.8)
Intermediate 14 (24.0) 35 (27)
Favourable 17 (29.0) 60 (46.0)
Normal 1 (1.7) 7 (5.3)
Not known 15 (26.0) 25 (19.0)
Ultrasonography correctly classified (%) 19 51
Prognosis on iuMRI, n (%) N = 54 N = 125
Poor 13 (24.0) 5 (4.0)
Intermediate 15 (28.0) 21 (17.0)
Favourable 20 (37.0) 76 (61.0)
Normal 1 (1.9) 12 (9.6)
Not known 5 (9.3) 11 (8.8)
iuMRI correctly classified (%) 24 70
Both ultrasonography and iuMRI prognosis N = 54 N = 125
Difference (95% CI) 5 (–7 to 18) 19 (10 to 30)
p-valuea 0.505 0.0004
a McNemar’s test between ultrasonography and iuMRI prognosis.
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TABLE 40 Primary analysis of project 2: prognosis on ultrasonography and iuMRI compared with the
neurodevelopmental category at 2- to 3-year follow-up in surviving and non-surviving infants
Prognosis Fetal or infant death
Combined surviving and
non-surviving infants
(weighting of 0.306)
Prognosis on ultrasonography, n (%) N = 78 N = 81.26
Poor 29 (37.0) 19.87 (25.0)
Intermediate 19 (24.0) 19.81 (24.0)
Favourable 10 (13.0) 20.06 (25.0)
Normal 2 (2.6) 1.61 (2.0)
Not known 18 (23.0) 20.51 (25.0)
Ultrasonography correctly classified (%) 38.00 30.63
Prognosis on iuMRI, n (%) N = 73 N = 76.34
Poor 36 (48.0) 24 (31.0)
Intermediate 18 (24.0) 21 (28.0.)
Favourable 9 (12.0) 23 (30.0)
Normal 2 (2.7) 2 (2.6)
Not known 10 (13.0) 8 (11.0)
iuMRI correctly classified (%) 49.00 38.99
Both ultrasonography and iuMRI, n (%) N = 73 N = 76.34
Difference (95% CI) 11 (–3 to 21) 8.37 (–4 to 17)
p-valuea 0.1456 0.2717
a McNemar’s test between ultrasonography and iuMRI prognosis.
TABLE 41 Primary analysis of project 2 repeated combining abnormal and at-risk groups
Prognosis Abnormal/at-risk development Normal development
Prognosis on ultrasonography, n (%) N = 84 N = 106
Poor 11 (13.0) 5 (4.7)
Intermediate 20 (24.0) 29 (27.0)
Favourable 28 (33.0) 49 (46.0)
Normal 2 (2.4) 6 (5.7)
Not known 23 (27.0) 17 (16.0)
Ultrasonography correctly classified (%) 13 52
Prognosis on iuMRI, n (%) N = 80 N = 99
Poor 15 (19.0) 3 (3.0)
Intermediate 20 (25.0) 16 (16.0)
Favourable 34 (43.0) 62 (63.0)
Normal 4 (5.0) 9 (9.1)
Not known 7 (8.8) 9 (9.1)
iuMRI correctly classified (%) 19 72
Both ultrasonography and iuMRI prognosis N = 80 N = 99
Difference (95% CI) 6 (–1 to 21) 20 (9 to 31)
p-valuea 0.099 0.0005
a McNemar’s test between ultrasonography and iuMRI prognosis.
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Project 3
Prevalence of impairment in participants with mild isolated ventriculomegaly
Of the 190 children included in project 2, 86 children had received a diagnosis of mild isolated VM on
ultrasonography and 71 children received this diagnosis on iuMRI; 60 children had the same diagnosis on
both modalities. In total, 19 (22%) participants diagnosed with isolated mild VM on ultrasonography had
an abnormal neurodevelopment, with a further 12 (14%) participants considered ‘at risk’. Among those
patients with a diagnosis of isolated mild VM on iuMRI, the incidences were 18% on ultrasonography and
13% on iuMRI. None of the children had received a poor prognosis on either modality (Table 44).
TABLE 42 Comparison of development categories according to BSID3 and ASQ-3 in participants who completed
both assessments (n = 84)
ASQ-3
BSID3
Abnormal Borderline Normal Total
Abnormal 17 7 1 25
Borderline 2 2 8 12
Normal 0 3 44 47
Total 19 12 53 84
TABLE 43 The number of cases correctly diagnosed as abnormal and normal using ASQ-3 alone when compared
with BSID3
Overall
Abnormal development cases correctly diagnosed Normal development cases correctly diagnosed
Number of cases Sensitivity (95% CI) Number of cases Specificity (95% CI)
17/19 90 (67 to 99) 44/53 83 (70 to 92)
TABLE 44 Developmental assessment in relation to the original prognosis
Prognosis
Included in follow-up, n (%) Not included, n (%)
Abnormal
(N= 19)
At risk
(N= 12)
Normal
(N= 55)
Did not consent
to project 2
(N= 173)
Non-livebirth
(N= 38)
Based on ultrasonography
Poor (< 50%) 0 (0) 0 (0) 0 (0) 1 (1) 2 (5)
Intermediate (50–90%) 2 (11) 2 (17) 8 (15) 32 (18) 5 (13)
Favourable (> 90%) 12 (63) 8 (66) 40 (73) 130 (75) 28 (74)
Normal 1 (5) 0 2 (4) 2 (1) 1 (3)
Not known 4 (21) 2 (16) 5 (9) 8 (5) 2 (5)
Based on iuMRI
Poor (< 50%) 0 (0) 0 (0) 0 (0) 0 (0) 3 (8)
Intermediate (50–90%) 5 (26) 0 (0) 7 (13) 21 (12) 5 (13)
Favourable (> 90%) 11 (58) 10 (83) 42 (76) 132 (76) 23 (61)
Normal 0 (0) 1 (8) 0 (0) 9 (5) 2 (5)
Not known 2 (11) 1 (8) 2 (4) 4 (2) 4 (11)
Not recorded 1 (5) 0 (0) 4 (7) 7 (4) 1 (3)
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Isolated mild VM cases showed a higher incidence of abnormal neurodevelopment than the commonly
quoted 5–10% incidence attributed to VM, irrespective of whether the diagnoses were based on
ultrasonography or iuMRI. These differences may arise from features other than VM as described below.
Severity
The severity of VM was similar across the normal, at-risk and abnormal groups, with the largest trigone
sizes being, on average, 11.0 mm, 11.0 mm and 11.1 mm, respectively, among the 86 cases imaged by
ultrasonography. The largest trigone, as measured by iuMRI, showed more separation, with means of
11.3 mm, 11.5 mm and 12.1 mm, respectively, among the 71 cases, but with substantial overlap in size
between the groups. A total of 62 out of the original 86 cases had ventricles within normal limits on ORD,
with fewer instances of a resolved VM in the abnormal group (9/19 in the abmormal group vs. 2/11 in the
at-risk group and 11/54 in the normal group).
Additional brain diagnoses
Ten (12%) children had additional brain diagnoses noted on ORD, although not all of these additional
findings were considered to be of significance when assessing the overall diagnostic agreement. Eight of
these diagnoses were also found on iuMRI. Proportionately more additional diagnoses were noted in the
abnormal neurodevelopmental group, in which 4 out of 19 children had an additional diagnosis, compared
with 2 out of 11 children in the at-risk group and 4 out of 54 children in the normal group. All 10 of the
additional diagnoses were made postnatally and no new diagnoses were reported at the 2- to 3-year case
review.
Other diagnoses and life events
A total of 15 children had either (non-brain) conditions or significant life events (e.g. cardiac complications,
chromosomal abnormalities or prolonged hospitalisation) that are likely to have led to a delayed development.
These were proportionately more common among children assessed as having abnormal neurodevelopment
(7/19) than among children assessed as having at-risk (4/12) or normal development (4/54). Four of these
children also had additional brain abnormalities (two in the abnormal group and two in the at-risk group).
Table 45 shows the prevalence of abnormal and at-risk neurodevelopment for children diagnosed with VM
for the subset with no additional diagnoses and for the subset with no diagnoses or other complications.
TABLE 45 Prevalence of abnormal and at-risk neurodevelopment at 2- to 3-year follow-up among cases of isolated
mild VM
VM diagnosis details
Abnormal At risk
n
Prevalence,
% (95% CI) n
Prevalence,
% (95% CI)
VM on ultrasonography
All cases (N = 86) 19 22 (14 to 32) 12 14 (7 to 23)
Excluding additional brain diagnoses (N = 76) 15 20 (11 to 30) 10 13 (6 to 23)
Excluding all additional diagnoses or complications (N = 65) 10 15 (8 to 26) 8 12 (17 to 40)
VM on iuMRI
All cases (N = 71) 13 18 (10 to 29) 9 13 (6 to 23)
Excluding additional brain diagnoses (N = 67) 12 18 (10 to 29) 9 13 (6 to 24)
Excluding all additional diagnoses or complications (N = 57) 7 12 (5 to 24) 8 14 (6 to 26)
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Chapter 6 Add-on study
Introduction
Background
Recruitment into the MERIDIAN study was restricted to women with fetuses for which a brain abnormality
was seen on ultrasonography. This allowed an assessment of the diagnostic accuracy of ultrasonography
and iuMRI in terms of the false-positive rate of detecting a fetal brain abnormality; however, the false-
negative rate cannot be estimated by the main MERIDIAN study. The add-on study addressed this by
recruiting pregnant women carrying a fetus without any form of abnormality detected on detailed
ultrasonography. This allowed us to describe the false-negative rate of ultrasonography.
Study aims and objectives
The aim of the add-on study was to answer the question ‘What is the false-negative rate of antenatal
ultrasound performed by fetal medicine specialists when trying to detect fetal brain abnormalities?’.
Methods
Participants and eligibility criteria
Inclusion criteria
Participants were recruited to the add-on study based on the following criteria:
l Had an ongoing singleton or multifetal pregnancy of at least 18 + 0 weeks’ gestation by
ultrasonography dating.
l Was thought to be carrying a fetus with no abnormality whatsoever (i.e. no brain or somatic
abnormality). This criterion was based on a normal mid-pregnancy abnormality scan in a fetal medicine
centre or was confirmed as normal by a senior sonographer or specialist midwife.
Exclusion criteria
A participant was excluded from the study if any of the following criteria were met:
l had a history of a fetal brain abnormality in a previous pregnancy
l was unable to give informed consent
l had a cardiac pacemaker, an intraorbital metallic foreign body or a recent surgery with metallic sutures
or implant
l had previously experienced or is likely to suffer severe anxiety or claustrophobia in relation to the
iuMRI examination
l was unable or unwilling to travel to Sheffield for specialist iuMRI
l was unable to understand English (except where satisfactory translation services were available)
l was < 16 years old
l was unwilling for the GP to be informed about the study and given copies of scan reports.
Participating MERIDIAN study sites displayed posters and leaflets in public areas that included details of the
add-on study. Potential participants could then ask staff about the study and receive the full participant
information sheet (PIS). Fetal medicine specialists and research midwives also informed women about the
study during their clinics and provided them with the PIS and leaflet. Clinic lists were also screened and
women who had attended the clinic for a detailed ultrasonography abnormality scan within the last 7 days
were sent a copy of the PIS by post. If the woman was interested in participating, the research midwife or
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fetal medicine specialist gained permission to pass the woman’s contact details on to the research team
at the Academic Unit of Radiology, University of Sheffield; alternatively, the woman could make direct
contact herself as details were provided on the study leaflet and PIS.
Local media, such as radio advertisements and newspapers, were also used to promote the study and
included details of how to express an interest to the research team.
The research team at the Academic Unit of Radiology contacted the potential participants by telephone to
complete a screening assessment and, if deemed eligible, arranged for them to attend the unit for the
iuMRI study.
When the participant attended for the scan, further background information was collected and written
informed consent was obtained.
Sample size
Starting from the assumption that no ultrasonography false negatives will be found, the study aimed to
recruit 200 fetuses on the basis of the 3/n rule,89 a large sample approximation of the upper 95% CI for
very rare events. This allowed the NPV of ultrasonography to be estimated to an upper confidence limit
of 1.5% in the absence of any abnormal scans and to within a standard error of ≤ 2% for an incidence of
< 10%.
Statistical methods
In this add-on study, the diagnostic accuracy of ultrasonography was defined as the probability that a
negative scan was correct; this corresponds to the NPV. For iuMRI, diagnostic accuracy was the percentage
of cases correctly diagnosed, and the proportion of normal diagnoses corresponds to the NPV of iuMRI
following ultrasonography. No attempt was made to estimate the sensitivity or specificity as the study was
not a prospective sample of all pregnancies.
The fetal brain was assumed to be normal if the iuMRI study was normal, but in cases when an
abnormality was suspected by iuMRI the pregnancy was followed up to ascertain whether
ultrasonography, iuMRI or neither were correct.
Results
Recruitment and scanning took place between November 2013 and May 2017. A total of 225 pregnant
women enquired about the study, of whom three did not meet the inclusion criteria because of pregnancy
complications, 21 failed to attend or cancelled their appointment, two gave birth before their appointment
and one iuMRI was abandoned owing to the participant feeling unwell. A total of 198 participants with
205 fetuses (14 twin pregnancies) were scanned successfully, of whom 26% were between 18 and 23
gestational weeks at the time of iuMRI.
The iuMRI studies were reported as normal for 203 cases but brain abnormalities were reported in two
fetuses from separate pregnancies. In the first, a pathology consistent with a focal cortical dysplasia or
cortical tuber was suggested on iuMRI and confirmed on postnatal MRI, although its exact nature remained
uncertain. The second difference was a mild VM with the trigones of both lateral ventricles measuring
between 10 mm and 11 mm; the fetus also had macrocephaly (biparietal diameter > 97th centile and
occipitofrontal on the 97th centile). The latter has been interpreted as a borderline and evolving diagnosis
for which both ultrasonography and iuMRI reached appropriate diagnoses; however, the first is a missed
negative for ultrasonography, resulting in a NPV of 99.5% (exact 95% CI 97.3% to 100.0%).
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Chapter 7 Discussion
Main findings
We conducted a large, multicentre, observational, cohort study designed to assess the diagnostic accuracy,
clinical impact and acceptability of iuMRI as an adjunct to detailed antenatal ultrasonography when
diagnosing fetal brain abnormalities. The primary findings are summarised below, along with some
unresolved questions.
Accuracy of diagnosis
Our main finding was that the overall diagnostic accuracies of ultrasonography and iuMRI were 67.9% and
92.8%, respectively, meaning that iuMRI showed an improvement in diagnostic accuracy of 24.9%. The
diagnostic accuracy of ultrasonography was lower in fetuses with a gestational age of > 24 weeks (64.2%)
than in those with a gestational age of 18–23 weeks (69.9%), whereas iuMRI remained similar at 93.5%
for those > 24 weeks’ gestational age and 92.4% for those with a gestational age of 18–23 weeks. This
indicates an improvement in diagnostic accuracy of 22.5% in the 18–23 weeks group and of 29.3% in the
> 24 weeks group. The reduced accuracy of ultrasonography observed in fetuses at > 24 weeks’ gestation
may be a result of several factors, including difficulties caused by the ongoing ossification of the fetal skull,
the increased physical size of the woman and the descent of the fetal head into the maternal pelvis.
The accuracy of positive ultrasonography in diagnosing fetal brain abnormalities has been the subject
of several previous studies.15–18 Our finding that ultrasonography was accurate in 69.9% of fetuses at
< 24 weeks’ gestation and in 64% of fetuses in later stages of gestation is consistent with those reports.
This leads us to suggest that iuMRI significantly increases the accuracy of fetal brain diagnoses compared
with ultrasonography alone in all fetuses at ≥ 18 weeks’ gestation.
The three commonest ultrasonography diagnoses were VM as the only intracranial abnormality (54%),
an abnormality restricted to the contents of the posterior fossa (15%) and failed commissuration (14%).
There were statistically significant improvements in diagnostic accuracy for iuMRI compared with
ultrasonography in all three subgroups (VM, 8.5%; posterior fossa, 22%; failed commissuration, 60.7%),
indicating that iuMRI has advantages in diagnosing a broad range of developmental abnormalities of
the brain and should be included in the diagnostic pathway regardless of the suspected pathology type.
Notably, additional brain abnormalities were present in 10.1% (31/306) of cases in which ultrasonography
diagnosed isolated VM. iuMRI accurately recognised 27 of these additional brain abnormalities, resulting in
a diagnostic accuracy of 98.4%, compared with ultrasonography alone at 89.9%.
Further to this, we were able to recruit women with low-risk pregnancies and normal fetuses on
ultrasonography to undergo iuMRI of the fetal brain. To our knowledge, this is the first study of this
population and our results confirm the ability of both ultrasonography and iuMRI to correctly confirm
when the brain development of the fetus is normal. This highlights the validity of ultrasonography as the
primary screening imaging method for pregnancy and further supports the need for additional iuMRI when
abnormalities are detected.
Diagnostic confidence
The importance of diagnostic confidence as well as diagnostic accuracy when assessing an imaging
technology is often overlooked and less well studied, even though Ng and Palmer58 have explained its
relevance. To the authors’ knowledge, there are no published studies that report on the diagnostic
confidence of iuMRI. Our study was designed to address this issue and our data show that iuMRI increased
the proportion of high-confidence diagnoses by 13%, from 82% on ultrasonography alone to 95% after
iuMRI. As highlighted by Ng and Palmer,58 an incorrect diagnosis made with high confidence can result in
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an inappropriate change in management (in this case an inappropriate TOP). We found that iuMRI gave
fewer high-confidence but incorrect diagnoses than ultrasonography (6% vs. 22% of the total number of
cases). Alternatively, TOP may not be offered if an imaging diagnosis is made with low confidence. This
again can bring about medical errors if the diagnosis is found to be correct, as withholding an intervention
may have detrimental effects. The MERIDIAN study data demonstrate that iuMRI resulted in fewer low-
confidence diagnoses (5% iuMRI vs. 18% ultrasonography alone) and fewer incorrect low-confidence
diagnoses (3% iuMRI vs. 8% ultrasonography alone).44
Counselling and management
As far as we were aware, this is the first prospective analysis of the clinical impact of iuMRI in fetuses
with brain abnormalities; in this paper we have shown that iuMRI brings about changes in counselling and
management in a high percentage of cases.44 Specifically, iuMRI provided additional diagnostic information
in 49% of cases, caused a documented change in prognosis in 44% of cases and had major effects on
counselling in 15% of cases. The contribution of iuMRI to overall clinical management was judged to
be ‘significant’ in 26% of cases and had either a ‘decisive’ or ‘major’ influence in a further 9% of cases.
This is a considerably larger effect than the 5% change in management anticipated at the design stage,
an increase that can be attributed to the greater than predicted improvement in diagnostic accuracy.44
Prognostic importance
The importance of the long-term functional significance of the suspected brain abnormality must not be
overlooked and is of great importance in preparing parents for the potential outcomes. There are limited
data available for many brain abnormalities (or combinations) of fetal abnormalities from which fetal
medicine experts can draw to predict outcome66 and to inform their counselling, although data on
outcomes for certain abnormalities, such as isolated VM and ACC, are more plentiful. The 2- to 3-year
follow-up study aimed to address this gap. Although recruitment figures were lower than anticipated, our
findings indicate that, despite the increase in diagnostic accuracy and confidence provided by iuMRI, fetal
medicine experts still find it difficult to prognosticate accurately, especially in terms of predicting abnormal
development. There are a number of possible explanations for this uncertainty when providing a prognosis,
including the experience of the fetal medicine expert in reading and interpreting the iuMRI report. It is
possible that a neonatologist or paediatric neurologist, who are more familiar with these types of reports
or conditions and may see affected children for long-term follow-up, may be more able to predict a
prognosis with greater accuracy. The growing culture of litigation in health care may also be leading to
concerns among fetal medicine experts regarding the counselling and management of a PND.90 The impact
of a brain abnormality, even if the abnormality is confirmed, can vary markedly between individual infants.
The prognosis of an abnormality can include a great deal of uncertainty and the information and steps
required to reach a decision can be complex.64
Our key finding in relation to long-term prognostic importance is that iuMRI appears to be better at ruling
out an abnormal developmental pattern than ultrasonography, most likely by excluding the diagnoses that
were suspected on ultrasonography. iuMRI was associated with a statistically significant improvement of
19% in predicting a ‘normal’ and ‘at-risk’ developmental outcome than ultrasonography alone. By contrast,
there was a smaller, non-statistically significant difference observed between iuMRI and ultrasonography in
predicting an abnormal development. This finding may be a result of the small number of participants from
the original cohort with a poor prognosis being included in the follow-up study.
Among the 54 children identified as having abnormal neurodevelopment at 2–3 years and for whom a
prognosis was available for both ultrasonography and iuMRI, 11 (19%) and 13 (24%) had received a poor
prognosis from ultrasonography and iuMRI, respectively (difference of 5%, 95% CI –7% to 19%; p = 0.505).
A total of 78 children died, either in utero or prior to the 2- to 3-year follow-up, of whom 73 had received
a prognosis on both modalities. Ultrasonography identified 29 (37%) children as having a poor prognosis
compared with 36 (48%) children on iuMRI (difference of 11%, 95% CI –3% to 22%; p = 0.146).
DISCUSSION
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Isolated mild VM is often associated with a favourable outcome;91 however, within our cohort 22% of
cases of isolated mild VM diagnosed by ultrasonography had abnormal development at 2–3 years of age
compared with 18% of cases on iuMRI. These findings are higher than the 11% identified in a review of
90 articles investigating the counselling and outcome when isolated mild VM is diagnosed on prenatal
screening,92 yet it remains unclear whether or not this value is higher than in the general population.
Our finding could be as a result of its association with other abnormalities.93 The majority of children
with isolated mild VM on either screening modality were recorded as having a resolved VM and no further
diagnoses on ORD, but proportionately more unresolved VMs were found among those children with
abnormal development at 2–3 years. Fifteen children had additional (non-brain-related) conditions or
significant life events (e.g. cardiac complications, chromosomal abnormalities or prolonged hospitalisation)
that are likely to have been associated with delayed development. These were proportionately more
common among children assessed as having abnormal neurodevelopment (7/19) than among those
assessed as having at-risk (4/12) or normal development (4/54).
Selection bias may play a role in this finding. Parents who have a particular concern about their child may
be more likely to enrol in a study such as this, especially if they have already been discharged from local
services or feel that their concerns are not listened to by health professionals.
Acceptability to patients
Considerable work has already been undertaken and published confirming the safety of iuMRI. The general
risks of MRI apply and include scanning people with contraindications (e.g. pacemakers) and the risk of taking
ferromagnetic objects into the scan room, which become a projectile threat. Rigorous screening procedures
are conducted prior to the procedure to mitigate these risks. Screening was performed successfully in our
study and led to a high completion rate of iuMRI (> 99%). Acceptability of the procedure was also high,
with at least 95% of women reporting that they would have an iuMRI study again if a future pregnancy
was complicated by a fetal brain abnormality.
Radiologists’ experience
The radiologists had a wide range of iuMRI-reporting experience before the start of the study. The most
experienced radiologist was from the host site (Sheffield), where approximately two-thirds of the cases in
the study were performed. The overall iuMRI error rate was 7.0% and our analysis has shown that those
with more experience were less likely to make errors. It must be noted that even the less experienced
radiologists consistently had an error rate of < 10%. The analysis of errors has allowed us to investigate
the factors that may influence the diagnostic accuracy of iuMRI, and this work has helped to identify
practices that could be implemented into a national screening programme to reduce the risk of diagnostic
errors.
Health economics
The health economic analysis estimated the incremental cost and benefits from iuMRI compared with
ultrasonography alone. As the MERIDIAN study was not a controlled trial, the outcomes following
ultrasonography alone had to be estimated. Three scenarios were considered to estimate the proportion of
people who had a TOP after iuMRI or ultrasonography. The base case used the proportion of people who
had a TOP after iuMRI for iuMRI, and the proportion of people who were offered TOP after ultrasonography
(and before iuMRI) for ultrasonography. Scenario 1 used the proportion of people offered a TOP after iuMRI
for iuMRI, and the proportion of people who were offered TOP after ultrasonography (and before iuMRI)
for ultrasonography. Scenario 2 used the proportion of people who had a TOP after iuMRI for iuMRI, and
adjusted the proportion of people offered a TOP after ultrasonography (and before iuMRI) by the proportion
of those who were offered TOP following iuMRI and who had a TOP for ultrasonography. Therefore, the
addition of iuMRI to the pathway changed the proportion of people who had a TOP instead of a delivery.
In the base case, more people had a TOP after iuMRI than after ultrasonography, but in scenarios 1 and
2 more people had a TOP after ultrasonography than after iuMRI.
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The addition of iuMRI to one ultrasonography scan increases costs per person by £264. The resource use
for investigations, further imaging and further consultations differed in the MERIDIAN study for participants
who had a TOP and for those who did not, with higher costs for those who had a TOP. However, a delivery
is much more expensive than a TOP, meaning that the total cost for a participant who had a TOP is less
than that for a participant who had a delivery. This means that if iuMRI led to sufficiently more participants
having a TOP than a delivery, it would be cost-saving. In the base case, the proportion of participants having
TOPs after iuMRI was much smaller than after ultrasonography, and so there was an incremental cost of
£480 and a cost per management decision correctly revised of £2203. In scenarios 1 and 2, the proportions
of participants having a TOP were much closer after iuMRI and ultrasonography, so the incremental costs
were much lower.
In addition, the difference in costs and in the cost per management decision appropriately changed are
sensitive to the assumptions around which costs should be included. Inclusion of participant-borne costs
increases the incremental cost as participants have to spend additional time travelling to and attending
iuMRI scans, but participant-borne costs are not routinely included in the evaluation of health technologies
conducted by the National Institute for Health and Care Excellence in England. The exclusion of TOP and
delivery costs reduces the uncertainty associated with the approach taken to estimate the number of TOPs
with iuMRI and ultrasonography, as the major cost driver is the cost of the iuMRI itself.
In all scenarios, the incremental cost is consistently < £600 and the cost per management decision
appropriately changed is always < £3000. In a scenario comparing iuMRI with repeat ultrasonography,
iuMRI is cost-saving.
Whether or not iuMRI represents value for money depends on the willingness to pay per management
decision appropriately changed. The probabilistic sensitivity analysis demonstrated that there is 100%
probability that iuMRI is cost-effective if decision-makers are willing to pay ≥ £4000 per management
decision appropriately changed.
Although the parameters for costs and effectiveness are uncertain, the maximum EVPIs for the base case
and scenarios 1 and 2 are very low, indicating that there is little value in conducting additional research to
determine more precise estimates for the parameters.
Sociological substudy
Prenatal diagnosis technologies attract significant social science attention because they constitute a case study
of intrinsic interest for those exploring ethical, legal and social dilemmas, an opportunity to interrogate how
social contexts shape understandings of health and medical knowledge. Our findings provide insights from
both the service users’ and professionals’ perspectives on how these issues affect a PND of brain abnormality
in the context of iuMRI. Service users provide insights into lay perspectives on acceptability of and barriers to
care, and professionals provide insights into the possible implementation of NHS health-care policies. We
consider both perspectives when exploring the social issues that, as Williams31 notes, are often neglected
when rolling out new technologies in fetal medicine. In both service users’ and health professionals’ accounts,
there was much similarity in how the understandings of acceptability of care were conceptualised in complex
ways, acknowledging trade-offs and weighing up options.
Our findings suggest that iuMRI in a PND for brain abnormality is broadly acceptable to both service users
and health professionals, but it is not considered a self-evident good. The acceptability of iuMRI was
conditional, with service users’ and professionals’ accounts demonstrating careful consideration of the
costs and benefits of iuMRI, and providing suggestions for how service user and professional acceptability
could be assured and enhanced in future implementation. Nevertheless, professionals found it easy to
recruit women to the trial, and the quantitative data from the patient survey demonstrate the high level
of women’s baseline acceptance of iuMRI as part of their care. Interviews with women showed that they
were usually ‘information hungry’ and prepared to tolerate significant discomfort to maximise information
prior to decision-making about their pregnancy. Apart from specific issues, such as claustrophobia,
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the main barriers to patient acceptability centred on having to travel (linked to, but not limited to,
socioeconomic costs). Professionals also conceptualised iuMRI as useful in the PND of brain abnormality,
but with diverse views on the types of brain abnormality for which iuMRI was considered to ‘add value’
to the PND process.
The balancing of the advantages and disadvantages of iuMRI in the PND for brain abnormality reveals
three main issues: accessibility, triangulation and quality assurance.
Accessibility
Accessibility was conceptualised in both geographic and temporal terms. Geographically, iuMRI provision
has emerged in areas with facilitating factors (e.g. interested clinicians and sufficient resources). Overall
case numbers do not warrant specialist centres in every region, so it is inevitable that although some
patients will live near a centre with expert iuMRI provision, many will have to travel much further to access
it. This is not unique to PND in the context of the need for cost-efficient use of NHS resources. However,
PND has unique characteristics that make geographical barriers more problematic. PND is highly sensitive to
temporal delay in accessing services because decisions about TOPs for fetal abnormality are time sensitive.
Both clinicians and service users rely on diagnostic and prognostic information to inform decisions about
whether or not ending a pregnancy is, first, legal to offer, and, second, the option that the parents select.
Delays in accessing information from iuMRI have serious consequences for those making these sensitive,
high-stakes decisions. The timely access to and reporting of iuMRI were seen as critical to service user
and professional experiences. Adequate resourcing was needed to ensure timely access to iuMRI.
Triangulation
Triangulation encompasses many of the perceived advantages of iuMRI in the PND for brain abnormality.
First, iuMRI was seen as complementary to ultrasonography, not as a replacement. iuMRI represented a
comparative view of the fetal brain, offering reassurance in the face of uncertainty after ultrasonography.
This triangulation effect had particular power in managing the inherent uncertainties associated with PND,
although definitive conclusions often remained elusive.73 Participants found iuMRI especially helpful in
cases that were closer to the borderline of normality (e.g. VM). The triangulation effect was evident in
clinicians’ views that MDT discussion was valuable. However, although visual representations were often
seen as a useful way of generating shared understandings, the magnetic resonance images were by no
means the only or the dominant form of communication supporting shared meaning-making. Many fetal
medicine specialists appreciated iuMRI as it provided access to a second professional opinion or an opinion
from a different imaging modality. Those in larger units (perhaps with more opportunities for informal
second opinions) tended to see the value as limited to specific brain anomalies.
Quality assurance
Quality assurance of iuMRI image interpretation was seen as crucial to its successful implementation, with
discussion focusing on transparency and reputation. For service users, transparency in the PND process
could be enhanced by using iuMRI images; those with the opportunity to view iuMRI images were more
likely to value iuMRI information. The interview findings suggested that it was the in-depth explanations
that were used as narration for viewing the iuMRI images that were of particular value to women and
their partners, which may mean that the valued transparency is an effect of having iuMRI images to
discuss, rather than inherent in the images themselves. Some health professionals also identified the visual
element of iuMRI as useful (e.g. seeing the brain as symmetrical). More commonly, clinicians identified the
transparency in reporting images (of both normality and abnormality) as their priority. In fetal medicine,
reporting of ultrasonography images is usually assured by using a standardised list and repeat scanning;
whereas in radiology, iuMRI is usually assured by the use of prescribed imaging protocols and the double
reporting of images. Clinicians were more confident of the value of the quality assurance mechanisms
associated with their home specialty, but all saw that transparently assuring standards was critical, given
the importance of the information in terms of decision-making. In the current system, when working
across specialty boundaries, much depends on respecting the reputation of the person interpreting the
image, in line with Reed et al.’s76 concept of the ‘bridging’ effect between professional groups.
DOI: 10.3310/hta23490 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 49
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Griffiths et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
Concepts of acceptability and satisfaction with care are context specific. Parents and health professionals
are working in challenging circumstances to produce the ‘least worst’ outcome rather than a truly positive
experience. The patient survey data demonstrate broad acceptability of iuMRI in the PND of brain anomalies,
with at least 95% of respondents indicating that they would choose iuMRI again if in similar circumstances.
But acceptability is strongly influenced by perceived utility in a difficult situation, with at least 80% of
respondents feeling that the information from iuMRI was useful to them. Interviews suggested that parents
appreciated that iuMRI offered them details that could help inform judgements about the severity of the
fetal brain abnormality. Similarly, ≈90% of patients felt that their care was either excellent or very good.
However, the broad acceptability of iuMRI needs to be balanced with the inconveniences that patients and
professionals will tolerate in the PND pathway. Such inconveniences are significant but tolerated because of
the lack of more palatable options.
Strengths and weaknesses
Strengths and weaknesses of the study
The MERIDIAN study was designed to address the weaknesses in the current literature by conducting an
appropriately powered, pragmatic, prospective, multicentre study. This allowed us to complete a robust
evaluation of the extent to which iuMRI improves the diagnostic accuracy of ultrasonography alone and to
assess the clinical impact on the counselling and management of the pregnancy. The pragmatic nature
of the study allowed us to assess and demonstrate how iuMRI could be incorporated in the diagnostic
pathway in the UK for diagnosing fetal brain abnormalities.
Our primary analysis included only cases for which the iuMRI was performed within 2 weeks of the
ultrasonography and an ORD was available, which addressed a weakness of many prior studies that often
did not rely on an ORD. To our knowledge, this is the first study to present an analysis of diagnostic
confidence and assess its impact on appropriate management decisions.
Within this study, we have not only been able to confirm the improved diagnostic performance of iuMRI
when diagnosing fetal brain abnormalities but we have also shown that ultrasonography and iuMRI are
both capable of confirming when the development of a fetal brain is normal. We believe that this is the
first study within this population to confirm this and will have implications for designing a national
antenatal screening programme.
The limitations of the study include the potential for reporting bias from the referring clinicians on the
diagnostic and prognostic outcomes, as well as the information about their confidence in the findings.
However, changes in the prognosis were under-reported by clinicians, suggesting that they were not
systematically going back to review their initial decisions at the time of reviewing the iuMRI results.
Two further limitations were the high proportion of participants without an ORD (24%) and the high
proportion of iuMRI scans undertaken at the host institution (67%). The first limitation arose because we
were unable to undertake diagnostic investigations solely for research purposes, meaning that our ORD
relied on collecting data from investigations completed for clinical purposes, which was not always done.
This was particularly an issue following TOP or fetal demise, which accounted for over half of the cases of
missing ORDs. The second issue is an important limitation because two-thirds of the scans were undertaken
by two radiologists who were experienced in undertaking MRI specifically in fetal abnormalities; other
centres will, at present, not have this level of expertise. To address this, we undertook two sensitivity
analyses. The first found that the improvement in diagnostic accuracy following iuMRI could not be
attributed to missing data, with even extreme imputation of missing data showing iuMRI following
ultrasonography to be superior to ultrasonography alone. The second showed only a marginally higher
accuracy at the host institution compared with other centres. Both of these analyses appear to confirm the
robustness of the difference in favour of iuMRI.
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Strengths and weaknesses of the 2- to 3-year follow-up study
The main limitation of the follow-up study was the small number of children included and for whom
developmental data could be collected. Owing to delays in study initiation, many of the children were out
of the age range to be offered the BSID3 assessment, owing to the ceiling effect. Therefore, we relied on
ASQ-3 data for many children. The ASQ-3 is a screening tool and its sensitivity, specificity, PPV and NPV
are not perfect. It is designed not to miss true positives at the risk of erroneously diagnosing some children
as abnormal who would then receive a correct diagnosis on further assessment by a clinician. Our analysis
of ASQ-3 classification compared with the BSID3 assessment confirmed that the PPV was relatively low.
Although this affects the generalisability of the data and limits the conclusions that can be drawn, it does
highlight the importance of further research into the uncertainty of the prognostic importance of brain
abnormalities diagnosed antenatally. There are a number of factors that influenced our recruitment rate;
these included a delayed start to the study (including delay with funding approval and issues with site
set-up). These delays meant that a number of the children were out of the age range for the BSID3
assessment and the ASQ-3 and, therefore, only a medical case note review could be completed. There was
also a high proportion of families who could not be contacted. The approach protocol was updated during
the study to increase the number and type of contact options available to the research team (as detailed in
Chapter 5, Protocol amendments after study initiation); however, many families had moved and there was
no follow-up address available or contact telephone numbers were out of use.
The BSID3 is a well-validated tool for assessing development in early infancy; it is widely used and generates
standardised scores that allow corrections for differences in age at measurement. We wish to highlight that
despite the widespread use of BSID3 in follow-up studies, and the lack of better alternatives, it remains a
tool to assess developmental stage and not a tool to accurately predict the final developmental or cognitive
outcome later in life; however, it is currently widely considered to be the reference standard. It is entirely
possible for a child who performs well on the BSID3 between 2 and 3 years to manifest developmental or
learning difficulties later in life and vice versa. Owing to the complexity of early childhood development,
the BSID3 may also fail to detect or predict the presence of important behavioural or psychological problems
in later life. It is also important to note that the cognitive measure is affected by the child’s motor ability
and, therefore, a lower score may be obtained that may not accurately reflect the child’s ultimate level of
cognitive function. The BSID3 is also time-consuming and more than half of the children did not undergo
the full BSID3 assessment, with the development instead ascertained by a brief questionnaire-based
assessment. Although unavoidable, this is likely to have contributed a degree of measurement error to the
final classifications.
Strengths and weaknesses of the economic analysis
The key limitations of this analysis lie in the form that the analysis takes and the outcomes that are used.
The outcome of a management decision appropriately revised combines both cases in which a decision to
continue the pregnancy was changed to TOP and cases in which a decision to terminate was changed to
a continuation of pregnancy. In reality, the willingness to pay per appropriately revised decision may differ
between those situations in which the intention to terminate a pregnancy was revised to a continuation
of the pregnancy and those situations in which the continuation of the pregnancy was revised to a TOP.
The analysis does not consider the implications of inappropriately changing a management decision (e.g.
when iuMRI was incorrect and changed the prognosis in 1.81% of cases). The impacts on decision-makers,
parents and children are clearly profound, both when a decision is taken to terminate a healthy fetus or
when the decision is to continue the pregnancy when a fetal abnormality exists. These limitations should
not be overlooked when considering the cost implications. Findings relating to these aspects of the study
are reported in other sections of this report and should be considered in conjunction with evidence of
cost-effectiveness.
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Strengths and weaknesses of the sociological substudy
There are limitations to this study. The use of purposive sampling for maximum variation in the substudy
samples allowed the small samples to encompass broadly representative ranges of views. The findings from
the analysis of the data are not intended to be generalised in a simplistic way to the relevant population,
but they do provide a robust account of the likely range of views within that population.78 Although all
eligible participants were included in the survey, not all participants responded to both surveys. Therefore,
the results of the surveys do not include information on non-respondents and we do not know whether
or not that subgroup had different views from those expressed by participants. In addition, all of our
participants were recruited from a subgroup that actively chose to get involved in the MERIDIAN study
(whether as a health professional or as a patient), and so the findings do not encompass the views of
those who did not take part in the larger clinical study.
Strengths and weaknesses of the add-on study
The add-on study was a prospective study of fetuses with no brain abnormalities on ultrasonography.
Although the sample size of 205 participants is notable, it was small in terms of its ability to estimate the
NPV of ultrasonography. The fact that one abnormality was found (a NPV of 99.5%, 95% CI 97.3% to
100.0%) is reassuring in terms of the low error rate but may raise concern in mothers who may not grasp
the possibility that ultrasonography is potentially an imperfect rule-out in 2% of pregnancies. Although the
false-negative rate is likely to be lower than this, our study was not of a sufficient size to estimate the error
rate more precisely.
Although the main focus of this study was on the use of iuMRI in fetuses with a suspected brain
abnormality, it is likely that iuMRI will be considered for fetuses that are considered ‘at risk’ but whose
brain appears normal on ultrasonography. The incident of a fetus with an abnormality not being detected
by ultrasonography (and indeed the second case with mild VM) is a timely reminder that ultrasonography
is imperfect. For the foreseeable future, it is not viable for iuMRI to be used routinely in the manner in
which ultrasonography currently is, but future research may be useful in assessing in which circumstances
the addition of iuMRI to the diagnostic pathway would be of benefit.
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Chapter 8 Conclusions
Our results indicate an overall absolute improvement in diagnostic accuracy of 24.9% when iuMRI isused as an adjunct to ultrasonography to diagnose fetal brain abnormalities. Statistically significant
differences were found in diagnostic accuracy in both gestational age groups studied, specifically with
an increase of 22.5% in the 18–23 weeks group and an increase of 29.4% in the ≥ 24 weeks group.
The use of iuMRI in the diagnostic pathway also improved diagnostic confidence when compared with
ultrasonography alone. The combination of improved diagnostic accuracy and confidence leads to changes
in counselling and management in a high proportion of cases. Our subgroup analysis demonstrates the
value of iuMRI across the three anatomical subgroups studied. iuMRI for the diagnosis of fetal brain
abnormalities has also been shown to be acceptable for both service users and health professionals.
However, our results suggest that despite the increase in diagnostic accuracy and confidence provided
by iuMRI, fetal medicine experts still find it difficult to prognosticate accurately, especially in terms of
predicting abnormal development.
The inclusion of iuMRI in the diagnostic pathway resulted in additional costs compared with ultrasonography
alone, owing to the cost of iuMRI itself and the costs from resulting management decisions. Across a range of
scenarios, the incremental cost was consistently < £600 and the cost per management decision appropriately
changed was always < £3000. Whether or not iuMRI represents value for money depends on willingness to
pay per management decision appropriately changed; if decision-makers are willing to pay ≥ £4000 per
management decision correctly revised, then there is a 100% probability that iuMRI is a cost-effective
addition to the diagnostic pathway.
These results, along with the high completion rates for the procedure in the MERIDIAN study and the
favourable safety profile of the technique, indicate that iuMRI has a major diagnostic and clinical impact on
the PND of fetal brain abnormalities.
Implications for practice and policy
This study provides robust data indicating that there would be significant benefits from the routine use of
iuMRI as an adjunct to ultrasonography in the diagnostic pathway for identifying fetal brain abnormalities.
The analysis of the types of diagnostic errors made by iuMRI has allowed us to identify and address several
clinical considerations of how a national programme with the best diagnostic accuracy achievable can be
provided. These include providing an iuMRI service at a small number of supraregional centres and/or
promoting collaboration between radiologists to form expert panels for cases, formal training to improve
radiologists’ knowledge base, supervision of the iuMRI study by the radiologist and the double reporting
of images. A number of these proposals have been supported by the views of patients and health
professionals, as detailed below.
The sociological substudy included not only the patients’ views of the iuMRI but also those of the health
professionals. Insights from both perspectives are important in informing the future development of service
provision. Although decisions on funding and policy may be made for a particular service, for them to be
effectively implemented they must be acceptable to patients, and also have the formal and informal
support of clinicians who deliver care, because professionals retain a relatively high level of professional
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discretion in how they carry out their work.94,95 The following discussion points represent the most
important implications for policy development in this area:
l Small changes to the organisation of iuMRI facilities have the potential to have a positive impact on
patient experience (e.g. allowing a supportive person to sit with the woman in the iuMRI room during
the scan and providing good information for parents). Most patients involved in the PND pathway are
anxious but information hungry. Providing more information for women, including reassurances about
the impact of iuMRI on themselves and on the fetus, and providing support while the women await
results, as well as a written summary of the iuMRI report, may help to reduce negative impacts on
women during an already anxiety-provoking process.
l Clear and transparent reporting of iuMRI images would have a significant benefit for both patients and
professionals. Women value clear explanations using a wide range of resources, including visual
representations (not necessarily iuMRI images). Professionals value robust quality assurance mechanisms
in image reporting, facilitating working across the geographical distances that cost-efficient use of
resources for specialist services requires. Consideration could be given to incorporating into the quality
assurance process the elements that are familiar to the professional groups involved [e.g. standardised
reporting of features (from fetal medicine) and double reporting of images (from radiology)]. A modest
investment in visibly robust quality assurance mechanisms could enhance professional engagement with
whatever cost-effective national provision framework is implemented.
l The timing of care provision is compressed in PND and, therefore, providing appropriately timed access
to iuMRI could help encourage professional and lay engagement with iuMRI, whereas lengthy delays in
accessing iuMRI may result in the proliferation of local arrangements, reducing opportunities for cost-
effectiveness and national oversight of care.
l For clinicians working across specialty boundaries, collaboration is considered to be crucial. Many
participants saw the value of more collaborative working across fetal medicine and radiology on the
issue of fetal imaging and in relation to specialty training, but also with regard to collaborative working
in MDTs.
l All of the issues listed above link back, in some way, to the issue of adequate resourcing. Demand for
MRI provision appears to be a limiting factor on both user experience and service development, but
increasing capacity in trained personnel and in terms of the number of MRI scanners is a lengthy and
expensive investment. It may be helpful to consider some shorter-term and longer-term plans for
dealing with the resource issues associated with implementing policies that increase the demand for
MRI provision.
Recommendations for future research
The MERIDIAN study recruited women carrying fetuses with a suspected brain abnormality shown on
ultrasonography, and the add-on study (see Chapter 6) included fetuses thought to have no form of
abnormality whatsoever. Therefore, cases of isolated microcephaly were not studied in the MERIDIAN
study. Microcephaly is often associated with other brain abnormalities and the severity correlates with the
risk of a poor outcome,96,97 yet there is a paucity of literature with regard to the use of iuMRI in fetuses
with microcephaly.
The use of iuMRI in the diagnosis of fetal spine abnormalities has not been well studied; however, data from
a small study of 33 participants98 suggest that iuMRI may have a role in the diagnosis of these abnormalities.
Further research is required to evaluate the use of iuMRI in the diagnosis of spine abnormalities.
As identified in the 2- to 3-year follow-up study (see Chapter 5), the functional significance of the brain
abnormality is more important to parents than the specific structural or anatomical diagnosis. We have
presented data from children aged 2–3 years and also discussed the limitations of the tools available to
assess development at this age. Therefore, we propose that longer-term follow-up studies of children
diagnosed with fetal brain abnormalities are required.
CONCLUSIONS
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Appendix 1 Unit costs (base case)
Cost
component Details Cost (£) Source
Consultation First consultation with
consultant
161 NHS Reference Costs 2015 to 2016:99 WF01B (Obstetrics)
Subsequent consultation
with consultant
121 NHS Reference Costs 2015 to 2016:99 WF01A (Obstetrics)
Ultrasonography
scan
Two-dimensional
ultrasonography
106 NHS Reference Costs 2015 to 2016:99 NZ21Z Outpatient
procedure (Obstetrics)
Three-dimensional
ultrasonography
146 NHS Reference Costs 2015 to 2016:99 NZ22Z Outpatient
procedure (Obstetrics)
MRI iuMRI (≥ 19 years) 146 NHS Reference Costs 2015 to 2016:99 RA01A – single area,
no contrast
iuMRI (< 19 years) 143 NHS Reference Costs 2015 to 2016:99 RA01B – single area,
no contrast
Termination TOP with feticide 1581 NHS Reference Costs 2015 to 2016:99 MA20Z – ≥ 20-week
gestation. Elective inpatient plus 0.84 excess bed-days
TOP without feticide 1136 NHS Reference Costs 2015 to 2016:99 MA18D – 14- to
20-week gestation. Elective inpatient plus 0.82 excess
bed-days
Delivery Delivery 2647 NHS Reference Costs 2015 to 2016:99 NZ25Z-NZ15C
weighted average
Investigations Karyotype 150 Great Ormond Street Hospital100
Fetal echocardiography 106 Assumed the same as a two-dimensional ultrasonography
TORCH screen 8 Sheffield Teaching Hospitals NHS Foundation Trusta
Antibody screen 9 Sheffield Teaching Hospitals NHS Foundation Trusta
Cystic fibrosis screen 257 West Midlands Regional Genetics Laboratory101
FGFR3 – related skeletal
dysplasias panel test
600 NHS UK Genetic Testing Network102
Non-invasive prenatal
testing
400 BabyCentre103
Array 291 Sagoo and Mohammed104
CMV 17 Sheffield Teaching Hospitals NHS Foundation Trusta
Toxoplasmosis 9 Sheffield Teaching Hospitals NHS Foundation Trusta
CMV, cytomegalovirus; FGFR3, fibroblast growth factor receptor 3; TORCH, toxoplasmosis, rubella cytomegalovirus, herpes
simplex and human immunodeficiency virus (HIV).
a Sheffield Teaching Hospitals, personal communication, 2016.
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Appendix 2 Probability distributions for input
parameters
Parameter
category Parameter Distribution Mean
Standard
error Alpha Beta
Cost (£) Consultant consultation: first Normal 161 0
Consultant consultation: subsequent Normal 121 0
Two-dimensional ultrasonography Normal 106 0
Three-dimensional ultrasonography Normal 146 0
MRI (≥ 19 years) Normal 146 0
MRI (6–18 years) Normal 143 0
TOP with feticide Normal
TOP average stay (≥ 20 weeks’ gestation) Normal 1232 28
TOP excess bed-day (≥ 20 weeks’ gestation) Normal 416 10
TOP without feticide Normal
TOP average stay (14–20 weeks’ gestation) Normal 910 42
TOP excess bed-day (14–20 weeks’ gestation) Normal 277 36
Delivery cost (average) Normal 2647 0
Karyotype Normal 152 30
Fetal echocardiography Normal 106 0
TORCH screen Normal 8 2
Antibody screen Normal 9 2
Cystic fibrosis screen Normal 263 53
FGFR3 – related skeletal dysplasias panel test Normal 600 120
Non-invasive prenatal testing Normal 400 80
Array Normal 298 60
Cytomegalovirus Normal 17 3
Toxoplasmosis Normal 9 2
Resource use Postcode miles: no TOP (miles) Log-normal 58.39 3.75
Postcode miles: TOP (miles) Log-normal 82.57 13.97
Hourly wage: no TOP (£) Log-normal 13.32 0.20
Hourly wage: TOP (£) Log-normal 14.68 0.49
Participant time: no TOP (minutes) Log-normal 229.67 12.19
Participant time: TOP (minutes) Log-normal 283.25 46.82
Proportion of patients, two-dimensional
ultrasonography: no TOP
Log-normal 0.97 0.01
Proportion of patients, two-dimensional
ultrasonography: TOP
Log-normal 1.00 0.00
Proportion of patients, three-dimensional
ultrasonography: no TOP
Log-normal 0.11 0.02
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Parameter
category Parameter Distribution Mean
Standard
error Alpha Beta
Proportion of patients, three-dimensional
ultrasonography: TOP
Log-normal 0.05 0.05
Proportion of patients, < 19 years: no TOP Log-normal 1.00 0.00
Proportion of patients, < 19 years: TOP Log-normal 1.00 0.00
Proportion of patients, follow-up
two-dimensional ultrasonography: no TOP
Log-normal 0.72 0.03
Proportion of patients, follow-up
two-dimensional ultrasonography: TOP
Log-normal 0.20 0.09
Proportion of patients, follow-up iuMRI: no TOP Log-normal 0.12 0.02
Proportion of patients, follow-up iuMRI: TOP Log-normal 0.15 0.08
Additional visits: no TOP (n) Log-normal 3.16 0.11
Additional visits: TOP (n) Log-normal 2.10 0.07
Proportion of patients, karyotype: no TOP Log-normal 0.38 0.04
Proportion of patients, karyotype: TOP Log-normal 0.80 0.12
Proportion of patients, fetal
echocardiography: no TOP
Log-normal 0.26 0.03
Proportion of patients, fetal
echocardiography: TOP
Log-normal 0.20 0.09
Proportion of patients, infection screen: no TOP Log-normal 0.85 0.03
Proportion of patients, infection screen: TOP Log-normal 0.75 0.12
Proportion of patients, NIPT: no TOP Log-normal 0.26 0.03
Proportion of patients, NIPT: TOP Log-normal 0.20 0.09
Proportion of patients, antibody testing: no TOP Log-normal 0.02 0.01
Proportion of patients, antibody testing: TOP Log-normal 0.10 0.07
Proportion of patients, cystic fibrosis screen:
no TOP
Log-normal 0.02 0.01
Proportion of patients, cystic fibrosis screen: TOP Log-normal 0.05 0.05
Proportion of patients, platelets: no TOP Log-normal 0.00 0.00
Proportion of patients, platelets: TOP Log-normal 0.00 0.00
Proportion of patients, FGFR3: no TOP Log-normal 0.00 0.00
Proportion of patients, FGFR3: TOP Log-normal 0.00 0.00
Proportion of patients, NIFTY: no TOP Log-normal 0.00 0.00
Proportion of patients, NIFTY: TOP Log-normal 0.00 0.00
Proportion of patients, array: no TOP Log-normal 0.00 0.00
Proportion of patients, array: TOP Log-normal 0.00 0.00
Proportion of patients, cytomegalovirus: no TOP Log-normal 0.00 0.00
Proportion of patients, cytomegalovirus: TOP Log-normal 0.00 0.00
Proportion of patients, toxoplasmosis: no TOP Log-normal 0.00 0.00
Proportion of patients, toxoplasmosis: TOP Log-normal 0.00 0.00
Proportion of patients, TOP with feticide: no TOP Log-normal 0.00 0.00
Proportion of patients, TOP with feticide: TOP Log-normal 0.55 0.11
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Parameter
category Parameter Distribution Mean
Standard
error Alpha Beta
Proportion of patients, TOP without feticide:
no TOP
Log-normal 0.00 0.00
Proportion of patients, TOP without feticide: TOP Log-normal 0.20 0.09
Proportion of patients, delivery: no TOP Log-normal 1.00 0.00
Proportion of patients, delivery: TOP Log-normal 0.00 0.00
Proportions iuMRI: proportion having TOP Beta 0.119 68 502
Ultrasonography: proportion of patients
offered TOP
Beta 0.247 135 412
Proportion of management decisions
appropriately changed
Beta 0.218 120 431
iuMRI: proportion of patients offered TOP Beta 0.352 189 348
iuMRI: proportion of patients offered TOP
who then had TOP
Beta 0.307 58 131
FGFR3, fibroblast growth factor receptor 3; NIFTY, non-invasive fetal trisomy test (a type of NIPT); NIPT, non-invasive
prenatal testing; TORCH, toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and human immunodeficiency virus (HIV).
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Appendix 3 Recruitment and participant flow
The reasons given on the approach form for not asking about entry to study and reasons given bymothers who declined to be in the study.
Reason n (%)
N 198
Not asked to be in the study (N = 86)
Considered clinically inappropriate/unhelpful 50 (58.0)
Likely to cause undue delay 6 (7.0)
Other 30 (35.0)
Asked to be in study but refused (N = 112)
Decision already made 18 (16.0)
Unwilling to travel 13 (12.0)
Does not want iuMRI 28 (25.0)
Too upset or distressed 11 (9.8)
Other 35 (31.0)
No reason given 7 (6.2)
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Appendix 4 Ultrasonography technical factors
The technical features reported during ultrasonography.
Technical feature n (%)
Number completing ultrasonography and iuMRI (N) 821
Two-dimensional ultrasonography only 681 (83.0)
Both two- and three-dimensional ultrasonography 140 (17.0)
Technical factors contributing to low confidence 237 (29.0)
Fetal position 115 (14.0)
High body mass index 107 (13.0)
Oligohydramnios 7 (0.9)
Gestational age 21 (2.6)
Other 50 (6.1)
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Appendix 5 Diagnostic accuracy
The diagnostic accuracy of ultrasonography and iuMRI in 570 cases and three subgroups within theprimary analysis population (i.e. first, single and repeat pregnancies within the MERIDIAN study
population).
Pregnancy characteristic
Ultrasonography
correct, n (%)
iuMRI
correct, n (%)
Percentage
difference (95% CI) p-valuea
Overall (N = 570) 388 (68.1) 530 (93.0) 24.9 (21.1 to 28.7) < 0.0001
First pregnancies (N = 563) 383 (68.0) 525 (93.3) 25.3 (21.4 to 29.0) < 0.0001
Singleton pregnancies (N = 539) 363 (67.3) 499 (92.6) 25.3 (21.3 to 29.2) < 0.0001
Repeat pregnancies (N = 7) 5 (71.4) 5 (71.4) 0
a McNemar’s test between ultrasonography and iuMRI.
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Appendix 6 Prognosis in relation to inclusion/
exclusion in primary analysis
Data are presented for all mothers who had complete data for clinical impact (n = 783). For multiplepregnancies, prognosis is given in relation to the pregnancy as a whole.
Prognosis
ORD available,
n (%) (N= 544)
ORD unavailable,
n (%) (N= 162)
Excluded,
n (%) (N= 77)
Overall, n (%)
(N= 784)a
Prognosis on ultrasonography
Not known 90 (17.0) 38 (24.0) 18 (23.0) 146 (19.0)
Poor (< 50%) 72 (13.0) 42 (26.0) 6 (7.8) 120 (15.0)
Intermediate (50–90%) 155 (29.0) 47 (29.0) 18 (23.0) 220 (28.0)
Favourable (> 90%) 214 (39.0) 29 (18.0) 34 (44.0) 278 (36.0)
Normal 13 (2.4) 6 (3.7) 1 (1.3) 20 (2.6)
Prognosis on iuMRI
Not known 41 (7.5) 15 (9.3) 9 (12.0) 65 (8.3)
Poor (< 50%) 112 (20.0) 64 (40.0) 12 (16.0) 188 (24.0)
Intermediate (50–90%) 116 (21.0) 27 (17.0) 12 (16.0) 155 (20.0)
Favourable (> 90%) 251 (46.0) 39 (24.0) 38 (49.0) 329 (42.0)
Normal 24 (4.4) 17 (11.0) 6 (7.8) 47 (6.0)
a One participant had one fetus in the ‘ORD available’ category and one fetus in the ’ORD unavailable’ category.
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Appendix 7 Prognosis on ultrasonography alone
versus in utero magnetic resonance imaging following
ultrasonography for all mothers who completed in
utero magnetic resonance imaging
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Ultrasonography alone
iuMRI prognosis (confidence), n (%)
Total, n (%)Not known Poor (< 50%) Intermediate (50–90%) Favourable (> 90%) Normal
Not known 32 (4.1) 28 (3.6) 32 (4.1) 40 (5.1) 13 (1.7) 145 (18.5)
Poor (< 50%) 4 (0.5) 94 (12) 15 (1.9) 5 (0.6) 2 (0.3) 120 (15.3)
Intermediate (50–90%) 16 (2.0) 57 (7.3) 88 (11.2) 53 (6.8) 6 (0.8) 220 (28.1)
Favourable (> 90%) 12 (1.5) 6 (0.8) 17 (2.2) 222 (28.4) 21 (2.7) 278 (35.5)
Normal 1 (0.1) 2 (0.3) 3 (0.4) 9 (1.1) 5 (0.6) 20 (2.6)
Total 65 (8.3) 187 (23.9) 155 (19.8) 329 (42.0) 47 (6.0) 783 (100.0)
Shading denotes where prognosis on ultrasonography and iuMR match.
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Appendix 8 Change in prognosis from
ultrasonography to in utero magnetic resonance
imaging following ultrasonography by category when
prognosis is unknown on one modality
Prognosis n (%)
Number of fetuses 178
Not known on both ultrasonography and iuMRI 32 (18.0)
Not known on ultrasonography, known on iuMRI 113 (63.0)
Prognosis on iuMRI
Poor (< 50%) 28 (16.0)
Intermediate (50–90%) 32 (18.0)
Favourable (> 90%) 40 (23.0)
Normal 13 (7.3)
Known on ultrasonography, not known on iuMRI 33 (18.5)
Prognosis on ultrasonography
Poor (< 50%) 4 (2.2)
Intermediate (50–90%) 16 (9.0)
Favourable (> 90%) 12 (6.7)
Normal 1 (0.6)
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Appendix 9 Change in counselling based
on ultrasonography alone and in utero magnetic
resonance imaging following ultrasonography in
774 cases with complete data
Counselling
TOP not
discussed, n (%)
TOP discussed, n (%)
Total, n (%)
Not
offered
Offered based
on substantial
disability risk
Offered,
other reason
Ultrasonography
TOP not discussed 285 (73.0) 41 (42.0) 52 (19.0) 3 (21.0) 381 (49.0)
TOP discussed
Not offered 87 (22.0) 39 (40.0) 64 (24.0) 4 (29.0) 194 (25.0)
Offered based on substantial
disability risk
18 (4.6) 10 (10.2) 143 (53.0) 5 (36.0) 176 (22.0)
Offered, other reason 3 (0.8) 8 (8.2) 10 (3.7) 2 (14.0) 23 (2.9)
Total 393 (51.0) 98 (13.0) 269 (35.0) 14 (1.8) 774
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Appendix 10 Composite case study
Composite case study
Anne and Jo were looking forward to their 20-week scan, as they were keen to find out if their baby was
going to be a girl. They had already had two sons, and they had tried for some time for a third child
without success. At the abnormality scan, the sonographer was more quiet than usual and this troubled them.
She then left suddenly and came back with a midwife who also looked concerned. Not knowing what to
think, Anne started to become tearful and the midwife tried to explain by saying that there was something
not quite right with the baby’s brain, and that it could mean that the baby had Down syndrome. She
could not say much more when asked, and told them that the consultant would be able to give them a
fuller explanation. Unfortunately, as it was a Friday, the next available appointment with the consultant
was on Monday. They endured a terrible weekend worrying about the condition and all that it could mean
for their baby.
On the Monday, the consultant did the scan herself and explained the features in the brain that were of
concern. They were told that there was no other test apart from an amniocentesis that could determine if
the baby had Down syndrome, so they went ahead with the test. The results came back clear, so the
consultant explained the option of having a MRI scan through the MERIDIAN study, a diagnostic accuracy
trial. The scan would be able to determine if the results of the ultrasound scan were accurate, and would
be able to look at other parts of the brain to see if it was developing normally. Anne was somewhat
claustrophobic so she was quite unwilling at first, but then, because they were desperate to know the
condition of their baby’s brain, they agreed to participate in the study. The scan was arranged for the
following Monday.
Before the scan, Anne read the generic MRI information sheet that indicated that pregnant women should
take extra care, especially in the first trimester. When she brought it up, she was told that no studies have
been conducted on those in the second trimester. This still raised alarm bells for her and caused her to
have doubts. She arrived at the room with her husband, expecting her husband to be allowed in with her,
but as they ushered him into the waiting room, she felt she could not object. Going into the machine, she
started to have a panic attack and asked to be taken out. She was given a pillow and asked to look out of
the tunnel or to close her eyes altogether, which helped her. But she still missed her husband’s presence.
The noise from the machine was so loud that she felt the baby reacting to it, which caused her some
concern. But she tried to keep as still as she could to minimise any problems they were having in taking
images of the baby’s brain. This was difficult for her because she had problems with her pelvis, which was
giving her pain, and the heat in the machine did not help. She was in the machine for over 1 hour.
It took over 1 week before the results of the scan were discussed with her. At that appointment, they
were told that the ‘ventriculomegaly’ was borderline and that she would have to be monitored over
the course of the pregnancy, as the condition could stay the same, worsen or improve. The idea that it
could worsen and could mean ending the pregnancy hung over them, and because of the uncertainty of
everything, they preferred to keep it to themselves. As they went in for scans every fortnight, the size of
the ventricles varied throughout the pregnancy. Eventually, their baby girl was born with no observable
problems. But because of their whole experience, they found that the bond with their baby had been
affected and that the whole pregnancy was ruined.
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Following the birth, there was very little follow-up on their baby’s case. Anne had to push for an ultrasound
scan to be done and to explain why it needed to be done. The baby was scanned at 15 days old, but
Anne and Jo had to wait until she was 12 weeks old before they were able to find out at a fetal medicine
consultation that the ventricles were within the normal range. Now, 6 months after the MRI, there are
signs that the baby has a mild hydrocephalus and her development needs to be monitored. They have been
looking for a written report and images of the MRI scan but were disappointed that these were not provided.
They are also no clearer as to how the condition arose.
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Appendix 11 Participant characteristic tables
TABLE 46 Inclusion in the follow-on study project 1 in relation to original prognosis
Prognosis
Overall,
n (%)
Consented,
n (%)
Did not
consent, n (%)
Died within original
follow-up,a n (%)
Not approached,
n (%)
N 829 239 316 188 86
Prognosis on ultrasonography
Not known 155 (19.0) 45 (19.0) 52 (17.0) 34 (18.0) 24 (28.0)
Poor (< 50%) 125 (15.0) 19 (7.9) 26 (8.2) 69 (37.0) 11 (13.0)
Intermediate (50–90%) 233 (28.0) 59 (25.0) 95 (30.0) 59 (31.0) 20 (23.0)
Favourable (> 90%) 295 (36.0) 107 (45.0) 138 (44.0) 21 (11.0) 29 (34.0)
Normal 21 (2.5) 9 (3.8) 5 (1.6) 5 (2.7) 2 (2.3)
Prognosis on ultrasonography and iuMRI
Not known 65 (8.2) 16 (7.1) 20 (6.5) 16 (9.1) 13 (16.0)
Poor (< 50%) 189 (24.0) 22 (9.7) 38 (12.0) 116 (66.0) 13 (16.0)
Intermediate (50–90%) 157 (20.0) 43 (19.0) 65 (21.0) 27 (15.0) 22 (27.0)
Favourable (> 90%) 334 (42.0) 129 (57.0) 164 (53.0) 12 (6.9) 29 (36.0)
Normal 47 (5.9) 16 (7.1) 23 (7.4) 4 (2.3) 4 (4.9)
a Deaths within original MERIDIAN include terminations, stillbirths, fetal deaths and deaths within 6 months of birth.
Note
Values do not total 100% owing to rounding.
TABLE 47 Inclusion in the follow-on study project 2 in relation to the original prognosis
Prognosis
Overall,
n (%)
Consented,
n (%)
Did not
consent, n (%)
Died within original
follow-up,a n (%)
Not approached,
n (%)
N 829 194 361 188 86
Prognosis on ultrasonography
Not known 155 (19.0) 41 (21.0) 56 (16.0) 34 (18.0) 24 (28.0)
Poor (< 50%) 125 (15.0) 16 (8.2) 29 (8.0) 69 (37.0) 11 (13.0)
Intermediate (50–90%) 233 (28.0) 49 (25.0) 105 (29.0) 59 (31.0) 20 (23.0)
Favourable (> 90%) 295 (36.0) 80 (41.0) 165 (46.0) 21 (11.0) 29 (34.0)
Normal 21 (2.5) 8 (4.1) 6 (1.7) 5 (2.7) 2 (2.3)
Prognosis on iuMRI
Not known 65 (8.2) 16 (8.7) 20 (5.7) 16 (9.1) 13 (16.0)
Poor (< 50%) 189 (24.0) 18 (9.8) 42 (12.0) 116 (66.0) 13 (16.0)
Intermediate (50–90%) 157 (20.0) 36 (20.0) 72 (20.0) 27 (15.0) 22 (27.0)
Favourable (> 90%) 334 (42.0) 99 (54.0) 194 (55.0) 12 (6.9) 29 (36.0)
Normal 47 (5.9) 14 (7.7) 25 (7.1) 4 (2.3) 4 (4.9)
a Deaths within original MERIDIAN include terminations, stillbirths, fetal deaths and deaths within 6 months of birth.
Note
Values do not total 100% owing to rounding.
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TABLE 48 Inclusion in the follow-on study project 2 in relation to the original prognosis
Prognosis N
Consented,
n (%)
Did not
consent, n (%)
Died within original
follow-up,a n (%)
Not approached,
n (%)
Ultrasonography prognosis
Not known 155 41 (27.0) 56 (36.0) 34 (22.0) 24 (16.0)
Poor (< 50%) 125 16 (13.0) 29 (23.0) 69 (55.0) 11 (8.8)
Intermediate (50–90%) 233 49 (21.0) 105 (45.0) 59 (25.0) 20 (8.6)
Favourable (> 90%) 295 80 (27.0) 165 (56.0) 21 (7.1) 29 (9.8)
Normal 21 8 (38.0) 6 (29.0) 5 (24.0) 2 (9.5)
iuMRI prognosis (%)
Not known 65 16 (25.0) 20 (31.0) 16 (25.0) 13 (20.0)
Poor (< 50%) 189 18 (9.5) 42 (22.0) 116 (61.0) 13 (6.9)
Intermediate (50–90%) 157 36 (23.0) 72 (46.0) 27 (17.0) 22 (14.0)
Favourable (> 90%) 334 99 (30.0) 194 (58.0) 12 (3.6) 29 (8.7)
Normal 47 14 (30.0) 25 (53.0) 4 (8.5) 4 (8.5)
a Deaths within original MERIDIAN include terminations, stillbirths, fetal deaths and deaths within 6 months of birth.
Note
Values do not total 100% owing to rounding.
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Not known
Poor (< 50%)
Intermediate (50 – 90%)
Favourable (> 90%)
Normal
(a)
Prognosis
Not known
Poor (< 50%)
Intermediate (50 – 90%)
Favourable (> 90%)
Normal
(b)
Prognosis
FIGURE 12 A waffle chart showing the MERIDIAN study cohort (n= 829). (a) By prognosis on ultrasonography
when compared with (b) those participants recruited to project 2 (n= 190).
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Not known
Poor (< 50%)
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Favourable (> 90%)
Normal
Not reported
(a)
Prognosis
Not known
Poor (< 50%)
Intermediate (50 – 90%)
Favourable (> 90%)
Normal
Not reported
(b)
Prognosis
FIGURE 13 A waffle chart showing the MERIDIAN study cohort (n= 829). (a) By prognosis on iuMRI when
compared with (b) those participants recruited to project 2 (n= 190).
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Appendix 12 Box plots of Ages and Stages
Questionnaire, Third Edition, and Strengths and
Difficulties Questionnaire scores
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FIGURE 14 Box plots of ASQ-3 subscale scores by ultrasonography and iuMRI prognosis in the MERIDIAN study.
(a) Communication, (b) fine motor, (c) gross motor, (d) problem-solving and (e) prosocial. (continued )
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FIGURE 14 Box plots of ASQ-3 subscale scores by ultrasonography and iuMRI prognosis in the MERIDIAN study.
(a) Communication, (b) fine motor, (c) gross motor, (d) problem-solving and (e) prosocial.
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FIGURE 15 Box plots of SDQ subscale scores by ultrasonography and iuMRI prognosis in the MERIDIAN study.
(a) Overall, (b) conduct, (c) emotional, (d) hyperactivity, (e) peer problems and (f) prosocial. (continued )
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FIGURE 15 Box plots of SDQ subscale scores by ultrasonography and iuMRI prognosis in the MERIDIAN study.
(a) Overall, (b) conduct, (c) emotional, (d) hyperactivity, (e) peer problems and (f) prosocial.
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Appendix 13 Descriptive statistics tables for the
developmental scores
TABLE 49 Summary of developmental outcome scores from the BSID assessment
BSID domain BSID score
n 86
Cognitive raw score
Mean (SD) 71.0 (12.6)
Median (IQR) 74 (67–80)
Min.–max. 23–87
Cognitive composite score
Mean (SD) 10.6 (4.5)
Median (IQR) 10 (8–14)
Min.–max. 1–19
Language raw score
Mean (SD) 102.3 (22.0)
Median (IQR) 100 (90–120)
Min.–max. 55–145
Language composite score
Mean (SD) 30.8 (10.3)
Median (IQR) 32.5 (24–38)
Min.–max. 0–49
Motor raw score
Mean (SD) 9.5 (4.0)
Median (IQR) 10 (7–12)
Min.–max. 0–19
Motor composite score
Mean (SD) 32.1 (9.8)
Median (IQR) 34 (27–39)
Min.–max. 0–47
Max., maximum; min., minimum.
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TABLE 50 Summary of developmental outcome scores from the ASQ-3
ASQ-3 domain ASQ-3 score
Communication
n 176
Mean (SD) 45.3 (19.0)
Median (IQR) 55 (35–60)
Min.–max. 0–60
Gross motor
n 175
Mean (SD) 40.8 (22.3)
Median (IQR) 50 (25–60)
Min.–max. 0–60
Fine motor
n 175
Mean (SD) 38.3 (19.8)
Median (IQR) 45 (25–55)
Min.–max. 0–60
Problem-solving
n 174
Mean (SD) 44.7 (18.9)
Median (IQR) 55 (35–60)
Min.–max. 0–60
Personal social
n 175
Mean (SD) 42.6 (17.9)
Median (IQR) 50 (35–55)
Min.–max. 0–60
Max., maximum; min., minimum.
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TABLE 51 Summary of developmental outcome scores from the SDQ
SDQ domain SDQ score
n 102
Overall
Mean (SD) 9.1 (6.4)
Median (IQR) 7.5 (4–12)
Min.–max. 0–28
Emotional problems
Mean (SD) 1.6 (1.5)
Median (IQR) 1 (0–3)
Min.–max. 0–7
Conduct problems
Mean (SD) 2.2 (1.9)
Median (IQR) 2 (1–3)
Min.–max. 0–8
Hyperactivity
Mean (SD) 3.6 (2.7)
Median (IQR) 3 (1–5)
Min.–max. 0–10
Peer problems
Mean (SD) 1.8 (1.8)
Median (IQR) 1 (0–3)
Min.–max. 0–7
Prosocial
Mean (SD) 7.3 (2.4)
Median (IQR) 8 (6–9)
Min.–max. 0–10
Max., maximum; min., minimum.
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Appendix 14 A breakdown of ultrasonography
and in utero magnetic resonance imaging prognoses
in ‘abnormal’, ‘normal’ and ‘borderline’ cases
Clinicians’ developmental assessment and ultrasonography/iuMRI
prognoses
TABLE 52 Ultrasonography prognosis category compared with iuMRI prognosis category in surviving infants who
completed the developmental assessment and were assessed as ‘abnormal’ (n= 53)
Ultrasonography prognosis
iuMRI prognosis
Poor Intermediate Favourable/normal Not known Total
Poor 7 2 1 0 10
Intermediate 5 5 1 1 12
Favourable/normal 0 3 13 0 16
Not known 1 4 6 4 15
Total 13 14 21 5 53
TABLE 53 Ultrasonography prognosis category compared with iuMRI prognosis category in surviving infants who
completed the developmental assessment and were assessed as ‘normal’ or ‘borderline’ (n= 125)
Ultrasonography prognosis
iuMRI prognosis
Poor Intermediate Favourable/normal Not known Total
Poor 2 1 2 0 5
Intermediate 1 11 17 4 33
Favourable/normal 1 3 56 3 63
Not known 1 6 13 4 24
Total 5 21 88 11 125
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FIGURE 16 Frequency of each ultrasonography prognosis category by developmental outcome. (a) Normal/at risk,
(b) abnormal and (c) death. (continued )
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FIGURE 16 Frequency of each ultrasonography prognosis category by developmental outcome. (a) Normal/at risk,
(b) abnormal and (c) death.
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FIGURE 17 Frequency of each iuMRI prognosis category by developmental outcome. (a) Normal/at risk,
(b) abnormal and (c) death. (continued )
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FIGURE 17 Frequency of each iuMRI prognosis category by developmental outcome. (a) Normal/at risk,
(b) abnormal and (c) death.
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